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1.  Abstract 
Gene therapy vectors based on the HIV-1 lentivirus are an attractive option for 
clinical applications because they enter a broad range of target cells efficiently and 
deliver stable gene expression through integration into host chromosomes. However, 
lentiviral vectors are known to integrate preferentially within actively transcribing 
genes. Leukaemia-like expansions observed in gene therapy trials using 
gammaretroviral vectors and are thought to have been caused by disruption of host 
proto-oncogenes at or close to the vector integration site, and the safety of these 
vectors may be related to the pattern of vector integration with respect to genes. The 
safety of integrating gammaretroviral and lentiviral vectors is therefore a significant 
concern with respect to their use in gene therapy. In this study, this problem was 
addressed by developing a novel hybrid vector which combines the efficient cell and 
nuclear entry properties of lentiviral vectors with chromosomal integration by the 
Sleeping Beauty transposase. Unlike the HIV-1 integrase enyme, Sleeping Beauty 
transposase does not exhibit a preference for integration within active genes. Non-
integrating lentiviral vectors were developed to carry Sleeping Beauty transposon and 
transposase expression cassettes. These were able to deliver transient transposase 
expression to target cells, and episomal lentiviral DNA was found to be a suitable 
substrate for integration by Sleeping Beauty transposase. Importantly, integration with 
this novel vector was found to occur significantly less frequently within active genes 
than a standard lentiviral vector. Finally, it was shown that the transposase protein can 
be incorporated into lentiviral vector particles in a manner analogous to HIV-1 
integrase. The development of vectors with safer integration patterns may lead to 
better clinical outcomes for patients treated with gene therapy.   4
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2.  Introduction 
This chapter describes the intellectual background to the work presented in this thesis, 
beginning with a history of gene therapy and the problem of genotoxicity in clinical 
trials due to vector integration. This is followed by a discussion of the factors 
contributing to insertional mutagenesis following vector integration. The major 
classes of integrating vectors are described. Finally, the reasons for developing a 
hybrid lentivirus-transposon vector are outlined. 
2.1.  Gene Therapy 
Gene therapy involves the introduction of genetic material into cells in order to treat 
or prevent disease. Classical gene therapy has been described as “using DNA as a 
drug”, in which DNA carrying genes is transferred into cells by artificial means. After 
decades of research, this approach has now been successfully used to treat a number 
of conditions in humans. This section presents the historical background to the 
development of gene therapy. 
Genes as theoretical units of inheritance were first described around 1900 by the 
botanists Erich von Tschermak, Hugo de Vries, and Carl Correns based on their 
observations of phenotypic segregation ratios in plants. In 1911, Thomas Hunt 
Morgan’s studies of sex-linked traits in fruit flies led him to suggest that the genes 
responsible were carried on the sex chromosomes and that all genes were associated 
with particular chromosomes. 
Although the physical location of genes was known to be chromosomes, for decades 
the biochemical nature of genes was controversial. Chromosomal proteins were a 
leading candidate owing to their complex chemical compositions. The problem was 
solved by Oswald Avery in 1944 when he isolated a chemical ‘transforming principle’ 
able to stably transform a strain of Pneumococcus Type II (small, rough colonies) into 
Pneumococcus Type III (large, smooth colonies) (2). He identified the transforming 
principle as “sodium desoxyribonucleate”, or in modern nomenclature, DNA. Avery’s 
work was later supported by Hershey and Chase’s demonstration in 1952 that bacteria   22
infected by radiolabelled bacteriophage took up only the DNA of the virus, not the 
protein shell (3). 
The structural basis by which information could be stored in DNA was suggested by 
the DNA double helix discovered by Franklin, Watson and Crick in 1953 (4). This 
discovery marked the beginning of the “Revolution in Molecular Biology” (5), a 
period of rapid progress in the 1950s and 60s from which emerged the Central Dogma 
of molecular biology – that information flows from DNA to RNA to protein – as well 
as the triplet genetic code described by Crick, Nirenberg, Khorana, and Brenner. 
This progress in the theory of molecular biology was paralleled by advances in the 
ability of molecular biologists to practically manipulate DNA itself. Over the course 
of the 1960s, Nathans, Arber, and Smith isolated restriction endonucleases from 
bacteria and characterised their ability to cleave DNA in a sequence-specific manner. 
In 1968, Khorana used T4 DNA ligase to join DNA molecules together (6). Work by 
Cohen, Boyer, and Berg led to the production of the first recombinant DNA molecule 
in 1973, a plasmid into which novel antibiotic resistance genes were inserted using the 
restriction enzyme EcoRI and T4 DNA ligase (7). 
The potential for the emerging technology to be applied outside of the laboratory was 
noted at the time. In a 1964 perspective paper, Edward Tatum declared (8): 
“Within the next hundred years great advances can be expected in the control of 
mutational processes, in the design and synthesis of genetic determinants, and in the 
development of techniques for the introduction of such new genetic determinants into 
the genome of living organisms. The next centennial program of this Academy may 
very well include a symposium on "Genetic Engineering and Controlled Evolution." 
With the increase of our knowledge in these and other areas, it is sincerely to be 
hoped that our ability to use this knowledge wisely will increase in proportion.” 
The (at the time, theoretical) introduction of genes into human beings to treat disease 
came to be known as gene therapy. As Friedmann notes in his history of gene therapy 
(9), the term ‘gene therapy’ itself first appeared in the Medline index around 1970 
(Figure 2.1).   23
 
Figure 2.1 Publication trends in gene therapy.  
A search of the Pubmed database was performed for each year with the search term “gene therapy”. 
A significant technical hurdle for the realisation of the gene therapy promise is the 
problem of inserting foreign DNA into mammalian cells. In 1961 Kay reported that 
cultured cells could take up naked DNA from the surrounding medium (10), but the 
process was extremely inefficient. A number of transfection reagents were later used 
to improve the efficiency of DNA uptake, and the first reasonably efficient solution to 
the problem was the calcium phosphate technique reported by Graham and coworkers 
in 1973 (11). In 1978, beta-globin became one of the first human genes to be cloned 
(12), and a number of authors were able to show that this and other functional human 
genes could be transfected into cells in culture (13). 
It was generally thought that calcium phosphate transfection was too inefficient to be 
clinically useful, but in 1979 Martin Cline at UCLA was able to show stable gene 
transfer of a drug resistance marker into mouse bone marrow transplants (14). In 
1980, Cline embarked on the first human gene therapy clinical trial in which bone 
marrow from beta-thalassaemia patients was transfected ex vivo with plasmids 
encoding the human beta-globin gene. Although no adverse effects were observed, no 
clinical benefit resulted either and the trial attracted much criticism for Cline’s failure 
to obtain permission for human studies from his university’s review board, as well as   24
the fact that the trial was performed in Israel and Italy, countries which had not yet 
established specific regulations for gene therapy trials. Cline subsequently lost his 
university chair and was stripped of most of his funding (reviewed in (15)). The 
controversy catalysed a significant public debate concerning the ethics and regulation 
of gene therapy trials, leading to the establishment of the National Institutes of Health 
Gene Therapy Subcommittee in 1984 for the regulation of gene therapy trials in the 
United States. The equivalent regulatory body in the United Kingdom, the Gene 
Therapy Advisory Committee, was established in 1993 on the advice of the Clothier 
Committee. 
The clear need for better vectors for the introduction of transgenic DNA into 
mammalian cells stimulated significant progress between 1979 and 1984, a brief 
period from which emerged virtually all of the major classes of gene therapy vector in 
use today. Viruses, as naturally-occurring vehicles for the introduction of foreign 
DNA into cells, were seen as promising candidates for vector development. This 
promise was realised with the publication of the first viral vector based on Simian 
Virus 40 in 1979 (16) followed in rapid succession by gammaretroviral vectors in 
1981 (17), adenoviral vectors in 1984 (18), and adeno-associated virus (AAV) vectors 
in the same year (19). A number of novel non-viral vectors were also first reported in 
this period, notably liposomes (20) and electroporation (21) in 1984. 
These vector systems were later refined, for example by splitting viral genomes so 
that viral protein coding sequences could be removed from vectors (22), the 
development of retroviral vectors based on the lentivirus HIV-1 for transduction of 
non-dividing cells (23), and the synthesis of the polycation polyethylenimine (PEI) for 
greatly improved non-viral transfection (24). A comparison of the major classes of 
gene therapy vectors is given in Table 2.1.  25
  Gamma-
retrovirus  Lentivirus Foamy  virus  Herpes  virus  Adenovirus  AAV  Non-viral 
Nucleic acid in 
vector 
RNA RNA RNA DNA DNA DNA DNA 
Packaging 
capacity 
~9kb  ~10kb ~12kb >30kb ~30kb 4.6kb  Unlimited 
Tropism  Broad Broad Broad  Neurotropic  Broad Broad Broad 
Packaging cell 
lines 
Good Poor  Moderate -  -  Poor  - 
Integration into 
host genome 
Yes Yes Yes  No  No  Rarely  Rarely 
Rearrangement 
of transgene 
+ - - - - - - 
Duration of 
transgene 
expression 
Long Long Long  Transient  Transient  Long  in 
postmitotic 
tissues 
Transient 
Transduction of 
postmitotic 
cells 
-  +  + +++  +++  ++ ++ 
Pre-existing 
host immunity 
None None None  Yes  Yes  Yes  None 
Safety 
concerns 
Insertional 
mutagenesis 
Insertional 
mutagenesis 
Insertional 
mutagenesis 
Inflammatory 
response 
Inflammatory 
response 
Low risk of 
insertional 
mutagenesis 
- 
Germline 
transmission 
-/+ +  ?  -  - +/- - 
Table 2.1 Properties of gene therapy vector types.  
Adapted from (25). AAV, adeno-associated virus; -, zero; -/+, equivocal; +, low; ++, moderate; +++, high. 
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The development of viral vectors improved the efficiency of gene transfer to the point 
where a clinical benefit from gene therapy could reasonably be expected and enabled 
the first fully regulated clinical trial in 1990 (26). In this trial, two children with 
severe combined immunodeficiency caused by a lack of adenosine deaminase activity 
(ADA-SCID) were treated by ex vivo retroviral transfer of the ADA gene into 
autologous T-lymphocytes which were subsequently returned to the patients. The use 
of autologous cells for immune transplants is preferable as it reduces the risk of acute 
graft versus host disease (27). No adverse effects were observed in the ADA-SCID T-
lymphocyte trial, and significant expression of ADA was detected in gene-modified 
cells recovered from the patients. However, transient transgene expression 
necessitated regular infusions of gene-modified cells, and the effectiveness of gene 
therapy may have been masked by continued use of polyethylene glycol-ADA 
enzyme replacement therapy, possibly removing the selective survival advantage 
conferred to gene-modified T-lymphocytes relative to their unmodified counterparts 
(28). 
The number of clinical trials initiated increased significantly over the course of the 
1990s, though by the end of the decade none had reported a clear and lasting clinical 
benefit. In 1999 the first serious adverse event due to a gene therapy protocol 
occurred during a trial using an adenoviral vector to treat the liver metabolic disorder 
ornithine transcarbamylase deficiency. An 18-year-old man named Jesse Gelsinger 
suffered a massive systemic inflammatory response to the adenovirus-5 serotype 
vector, leading to multiple organ failure and death within days of vector 
administration (29).   27
 
Figure 2.2 Gene therapy clinical trials approved worldwide 1989-2007.  
Source: Journal of Gene Medicine Clinical Trials database (30). 
The first clear success of gene therapy was reported in a French trial for X-linked 
severe combined immunodeficiency (SCID-X1) in 2000 (31). In this trial, the bone 
marrow of ten infants was extracted and cells were selected for the CD34 marker to 
enrich for haematopoietic progenitors. These were transduced ex vivo with a retroviral 
vector encoding the interleukin-2 receptor common gamma chain and infused into 
patients intravenously. In all but one patient, the protocol resulted in a normal T-
lymphocyte count within months of treatment and an antigen-specific response to 
immunisation. The effective immune system reconstitution enabled the withdrawal of 
immunoglobulin therapy in the majority of patients. A similar trial to treat ten patients 
in Britain also resulted in effective immune system reconstitution (32). However, both 
trials experienced serious adverse events in the form of T-cell leukaemia-like 
expansions originating in the thymus (33-35). To date, this event has occurred in four 
patients in the French trial, resulting in one death, and one expansion has also 
occurred in the British trial. It is presently believed that the initiating event in these 
expansions is chromosomal insertion of the retroviral vector causing dysregulated   28
expression of nearby proto-oncogenes through the action of an enhancer contained 
within the vector (36). The subject of insertional mutagenesis is discussed more fully 
in Section 2.2. 
Other notable gene therapy clinical trials (reviewed in (37;38)) include retroviral 
transduction of CD34 haematopoietic progenitors for the treatment of ADA-SCID 
(39;40), retroviral T-cell suicide gene therapy to control proliferation following T-cell 
and bone marrow transplant for leukaemia (41), retroviral anti-melanoma T-cell 
receptor immunotherapy (42), AAV-mediated neurotransmitter production for 
treatment of Parkinson’s disease (43), and AAV expression of RPE65 in retina for 
treatment of Leber’s congenital amaurosis (44). 
Effective gene therapy for other conditions is currently hampered by a number of 
technical hurdles. Firstly, patients may experience an immune response to the 
transgene product or the gene transfer vector itself, as was observed in a clinical trial 
using an AAV serotype 2 vector to treat haemophilia B (45). Secondly, efficient 
engraftment and expansion of cell transplants modified ex vivo may be limited in the 
absence of a significant survival advantage for transduced cells, as has been observed 
in clinical trials for anti-HIV gene therapy (46). Thirdly, expression of the transgene 
may be lost following promoter silencing, as may have occurred during a clinical trial 
to treat chronic granulomatous disease (CGD) (47;48). Fourthly, there may be no 
vector presently able to efficiently transduce the target cell population, as appears to 
be the case with gene therapy for cystic fibrosis (49). 
Although it has taken several decades for gene therapy to justify even a fraction of the 
early hype, the field is flushed with optimism following recent successes in clinical 
trials (50). Clinical application of gene therapy remains experimental, as witnessed by 
the fact that no gene therapy product has yet been approved for sale by the US Food 
and Drug Administration. Important technical challenges remain, but many are 
gradually yielding to a sustained research effort. Gene therapy protocols have resulted 
in the deaths of two patients as well as significantly improved health for dozens of 
others. In this sense gene therapy is maturing not into a miracle panacea, but rather a 
normal medical intervention.   29
2.2.  Insertional Mutagenesis 
Gene therapy for the group of haematopoietic disorders known as severe combined 
immunodeficiency (SCID) represents one of the most significant achievements within 
the field to date. SCID is a group of primary immunodeficiencies characterised by a 
severe defect in T-cell production and function, often accompanied by defects in B 
and NK cells. SCID is inherited in an X-linked or autosomal recessive fashion with an 
incidence of approximately 1 in 69,000 live births (51). A number of genes are known 
to produce a SCID phenotype, and the molecular basis of over 80% of SCID cases is 
known (52). The most common form (accounting for around half of all cases) is X-
linked SCID (SCID-X1) resulting from molecular defects in the IL2RG gene present 
on the X chromosome. IL2RG encodes the common gamma chain component (γc) 
which is present in a number of interleukin receptors. The loss of γc function disrupts 
multiple interleukin signalling pathways necessary for the development of 
haematopoietic cells, resulting in a T(-) B(+, but dysfunctional) NK(-) phenotype. 
These haematopoietic defects mean that children presenting with SCID have a 
severely compromised adaptive immune response to infection, and if untreated most 
will not survive beyond the second year of life. 
The immediate management of SCID includes antimicrobial drugs or 
immunoglobulin or enzyme replacement therapy. Long term immune reconstitution 
can be achieved through an allogeneic bone marrow transplant, which enables 
engraftment of haematopoietic stem and progenitor cells which are able to 
differentiate normally to produce T-cells. If a transplant can be obtained from an 
HLA-matched family donor, the long-term survival rates following this procedure are 
over 90% (53). However, survival rates are reduced in patients where a haploidentical 
donor is the best that is available, owing to a longer reconstitution phase and the need 
to use ablative chemotherapy to condition the patient for engraftment and immune 
reconstitution. There was previously a risk of graft-versus-host disease resulting from 
allogeneic T-cells present in the transplant (54), although this has been effectively 
addressed by the use of T-cell depletion of transplants. 
Gene therapy involving the transfer of DNA encoding the IL2RG gene into patient 
cells for autologous transplant represents an alternative to allogeneic bone marrow   30
transplant for SCID-X1. SCID-X1 is a particularly attractive candidate for gene 
therapy for a number of reasons, including the high cost of conventional treatments 
and a favourable risk-benefit ratio where an HLA-matched donor is not available as 
well as a proposed survival advantage for IL2RG-expressing cells resulting in a large 
and persistent population of these cells in patients after transplant. The existence of 
the IL2RG survival advantage is supported by a spontaneous reversion event in a 
SCID-X1 patient in which partial phenotypic correction resulted from a single 
somatic mutation (55). 
Two principal trials for gene therapy of SCID-X1 have been performed, each treating 
10 patients (32;56). The conduct of these two trials was very similar. Autologous 
bone marrow was extracted from patients, selected for CD34 to enrich for 
haematopoietic progenitor cells, and transduced ex vivo with a gammaretroviral vector 
carrying the IL2RG cDNA. Cells were then infused back into patients. Both trials 
were highly successful, resulting in engraftment and expansion of modified cells, 
correction of γc signalling, and significant immune reconstitution. However, four 
patients in the French trial and one in the British trial experienced a serious adverse 
event in the form of a dysregulated expansion similar to T-cell acute lymphoblastic 
leukaemia (T-ALL) (57-61). One of these patients subsequently died, but the others 
responded well to standard anti-leukaemia chemotherapy and retained a functioning 
adaptive immune system after treatment. The initiating event in these leukaemic 
events appears to have been integration of the gammaretroviral vector into host 
chromosomes leading to dysregulation of nearby known T-ALL proto-oncogenes. 
Vector integration into host chromosomes is necessarily a mutagenic event in that it 
alters the primary DNA sequence of the host. Semi-random integration patterns, as 
observed for retroviruses and DNA transposons, result in integration sites scattered 
widely throughout the genome. Insertion of DNA may affect functional elements 
already present at the integration site in a number of ways. Firstly, vectors may insert 
into and disrupt coding sequences, resulting in abnormal or prematurely terminated 
transcripts. Secondly, vectors may contain promoters able to read through the vector 
transcription termination site into neighbouring host genes. Thirdly, vectors may have 
enhancer activity able to dysregulate host promoters at distances up to hundreds of   31
kilobases in either direction from the integration site (62). Fourthly, vector insertion 
may disrupt other regulatory elements such as microRNA cistrons (63). 
Disruption of host sequences involved in cell cycle control, such as proto-oncogenes 
or tumour suppressor genes, can result in cell transformation and tumourigenesis. 
Insertional mutagenesis with retroviral or transposon vectors has been successfully 
used to identify cancer genes in large screens of mice (64;65). As an aside, it is 
important to note that the vectors used in these screens differ from gene therapy 
vectors in that they have been designed for maximum disruption of nearby host 
elements, for example by incorporating strong outward-facing promoters and splice 
donor or acceptor sites. Nonetheless, integration of conventional retroviral vectors 
resulting in transformation has been observed in both animal models (66) and two 
gene therapy clinical trials (67;68). Understanding and preventing this process is one 
of the major challenges facing the gene therapy field at the present time. 
Although the precise mechanism of leukaemic transformation in the SCID-X1 trials 
continues to be the subject of much study, a great deal is already known. In all cases, 
a latent period on the order of years was observed between transplantation of gene 
modified cells and subsequent leukaemic expansions. At the time of expansion, the 
polyclonal T-cell population became dominated by one or a small number of T-cell 
clones. In four of the five leukaemic patients, dominant clones were found to contain 
retroviral insertions within or near the known T-ALL proto-oncogene LMO2 (69;70). 
This gene was overexpressed in mature T lymphocytes, probably as a result of the 
enhancer activity of the vector promoter. Insertions near other T-ALL proto-
oncogenes such as LYL1 have also been identified. A general model has been 
proposed in which insertional mutagenesis leads to continued expression of 
developmental genes which are normally expressed in haematopoietic stem cells but 
subsequently downregulated during immature T-cell development, and this continued 
expression disrupts the normal T-cell expansion and maturation processes in the 
thymus (71). Although a single retroviral insertion appears to be sufficient to initiate 
progression to leukaemia, other insertions and acquired somatic mutations most likely 
contributed to the observed expansions (72). 
Interestingly, clonal dominance in granulocytes caused by retroviral integration near 
proto-oncogenes was also observed in a gene therapy clinical trial to treat CGD,   32
though in this case it is believed the expansions contributed to the temporary 
therapeutic benefit observed in these patients by increasing the number of gene 
corrected cells in circulation (73).  
Much effort has been made to understand the risk factors underlying these events so 
that the lessons can be applied to future gene therapy trials for both SCID-X1 and 
other conditions. The major suspects in SCID-X1 leukaemogenesis include the 
immune deficiency of the patients, haematopoietic ‘stress’ experienced during 
immune reconstitution, the enhancer activity of the vector promoter, the proposed 
oncogenic potential of the IL2RG transgene, and the integration preferences of 
gammaretroviral vectors. 
It is known that immunodeficiency increases the risk of malignancy, and it has been 
suggested that the low NK cell number following SCID-X1 gene therapy might have 
compromised immunosurveillance of leukaemic cells (74;75). However, an increased 
incidence of leukaemogenesis has not been reported in patients receiving an 
allogeneic bone marrow transplant for SCID-X1. Typically, these patients also have 
low NK cell counts. 
It has been suggested that transplanted cells experience haematopoietic ‘stress’ due to 
rapid expansion and forced clonal selection for gene modified cells (76). For example, 
murine bone marrow transduced with retroviral vectors expressing a reporter gene can 
become leukaemic following serial transplantation (77). A rhesus macaque which 
received a bone marrow transplant marked with a drug resistance gene developed 
leukaemia some years after cytotoxic chemotherapy to select for gene modified cells 
(78). The dramatic selective proliferation advantage conferred to engrafted cells 
during SCID-X1 gene therapy may have resulted in a similar clonal imbalance. 
The best-defined risk factor in the SCID-X1 leukaemic events remains overexpression 
of the LMO2 proto-oncogene (79), most likely driven by the enhancer activity of the 
gammaretroviral vector long terminal repeat (LTR) promoter. It seems probable that 
this event is particular to the biology of SCID-X1, though other tissues and conditions 
may have their own oncogenic soft spot as was shown by a common insertion site 
present in mouse hepatocellular carcinomas following insertional mutagenesis by an 
AAV vector (80). Modifications to the vector design which minimise enhancer   33
activity may improve the safety of these vectors. For example, self-inactivating 
gammaretroviral vectors in which the strong LTR promoters are replaced with an 
internal promoter show reduced transactivation of neighbouring genes and in vitro 
immortalisation, though a lower level remains if the internal promoter also possesses 
enhancer activity (81). Reduction of enhancer activity may be achieved through 
careful choice of the internal promoter (82), and also by placing chromosomal 
insulators within vectors in order to prevent enhancers within the vector from acting 
on neighbouring host genes (83;84). 
Constitutive retroviral expression of the IL2RG transgene has been argued to be 
oncogenic. A mutagenesis screen identified a tumour carrying insertions at both 
IL2RG and LMO2 (85), and a study was performed in which SCID-X1 mice treated 
with a lentiviral vector expressing IL2RG developed T-cell lymphomas while the 
enhanced green fluorescent protein (eGFP) expressing control mice did not (86). This 
study has been disputed by others on the grounds that the high vector copy numbers 
and overexpression of IL2RG in this model did not accurately reflect the conditions of 
the clinical trials (87). 
Lastly, the integration site preferences of the gammaretroviral vectors used in the 
SCID-X1 trials may have contributed to their leukaemic potential. It is known that 
gammaretroviral vectors integrate preferentially near transcription start sites and CpG 
islands (88). The level of risk due to these preferences relative to randomly distributed 
integration sites is not known, but alternative integrating vectors with different 
preferences do exist. For example, lentiviral vectors integrate preferentially within 
active genes (89) and the Sleeping Beauty transposon has an almost random 
integration profile (90). A direct in vitro or in vivo comparison of the oncogenic 
potential of these different integration patterns is difficult because these vectors differ 
greatly in their target cell tropism. In a tumour-prone mouse model, self-inactivating 
lentiviral vectors carrying an enhancerless internal promoter showed no detectable 
increase in tumour formation, in contrast to gammaretroviral vectors carrying full 
LTR promoters (91). This study did not address the relative roles of the promoters and 
integration profiles in tumourigenesis. Rarely, patients infected with wildtype HIV 
develop lymphomas associated with a common chromosomal insertion site (92), but 
the relevance of this observation for pseudotyped lentiviral vectors in other cell types   34
is not clear. An understanding of the role played by integration site preferences in 
vector oncogenic potential requires a like-for-like comparison in relevant in vivo 
models for insertional mutagenesis, and such studies have not yet been reported. 
2.3.  Integrating Vectors for Gene Therapy 
A number of vectors currently being developed for gene therapy actively integrate the 
vector DNA into target cell chromosomes. The main advantage of integration is that it 
is capable of yielding stable, long-term transgene expression, particularly in mitotic 
tissues. 
All episomal nuclear DNA is probably capable of ‘background’ integration into 
chromosomes under the action of host DNA repair proteins. For example, adenoviral 
vectors integrate into chromosomes at low frequency (~10
-4 integrations per 
intracellular vector genome), often through illegitimate recombination between 
regions of microhomology on both vector and chromosome (93). However, this 
phenomenon is likely to be too inefficient to be useful for most applications. By 
contrast, integrating vectors actively catalyse integration using vector-derived 
proteins. This section describes the major classes of integrating vector employed to 
date. 
2.3.1.  Retroviral Vectors 
The family of retroviruses is known as Retroviridae and consists of a number of 
enveloped positive-sense single-stranded RNA viruses for whom reverse transcription 
and chromosomal integration of the viral genome are essential stages of the cell cycle. 
Within this family, the gammaretrovirus, lentivirus, and spumavirus (foamy virus) 
genera have been developed as vectors for gene therapy. 
The retroviral vector used in this study was an HIV-1-based lentiviral vector, so the 
following summary is focused principally on this virus. However, where important 
differences exist between lentiviruses and gammaretroviruses or foamy viruses, these 
are described.   35
2.3.1.1.  The Molecular Biology of HIV-1 
 
Figure 2.3 Life cycle of a simple retrovirus. 
 
Over the course of their life cycle, retroviruses alternate between two major forms 
known as the provirus and the virion (Figure 2.3; reviewed in (94)). The provirus 
consists of double-stranded DNA integrated into a host cell chromosome. Viral RNA 
and proteins are expressed from the provirus using the host’s own transcription and 
translation apparatus. These are subsequently packaged at the host plasma membrane 
into virion particles which are enveloped by a host-derived lipid membrane. The 
resulting virion can bind to and enter a new host cell, reverse transcribe its genome to 
regenerate the DNA form, and then integrate this into a host cell chromosome as a 
new provirus.   36
 
Figure 2.4 HIV-1 provirus and polyprotein structure.  
(a) Structure of an HIV-1 provirus. LTR, long terminal repeat (subdivided into U3, R, and U5 regions); 
PBS, tRNA primer binding site; Ψ, RNA packaging signal; gag, polyprotein encoding virion structural 
components; pro-pol, polyprotein encoding viral enzymes; vif, vpr, vpu, and nef, accessory genes; rev 
and tat, regulatory genes; PPT, polyprurine tract. (b) HIV-1 Gag and Gag-Pol polyproteins. MA, 
matrix; CA, capsid; p1, p2, and p6, spacer peptides; NC, nucleocapsid; fs, ribosomal frameshift site; 
PR, protease; RT, reverse transcriptase; IN, integrase. 
Transcription 
Transcription of proviral DNA by the host RNA polymerase II (PolII) enzyme is 
driven by the U3 promoter within the 5’ long terminal repeat (LTR). Most of the 
regulation of transcription occurs through host transcription factors acting on binding 
sites present within the U3 promoter (compiled in (95)). HIV-1 regulates its own 
transcription through the virus-encoded Tat protein. In the absence of the Tat protein, 
viral transcription from the HIV-1 5’ LTR yields short, non-polyadenylated RNA 
(96;97). Tat binds to a trans-activator response region which forms a stem-loop 
structure within the 5’ R region of the nascent viral RNA (98). It is thought that this 
interaction allows Tat to recruit host proteins concerned with transcription and 
chromatin remodelling, allowing viral transcription to continue normally. 
Gammaretroviruses do not regulate their transcription in this way, but foamy viruses 
express a transactivator protein with a similar function (99). 
During processing the transcript receives a 5’ cap (100) and a 3’ poly-A tail (101) 
using the same machinery as host PolII-transcribed mRNA. HIV-1 produces at least   37
thirty different mRNAs through alternative splicing at approximately four splice 
donor and eight splice acceptor sites, though at least half of its mRNA remains 
entirely unspliced (102). This complexity enables HIV-1 to express multiple genes 
from a single promoter, and also contributes significantly to the plasticity of HIV-1 
gene expression. Splicing in gammaretroviruses is less complex, resulting in only two 
mRNA species. 
Splicing of cellular mRNAs is linked to their nuclear export. Typically, unspliced host 
mRNAs remain in the nucleus until they are degraded. The unspliced virus mRNA 
species is necessary for both the production of the proteins it encodes and its role as 
the virion genome, so specialised nuclear export mechanisms have evolved. The Rev 
protein of HIV-1 binds to the Rev response element (RRE) on unspliced viral RNA, 
mediating its nuclear export (103) via a leucine-rich nuclear export signal (104). 
Gammaretroviruses do not express a Rev protein, but the packaging signal (Ψ) may 
contribute to nuclear export of unspliced mRNA (105). 
Translation 
Translation of retroviral mRNA is carried out by host ribosomes. The HIV-1 Rev 
protein has been shown to enhance the translation of RRE-containing mRNA through 
increased ribosomal association (106). This may be a means of compensating for the 
low basal rate of translation due to the very different codon usage in HIV-1 and 
humans (107). 
Although viral transcripts carry a 5’ cap, initiation of translation does not occur 
through the normal ribosome-scanning mechanism, possibly because there is 
significant RNA secondary structure upstream of the translation start site. Instead, an 
internal ribosome entry site (IRES) upstream of gag may be used to initiate translation 
of unspliced transcripts (108). 
Translation of unspliced viral mRNA gives rise to the Gag and Gag-Pol polyproteins. 
Gag contains the structural proteins matrix (MA), capsid (CA), and nucleocapsid 
(NC). In addition to these, Gag-Pol contains the enzymes protease (PR), integrase 
(IN), and reverse transcriptase (RT). Gag and Gag-Pol are translated from the same 
mRNA transcripts in a ratio of approximately 20:1 (109). Translation of Gag-Pol   38
requires bypassing of the Gag termination codon. HIV-1 achieves this through 
ribosomal frameshifting, whereby the ribosome slips back one nucleotide into the Pro-
Pol reading frame when it reaches the end of gag (110). This process is enabled by the 
presence of a 7 nucleotide ‘slippery’ sequence which allows the slippage and 
subsequent restoration of base-pairing between the A and P site tRNAs and the 
transcript (111) and is augmented by an RNA stem loop downstream of the shift site 
(112). 
Gag is myristoylated during translation in the cytosol (113). This involves the 
attachment of the 14-carbon fatty acid myristate to the N-terminal glycine of Gag. The 
myristate moiety acts together with a basic N-terminal membrane binding (M) domain 
(114) to allow Gag to become membrane-associated. 
The retroviral envelope protein is encoded by env. This is translated as a polyprotein 
from a spliced mRNA. Like virtually all host transmembrane proteins, the Env 
polyprotein carries an N-terminal signal peptide which allows targeting to the rough 
endoplasmic reticulum by the signal recognition peptide. The C-terminal region 
contains a stretch of hydrophobic amino acids that are inserted into the membrane, 
where they act as a transmembrane anchor (115). Env is glycosylated in the 
endoplasmic reticulum during translation. This occurs at 24 sites in HIV-1 (116), and 
the sugars are subsequently modified by host enzymes. Glycosylation moieties are 
critical for correct Env folding and cleavage but Env remains functional if they are 
removed after these processes are complete (117;118). In addition to its role in Env 
processing, glycosylation probably acts to protect the peptide backbone of the 
envelope protein from neutralising antibody recognition (reviewed in (119)). 
Env oligomerises in the Golgi apparatus, thus becoming competent for receptor 
binding. Recent results suggest that the HIV-1 Env polyprotein forms trimers (120). 
In their oligomeric form, the polyproteins are cleaved by host proteases at the furin 
recognition site (121), resulting in heterodimers of surface (SU) and transmembrane 
(TM) proteins. This cleavage exposes the fusogenic peptide of TM (122), making the 
Env oligomers competent for cell fusion. 
All retroviruses express the basic genes gag, pro, pol, and env. In addition, HIV-1 
expresses the essential regulatory genes tat and rev described above and the four   39
accessory genes vif, vpr, vpu, and nef. The accessory genes are often multifunctional 
and their diverse roles in the HIV-1 life cycle are an area of active research (reviewed 
in (123)). However, a unifying theme that has recently emerged is that HIV-1 
accessory genes frequently act to protect the virus from restriction factors, host 
proteins which serve as antiviral defences at multiple points in the viral life cycle. 
Vif is thought to be a viral countermeasure against the antiviral activity of the host 
cytidine deaminase APOBEC3G (124). In the absence of Vif, APOBEC3G is 
packaged into virions (125), where it reduces virion infectivity by editing the viral 
genome (126). When Vif is expressed in producer cells, APOBEC3G is targeted for 
degradation by proteasomes (127). 
The Vpr protein has at least five proposed functions: enhancing the fidelity of reverse 
transcription, possibly by recruiting a host uracil DNA glycosylase to virions 
(128;129); assisting nuclear import of the preintegration complex (130); causing cell 
cycle arrest at the G2/M boundary (131;132); activating transcription from the HIV-1 
LTR promoter (133); and cell killing (134;135). 
Vpu may protect the provirus from superinfection by targeting the viral receptor CD4 
for degradation (136;137) and also enhances the release of virions from cells by 
counteracting the host restriction factor tetherin (138). 
Among other functions, Nef also reduces CD4 presentation at the cell surface (139). It 
downregulates the cell surface presentation of MHC class I (140) and class II (141). 
The advantage of these activities to the virus is not well understood. Nef is also 
thought to assist infectivity by enhancing penetration of the viral core through the 
actin network adjacent to the cell surface (142). 
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Virion Assembly and Budding 
 
Figure 2.5 HIV-1 virion budding.  
Transmission electron micrographs showing HIV-1 virions (a) during and (b) after budding from a T-
lymphocyte. Source: Public domain images from (a) the Centers for Disease Control Public Health 
Image Library and (b) the National Institutes of Health AIDS History Image Archive. 
Virion assembly requires the subcellular co-localisation of the viral Gag, Gag-Pol, 
and Env proteins together with the viral RNA genome and a number of essential host 
factors. 
The Gag polyprotein is the major structural component of the immature virion and 
can induce the assembly and budding of virus-like particles in the absence of other 
viral components (143;144). Gag multimerisation is an essential step in the formation 
of virions. Gag-Gag interactions are mediated by the interaction (I) domain (145) and 
occur almost exclusively on cellular membranes following myristoylation. Gag-Pol 
may multimerise in the same way using its Gag region, but it can package into virions 
independently of this (146). There are estimated to be 2000-5000 molecules of Gag in 
each HIV-1 virion (147).   41
A number of HIV-1 accessory genes are packaged into virions. Vpr appears to be 
packaged in a molar ratio of about 1:7 with Gag (148). Packaging of Vpr occurs 
through an interaction with the p6 region of Gag (149). Nef is estimated to be present 
at 10 to 100 particles per virion (150). Vif is present at detectable levels in immature 
virions but is largely absent following maturation (151). 
Unspliced viral genomic RNA is recruited to nascent virions as a dimer through an 
interaction between the nucleocapsid (NC) region of Gag and a packaging signal (Ψ) 
which for HIV-1 consists of four stem loops present in the RNA secondary structure 
(152).  
Host factors recruited to virions include the tRNA primer for first strand DNA 
synthesis during reverse transcription (tRNA
lysine-3 for HIV-1) which is packaged via 
an interaction with the Gag-Pol polyprotein (153). Many host proteins are also 
packaged into retroviral virions (reviewed in (154)). Well-studied examples include 
HLA-II, cyclophilin A, and actin. For most of these proteins it is not known whether 
they serve some function for the virus, represent a host antiviral defence, or are 
packaged unintentionally because of their subcellular location. 
Recruitment of Env to nascent virions is poorly understood. No region of Env that is 
necessary or sufficient for efficient packaging into virions has been defined. 
Paradoxically, nascent retroviral virions are able to incorporate envelope proteins 
from other enveloped viruses which show no homology to their own Env protein, a 
phenomenon known as pseudotyping (155). This suggests that rather than specific 
recognition between the Gag and Env proteins, co-localisation of these factors occurs 
within a specific subcellular structure, possibly lipid rafts (reviewed in (156)). The 
lipid raft model of virion assembly suggests that lipid rafts provide foci within cell 
membranes in which viral components interact weakly but cooperatively until they 
form aggregates capable of budding.  
Budding is the process by which rafts of multimerised Gag and other components 
form into spherical bodies surrounded by a host-derived lipid membrane which has 
been separated from the producer cell. It has been suggested that retroviruses make 
use of a pre-existing host exosomal pathway (multivesicular budding, MVB) in both 
virion budding and cell entry (157). Exosomes are small membrane-bound bodies   42
which bud away from the host cell during normal cellular exchanges with the external 
environment. Retroviral virions are a similar size to exosomes (~100nm), and the 
MVB protein Tsg101 plays an essential role in HIV-1 budding through an interaction 
with the p6 region of Gag (158). Exosomes can form either immediately in endosomal 
domains at the plasma membrane or via budding into endosomes within the cell. This 
parallels the observation that HIV-1 buds into endosomes in macrophages and at the 
cell surface in T-cells (159). 
Virion Maturation 
During or soon after budding, virions undergo a dramatic morphological transition 
known as maturation. Maturation causes a shift in virion electron density from the 
envelope into the core. This process is dependent upon processing of viral Gag and 
Gag-Pol by the viral protease to yield active virus proteins. Virions are non-infectious 
prior to maturation. 
 
Figure 2.6 Schematic view of a mature retroviral virion.  
Adapted from (160). 
Processing of the polyproteins takes place in an ordered fashion due to differences in 
the rate of cleavage at each site. In HIV-1 Gag, cleavage occurs first between the p2 
peptide and NC, then at the MA-CA and p1-p6 boundaries, and finally at the CA-p2 
and NC-p1 boundaries. In Gag-Pol, p2-NC cleavage is followed by cleavage at the   43
RT-IN and MA-CA boundaries, and lastly sites flanking PR (161). It is not known 
whether the ordering of cleavage events has any biological significance. Nef is also 
cleaved by the viral protease during maturation (162). 
In the mature virion (Figure 2.6), MA is proposed to be bound to the envelope, CA 
forms the outer shell of the virion core, and NC associates with the viral genome. 
Thus, the shift in electron density during maturation is likely to be the result of the 
release of CA and NC from membrane-bound Gag followed by their migration and 
reassembly at the virion core. 
NC has been shown to promote proper annealing of the tRNA primer to the genomic 
RNA primer binding site (PBS) during maturation (163), probably by helping to open 
the RNA secondary structure (164). The mechanism of annealing is controversial 
(reviewed in (165)). 
Cell Entry 
The major determinant of viral tropism is recognition of a host cell surface receptor 
by the virion Env protein. However, this is not the initial contact between the virion 
and the cell. A number of non-receptor molecules have been implicated in initial 
binding of HIV-1 to the cell surface, including nucleolin (166), LFA-1 (167), heparan 
sulphate proteoglycan (168), and a dendritic cell surface protein known as DC-SIGN 
(169), perhaps allowing HIV-1 to use dendritic cells as a vehicle for transport into 
lymph glands in order to reach the host T cell population. 
Following the initial contact, a specific interaction between Env and the host receptor 
is necessary for successful viral entry. The primary receptor for HIV-1 is CD4 (170), 
but successful infection also requires the coreceptors CCR5 (171-175) and/or CXCR4 
(176), which are both involved in chemokine signalling. Initial binding between the 
HIV-1 Env protein and CD4 alone does not enable an interaction between the fusion 
peptide and the cell membrane. Instead, it is thought that the initial contact between 
SU and CD4 induces a conformational change in SU, revealing a strongly conserved, 
high-affinity coreceptor binding domain. In this way, HIV-1 is able to keep its 
conserved binding site buried until it is immediately adjacent to the cell surface, by 
which point neutralising antibody recognition is sterically impossible (177).   44
Coreceptor binding leads to exposure of the TM fusion peptide (178), which may 
allow a hydrophobic stretch of TM known as the fusion peptide to interact with the 
cell membrane, possibly in a manner resembling the ‘spring-loaded’ mechanism of 
influenza haemagglutinin (179). 
For the viral capsid to enter the cytosol, fusion between the host and virus membranes 
must take place. Retroviruses employ the type I fusion pathway (reviewed in (180)). 
After receptor recognition, the viral TM is believed to insert its fusion peptide into the 
host cell membrane. It subsequently collapses into a six helical bundle (6HB) 
conformation, releasing free energy and bringing the membranes into close proximity 
for fusion (181). This initially results in a small, labile pore but later develops into a 
larger, robust pore that can pass the capsid into the cytosol. 
As with budding, the site of virus membrane fusion is open to question. Enveloped 
viruses are able to fuse with host membranes at the cell surface or at endosomal 
membranes following endocytosis. Endocytosis can take place via clathrin-coated 
pits, caveolae, and pathways independent of both clathrin and caveolae such as 
macropinocytosis. It was initially thought that uptake of HIV-1 particles by 
macropinocytosis was possible but unlikely to lead to productive infection as virions 
were ultimately degraded in the lysosome (182). However, virus infectivity by this 
pathway is dependent upon the culture conditions employed (183). Associations 
between HIV-1 infection and clathrin-mediated (184) and caveolar (185) endocytosis 
have been identified.  
Reduction of host membrane glycosphingolipid (186) and cholesterol (187) content is 
known to reduce HIV-1 fusion, suggesting a role for lipid rafts in this process. CD4 
and CCR5 appear to be associated with lipid rafts during productive HIV-1 infection 
(188), though this association may not be necessary for successful viral entry (189). 
Expression of Nef in the producer cell may increase HIV-1 entry via an endocytic 
pathway (190), possibly by enhancing the cholesterol content of the virions (191) and 
its influence on fusion. However, other studies have cast doubt on the role of Nef in 
fusion (192;193), and Nef is not required for HIV-1 pseudotypes which enter cells via 
pH-dependent endocytosis (194). These seemingly contradictory results may reflect 
the existence of multiple pathways for cell entry of HIV-1.   45
Uncoating 
Uncoating refers to post-entry changes in the protein composition of the intact viral 
core as it becomes first a reverse transcription complex (RTC) in which viral DNA 
synthesis occurs, and then a preintegration complex (PIC) which is competent for 
integration into the host genome. Uncoating, reverse transcription, and transport to the 
nucleus appear to be related processes. For example, intact cytoskeletal actin 
microfilaments are essential for efficient reverse transcription (195). However, the 
timing, location, and protein requirements of the post-entry processes are poorly 
understood.  
HIV-1 cores appear to carry out most uncoating soon after entry. RT, IN, NC, 
phosphorylated MA (196), and Vpr have been detected in the HIV-1 RTCs and PICs, 
but CA appears to rapidly dissociate (197-199). Nef has been ascribed a possible role 
in uncoating or reverse transcription (200) and may contribute to the progression of 
infaction by disrupting the cortical actin network and allowing the viral core to 
proceed into the cell (201). In human cells, post-entry association of viral cores with 
target cell-derived cyclophilin A appears to promote infection. The mechanism is not 
known, but may be related to the action of the host TRIM5α restriction factor which 
acts during uncoating (202;203). 
RTC/PICs are too large to diffuse through the cytoplasm at the speeds necessary for 
productive infection, so it is thought that they migrate towards the nucleus through 
interactions with the host cytoskeleton. An interaction between HIV-1 MA and actin 
microfilaments has been identified soon after viral entry (204), IN is known to interact 
with yeast microtubule associated proteins (205), and NC enables packaging of actin 
into budding virions (206). McDonald et al have visualised the movement of eGFP-
tagged PICs along microtubules towards the centrosome (207). These observations 
are consistent with a model in which HIV-1 initially uses actin microfilaments in 
order to access the microtubule network. 
Reverse Transcription 
The requirement for reverse transcription during the replicative cycle is the defining 
feature of retroviruses. Most (but not all) HIV-1 RTCs are thought to complete   46
reverse transcription prior to nuclear entry (208). The essential catalytic activities for 
this process are provided by reverse transcriptase (RT). Interestingly, foamy viruses 
are able to reverse transcribe their DNA prior to budding from the producer cell (209). 
HIV-1 RT has two major activities. Its C-terminal portion has RNase H activity which 
cleaves RNA, but only in RNA:DNA duplex form. The N-terminal portion carries out 
RNA- or DNA-dependent DNA polymerisation. The viral genomic RNA is cleaved 
into 6-14nt fragments by RNase H activity during minus strand DNA synthesis, but 
these activities are functionally uncoupled and so need not be catalysed by the same 
enzyme (210-212). DNA synthesis by RT is thought to be relatively error-prone, with 
estimated mutation rates of 10
-4 to 10
-5 mutations per base-pair per cycle (reviewed in 
(213)).  
Reverse transcription begins with synthesis of minus strand DNA by RT. The primer 
for minus strand DNA synthesis during reverse transcription is a host-derived 
tRNA
lysine-3 primer (214) which is annealed to the primer binding site (PBS) through 
the action of NC during maturation (215). The initiation complex is initially unstable 
resulting in slow synthesis of DNA, but the rate of polymerisation increases 3400-fold 
upon addition of the seventh dNTP (216). 
Minus strand DNA synthesis proceeds to the 5’ end of the viral genomic RNA and is 
followed by transfer of the minus-strand cDNA to the RNA 3’ end (217). The minus-
strand cDNA product synthesised before minus-strand transfer is also known as 
minus-strand strong stop DNA (-sssDNA) from in vitro experiments, but the difficulty 
of detecting it in vivo implies that minus-strand transfer is relatively efficient (218). 
This transfer can occur either intra- or intermolecularly (219) and may be enhanced 
by the ability of NC to act as a chaperone for processes which require melting and 
reannealing of nucleic acids (220). 
Minus-strand transfer occurs through interactions between the cDNA and 3’ RNA R 
sequences. There is some debate as to the relative importance of R sequence 
homology, cis elements, and local secondary structure for efficient transfer (221-223). 
An acceptor invasion mechanism for minus-strand transfer has been proposed (224) in 
which initial binding between the cDNA and the 3’ RNA is followed by displacement   47
of cleaved RNA remnants from the cDNA by branch migration. Ultimately, the 
cDNA 3’ terminus is transferred onto the 3’ RNA.  
The transferred minus-strand DNA acts as a primer for continued DNA synthesis up 
to the 5’ end of the remaining RNA (the 5’ end of the PBS). As it proceeds, this 
process creates an RNA:DNA duplex which is cleaved by the RNase H activity of RT 
in a relatively sequence-independent manner. However, a polypurine tract (PPT) 
immediately upstream of their 3’ LTR is recognised and cleaved specifically at its 3’ 
terminus and also at or near the 5’ terminus by the RNase H activity of RT (reviewed 
in (225)). The resultant DNA-duplexed RNA acts as the primer for plus-strand DNA 
synthesis by RT. 
RT commences plus-strand DNA synthesis using the PPT as a primer and the minus-
strand DNA as a template. The RNA-DNA junction at the 3’ end of the PPT is later 
cleaved by a second RT enzyme (226). Plus-strand synthesis continues until it reaches 
the end of the tRNA PBS. The formation of a short tRNA:DNA duplex allows 
removal of the tRNA primer by RNase H activity (227). Following the completion of 
plus-strand synthesis, plus-strand transfer takes place. 
The DNA strand formed from the first period of plus-strand synthesis is known as 
plus-strand strong stop DNA (+sssDNA). Plus-strand transfer occurs through base-
pairing of the PBS on the two DNA strands (228). 
Following plus-strand transfer, DNA synthesis continues in both directions to the end 
of the LTRs. Unlike other retroviruses, a second, central polypurine tract (cPPT) has 
been identified in a number of lentiviruses including HIV-1 (229). This acts as a 
second primer for plus-strand synthesis. After plus-strand transfer, continued 
synthesis through the cPPT leads to strand displacement and the formation of a 99 
nucleotide single-stranded DNA flap (230). This flap was thought to play a critical 
role in the ability of lentiviruses to infect nondividing cells, but this has been 
questioned in later reports. 
Nuclear Entry   48
Lentiviruses such as HIV-1 can integrate into and productively infect non-dividing 
cells (231), while gammaretroviruses such as the Moloney murine leukaemia virus 
(MoMLV) cannot (232). This observation led to the hypothesis that 
gammaretroviruses are unable to cross the nuclear envelope and so can only gain 
access to chromosomes for integration when the envelope breaks down during 
mitosis, while lentiviruses possess at least one element which permits transport of the 
PIC across the nuclear membrane.  
The cPPT, MA, IN, and Vpr were all suggested as possible candidates, but further 
research has cast doubt on all of these (reviewed in (233)). The cPPT-derived central 
DNA flap been shown to enhance lentiviral vector-based gene transfer to non-
dividing cells under some conditions (234), but its effectiveness has proven to be 
highly variable (235;236). MA carries two basic nuclear localisation signals (NLS) 
(237) which allow it to enter via the nuclear pore through interactions with importin 
proteins, but viruses severely depleted in MA are still able to enter the nucleus, so it 
does not appear to be essential for this process (238). A putative IN NLS was found 
(239) but later disputed (240;241). Vpr-deficient virus can productively infect 
nondividing cells with reduced efficiency (242). 
Yamashita and Emerman constructed an HIV-1-based virus in which Vpr was 
removed, the cPPT was inactivated by mutation, and the HIV-1 IN and MA were 
replaced with their MoMLV counterparts (243). This virus showed no difference in 
infectivity between dividing and nondividing cells, implying that the ability of 
lentiviruses (but not gammaretroviruses) to infect nondividing cells has little to do 
with any of these proposed nuclear-localising factors. The authors argued instead that 
CA is the key determinant, and HIV-1 particles carrying the MoMLV CA protein are 
indeed unable to infect nondividing cells (244). CA is thought to dissociate relatively 
rapidly from HIV-1 cores during uncoating but remain associated with MLV cores up 
to the nuclear envelope. Complete retroviral capsids may be too large to enter the 
nucleus through nuclear pores. 
Integration 
Integration of the viral DNA into a host chromosome regenerates the provirus and is 
an essential step in the retroviral life cycle (reviewed in (245)). Integration is   49
catalysed by the integrase, a ~290 amino acid protein consisting of three domains: an 
N-terminal domain containing an HHCC zinc finger motif (246); the catalytic core 
domain in which a DDE motif coordinates the Mg
2+ ions that catalyse integration 
(247); and a C-terminal domain which contains an SH3 fold involved in sequence-
nonspecific DNA binding (248). It is likely that all three domains contribute to DNA 
binding (249;250).  
Linear viral DNA in the nucleus may be converted to 1-LTR or 2-LTR circles by 
homologous recombination or non-homologous end joining in the nucleus. Unlike the 
linear form, these are not efficient substrates for the integration reaction (251;252).    50
 
Figure 2.7 HIV-1 integration.  
The 3’ ends of the preintegration complex are first processed by HIV integrase, releasing two GT 
dinucleotides. The resulting recessed 3’ hydroxyl groups attack phosphate groups on the target 
chromosome during the strand transfer reaction. Host DNA repair proteins subsequently remove the 
dinucleotide overhangs and fill in the single stranded DNA, resulting in a short duplication of host 
sequence flanking the integrated provirus. P, phosphate group in DNA backbone. Adapted from (253). 
Two nucleophilic attacks comprise the integration reaction mechanism at each end of 
the linear DNA molecule. Initially, the Mg
2+ ion of integrase deprotonates water 
molecules, activating them as nucleophiles able to attack near each 3’ end of the viral   51
DNA, displacing two nucleotides and exposing a conserved CA dinucleotide. This 
reaction is known as 3’ end processing (254). It is thought to take place very soon 
after the completion of reverse transcription, which for most PICs means prior to 
nuclear entry. Subsequent nuclear entry and binding of integrase to a host cell 
chromosome brings the viral and target DNAs into close proximity. The 3’ hydroxyl 
group on the processed viral LTR is sufficiently nucleophilic to attack the target DNA 
strand. This is known as the strand transfer reaction. Both LTRs attack the target 
DNA at sites a few base pairs apart, resulting in a joining intermediate (255). The 
intermediate is resolved by unpairing the target strand bases between the two 
positions at which the strands are joined. This results in two sections of 
complementary, unpaired sequence at either end of the proviral insertion which are 
most likely repaired by host DNA repair factors (256), producing a 5bp duplication of 
host sequence at either end of the insertion. 
A number of host proteins may participate in HIV-1 integration (reviewed in (257)). 
Significant among these is the chromatin-tethering factor LEDGF/p75 (reviewed in 
(258)). In addition to its tight association with chromatin throughout the cell cycle, 
LEDGF/p75 binds to HIV-1 integrase via a C-terminal integrase binding domain 
(IBD) (259). Knockdown of LEDGF/p75 expression or overexpression of dominant 
negative LEDGF/p75 containing an IBD but no chromatin binding domain severely 
inhibits HIV-1 integration (260). It has been suggested that chromatin-associated 
LEDGF/p75 acts as a chromosomal receptor for the HIV-1 PIC, tethering it to the 
chromosome and thereby promoting the strand transfer reaction. 
The pattern of chromosomal integration by HIV-1 and other retroviruses was for 
many years believed to be virtually random. More recently, the occurrence of severe 
adverse events related to retroviral integration during gene therapy, combined with the 
availability of methods to clone, sequence, and map integration sites, has led to a 
greater understanding of retroviral integration site preferences. Retroviral integration 
is not thought to be strongly dependent upon primary sequence, but weak consensus 
sequences have been detected at HIV-1 integration sites (261-263). Interestingly, the 
consensus sequences are palindromic, and the centre of rotation is the centre of the 
host sequence that is duplicated during integration. The weakness of the consensus 
sequences suggests that the contribution of primary sequence to HIV-1 integration site   52
selection is not one of specific recognition of base pairs by integrase, but rather that 
particular sequences result in local physical properties of DNA such as bendability 
and protein deformability that are conducive to the mechanism of integration (264). 
The position of DNA binding proteins can affect local target site selection. Sequence-
specific DNA binding proteins can block integration into their binding site, possibly 
through steric interference (265). The outward-facing major groove of DNA wrapped 
around nucleosomes is favoured as a target for integration in vitro and  in vivo   
(266;267), perhaps because the distortion of the target DNA makes the integration 
reaction more energetically favourable. 
On a larger scale, HIV-1 displays a preference for integration into actively 
transcribing genes (268). The mechanism by this preference comes about is not well 
understood (reviewed in (269)). Knockdown of LEDGF/p75 in target cells biases 
HIV-1 integration away from active genes and towards CpG islands and transcription 
start sites, suggesting a role for this factor in HIV-1 integration site selection (270). 
Although there is a high degree of sequence homology between retroviral integrases, 
gammaretrovirus (271) and foamy virus (272) integrases do not interact with 
LEDGF/p75 and integrate preferentially near CpG islands and transcription start sites. 
Following integration, the presence of a provirus may disrupt nearby host genes or 
regulatory elements with potentially deleterious effects on host cell function, as 
described in Section 2.2.   53
2.3.1.2.  Lentiviral Vector Development 
 
Figure 2.8 HIV-1 genome and second generation lentiviral vectors.  
(a) Map of a wildtype HIV-1 provirus. LTR, long terminal repeat (subdivided into U3, R, and U5 
regions); PBS, tRNA primer binding site; Ψ, RNA packaging signal; gag, polyprotein encoding virion 
structural components; pro-pol, polyprotein encoding viral enzymes; vif, vpr, vpu, and nef, accessory 
genes; rev and tat, regulatory genes; PPT, polyprurine tract. (b) Map of a three plasmid second 
generation lentiviral vector system. Δgag, truncated gag gene lacking an ATG start codon; RRE, Rev 
response element; cPPT, central polypurine tract; WPRE, woodchuck hepatitis virus posttranscriptional 
regulatory element; SIN 3’ LTR, self-inactivating long terminal repeat; ΔU3, self-inactivating 3’ U3 
region lacking promoter activity; CMV, human cytomegalovirus immediate early promoter; pA, 
polyadenylation signal; VSV-g env, envelope protein from the vesicular stomatitis virus. 
Retroviral vectors based on gammaretroviruses were among the earliest viral vectors 
developed for mammalian gene transfer (273). Lentiviral vectors based on HIV-1 and 
foamy virus vectors were developed later using many of the principles of the original 
gammaretroviral systems (274;275). 
The largest structural change in moving from virus to vector was to split the genome 
into the non-coding sequences required in cis for gene transfer and the viral coding   54
sequences required only in trans in the producer cell. This separation renders the 
vector capable of one round of infection only, since no viral proteins will be produced 
in the target cell. A common split-genome system results in three plasmids: a transfer 
vector containing the essential cis elements and the transgene; a packaging plasmid 
expressing the essential polyproteins Gag and Gag-Pol and sometimes Tat, Rev, and 
the accessory proteins for HIV-1 vectors; and a plasmid for expression of the viral 
envelope. Separation of the genome onto multiple plasmids reduces the risk of 
recombination resulting in the production of replication-competent retroviruses 
(RCRs). This was historically a significant safety concern for early retroviral vector 
production systems which routinely gave rise to replication competent viruses through 
recombination (276) but has not been observed with modern split-genome systems. 
The transfer vector consists of the viral LTRs, the RNA packaging signal (Ψ), and the 
transgene expression cassette. The viral LTRs contain sequences essential for 
transcription, reverse transcription, and integration of the vector. The packaging 
signal extends into the beginning of the gag coding sequence, but the start codon of 
gag has been inactivated by mutation. Later improvements to the transfer vector 
include the insertion of a cPPT element into lentiviral vectors to enhance transduction 
of nondividing cells (277) and a woodchuck posttranscriptional regulatory element 
(WPRE) which enhances viral titre and possibly transgene expression (278). It was 
reported that a short ‘X-protein’ encoded within the WPRE might be oncogenic (279), 
but inactivation of X-protein expression does not affect WPRE function (280). Self-
inactivating transfer vectors were developed for improved safety in which almost all 
of the 3’ U3 element is removed (281;282) in order to eliminate its promoter/enhancer 
activity. The mechanism of reverse transcription is such that both proviral U3s 
originate from the 3’ LTR of the RNA genome, so proviruses resulting from infection 
with this vector lack LTR-driven transcription and cannot transcribe their full 
genome. Though strong constitutive promoters are commonly used to drive transgene 
expression, regulated expression from transfer vectors can be achieved to some extent 
through the use of tissue-specific or inducible promoters or microRNA target 
sequences (283;284). 
The first generation HIV-1 vector packaging plasmid supplied all viral coding 
sequences except env (285). In the second generation, the accessory proteins were   55
eliminated as it was shown that they were not essential for vector function (286). In 
the third generation, Tat was eliminated from the packaging system by replacing the 
5’ U3 promoter of the transfer vector with viral promoters which do not require Tat. 
Rev is supplied on a fourth plasmid in this system (287). It has been demonstrated that 
Rev can be removed from the packaging system by stabilising viral transcripts 
through codon optimisation, but this system has not been widely adopted (288). Non-
integrating lentiviral vectors have been developed which contain class I mutations to 
the integrase catalytic site. These display an integration efficiency which is estimated 
to be 10
-4 times that of standard vectors (289). 
Retroviral vectors are able to incorporate envelope proteins from a wide range of 
enveloped viruses if they are co-expressed in producer cells, a phenomenon known as 
pseudotyping (290). The choice of envelope plasmid used to pseudotype the vector 
alters the target cell specificity and physical properties of the virion (291). The most 
commonly used envelope protein is the vesicular stomatitis virus glycoprotein (VSV-
G) which confers stability and broad tropism upon virions (292), though vector 
preparations produced with this envelope may contain immunostimulatory 
contaminants (293). Interestingly, the receptor for VSV-G is not definitively known 
(294;295). 
The level of expression from integrated retroviral vectors is subject to positional 
effects whereby adjacent chromosomal elements modulate the level of transgene 
expression (296). Interestingly, it has recently been reported that integrating lentiviral 
vectors express more strongly overall than non-integrating vectors (297;298). 
Positional effects can be reduced through the inclusion of chromatin insulators in the 
vector backbone (299). Transgene silencing occurs through mechanisms that are not 
well understood but may include methylation and histone deacetylation as part of host 
defences against transposable element expansion (300).  
Vector systems based on other lentiviruses have also been reported, including human 
immunodeficiency virus type 2 (HIV-2), simian immunodeficiency virus, feline 
immunodeficiency virus, equine infectious anaemia virus, and others (reviewed in 
(301-303)).    56
2.3.2.  Adeno-Associated Virus Vectors 
The adeno-associated virus (AAV) is a single-stranded, non-enveloped DNA virus 
belonging to the family Parvoviridae. Unlike retroviruses, AAV does not require 
chromosomal integration for progression through the cell cycle. Perhaps as a 
consequence, the efficiency of AAV integration is considerably lower than that of 
retroviruses. Nonetheless, two types of AAV integration are known. In the presence 
of AAV large replication protein Rep78/68 (Rep), wildtype AAV integrates 
preferentially into a site on human chromosome 19 known as AAVS1 (304). In 
recombinant AAV vectors lacking Rep, integration occurs more randomly throughout 
the genome. 
The large Rep proteins are essential non-structural proteins with helicase and strand- 
and sequence-specific endonuclease activities (305). During replication of the AAV 
DNA genome, Rep binds to a (GAGC)3 Rep binding element (RBE) present in the 
virus terminal repeats (TR) and nicks the double-stranded DNA genome at a terminal 
resolution site (trs). An RBE is also present at the AAVS1 site on chromosome 19, 
and Rep is able to tether the AAV genome to the AAVS1 site (306). However, most 
intracellular wildtype AAV genomes do not integrate. The mechanism of site-specific 
integration is not known, but is likely to be complex given that it frequently results in 
multiple insertions and significant and unpredictable rearrangements to both vector 
and host DNA (reviewed in (307)).  
Commonly used recombinant AAV (rAAV) vectors for gene therapy do not carry the 
Rep protein and persist in target cells largely as episomal DNA, initially as small 
circles but gradually developing into large concatemers over time (308). As with 
wildtype AAV, rAAV integration takes place through a complex and poorly 
understood mechanism which results in significant rearrangement of host and vector 
DNA (309). Large scale rAAV integration site analysis revealed integrations 
throughout the genome, with a weak preference for integration near CpG islands or 
within transcription units. Interestingly, 8% of integration sites were found within 
ribosomal DNA (310). 
Although initially considered to be an integrating vector, the current view of rAAV 
vectors is that they are principally non-integrating but may integrate at low efficiency.   57
It has been estimated that the efficiency of both wildtype AAV site-specific 
integration by Rep and rAAV non-targeted integration is approximately 10
-3 
integrations per intracellular vector genome (311), two orders of magnitude less than 
that of lentiviral vectors. 
2.3.3.  Sleeping Beauty: A DNA Transposon Vector 
Sleeping Beauty is a Tc1/mariner-type DNA transposon that was reconstructed by 
consensus alignment of inactive transposon “fossils” from a number of salmonid fish 
(312) and has been explored as an integrating vector for transgenesis in many 
eukaryotic species. The complete wildtype transposon consists of a transposase 
protein coding sequence flanked by two nonidentical 230bp inverted repeats (IRs). A 
32-34bp transposase binding site is present at the inner and outer end of each IR 
(313). The 5’ untranslated region between the left IR and the transposase coding 
sequence is able to promote weak transcription of transposase. The right IR also has 
weak promoter activity directed towards the centre of the transposon, raising the 
possibility of double-stranded RNA formation and transposon silencing by RNAi 
(314;315). 
 
Figure 2.9 Genetic maps of the Sleeping Beauty transposon and vector system.    58
(a) Wildtype Sleeping Beauty transposon consisting of flanking inverted repeats and a transposase 
coding sequence. Adapted from (316). (b) Two plasmid Sleeping Beauty vector consisting of a vector 
plasmid containing a transgene expression cassette flanked by inverted repeats and a transposase 
expression plasmid. IL, left inverted repeat; IR, right inverted repeat; NLS, nuclear localisation signal; 
DDE, integrase catalytic motif; pA, polyadenylation signal; CMV, human cytomegalovirus immediate 
early promoter. 
The 340 amino acid transposase protein consists of an N-terminal, pairlike DNA 
binding domain with two helix-turn-helix motifs, an overlapping nuclear localisation 
signal, and a C-terminal DDE-type catalytic domain which is common to integrases 
and transposases from many mobile elements, including retroviruses (317;318). 
Transposase catalyses the excision of the transposon from flanking DNA and its 
reintegration elsewhere in a ‘cut-and-paste’ process known as transposition. 
Transposition initiates with binding of transposase protein molecules to the two 
binding sites present within each IR (i.e. four sites in total) (319). Binding takes place 
more strongly at the inner than outer sites (320). It has been reported that transposase 
displays a high binding affinity for transposon DNA which is packaged into 
heterochromatin (321;322). It has also been reported that linearised, non-supercoiled 
DNA is 15-20 fold less efficient as a substrate for transposition (323;324). After 
binding, the four transposase proteins form a tetramer, bringing the two IRs into close 
proximity in a structure known as the synaptic complex (325). This process requires 
the presence of the host DNA-bending protein HMGB1 (326) and is enhanced by an 
11bp ‘half-direct repeat’ transpositional enhancer present only in the left IR (327).  
Once the synaptic complex has formed, the transposase catalytic domain cleaves the 
DNA at the IR ends to excise the transposon. Cleavage is dependent upon the 
presence of flanking TA dinucleotides and is enhanced when the transposon is flanked 
by TATA motifs (328;329). Cleavage is staggered so that the excised transposon 
possesses 3 nucleotide 3’ overhangs at both ends (330). The excised transposon 
subsequently integrates into a new target DNA at a TA-dinucleotide. DNA repair 
pathways such as non-homologous end joining (NHEJ) repair the donor and target 
DNA strands, resulting in a 3bp transposon footprint on the donor DNA and 
duplication of the TA-dinucleotide on the target DNA (331;332). Sleeping Beauty 
transposase interacts with the NHEJ repair pathway component Ku, and Ku is 
necessary for efficiency and fidelity of the transposition reaction (333;334).   59
Transposase also interacts with Miz-1, and this leads to downregulation of cyclin D1 
expression and subsequent extension of the G1 phase of the cell cycle (335). NHEJ 
activity is high during G1, so it is likely that this manipulation of the cell cycle is a 
selfish transposon strategy to enhance its transposition. This may be a general strategy 
for mobile parasitic elements, as HIV-1 also manipulates the cell cycle to its 
advantage through the action of Vpr (336;337). 
 
Figure 2.10 The mechanism of Sleeping Beauty transposition.  
An integrated transposon is excised by molecules of the transposase protein, leaving the donor 
chromosome with 3bp transposon-derived overhangs. These are repaired by non-homologous end-
joining (NHEJ), resulting in a transposon ‘footprint’. The excised transposon remains bound to 
transposase as a preintegration complex. When this encounters a suitable target chromosome 
containing a TA dinucleotide, a strand transfer reaction inserts the transposon at this position. Filling of 
single stranded DNA by host DNA repair proteins results in a duplication of the target TA dinucleotide 
at each end of the transposon integration site. P, phosphate group in DNA backbone. Adapted from 
(338).   60
As with retroviruses, Sleeping Beauty transposons are able to integrate throughout the 
genome. Sleeping Beauty reintegration occurs preferentially on the same donor 
molecule (including plasmid donors), a phenomenon known as ‘local hopping’ (339). 
Potential target TA-dinucleotides differ in their attractiveness for integration due to 
local DNA properties such as DNA deformability, and algorithms have been 
constructed which predict this attractiveness (340). A weak consensus sequence at 
integration sites was found to be 5’-RCAYATATRTGY-3’ (341). Integration site 
analysis in cell lines has shown that integration of Sleeping Beauty is almost random 
with respect to genomic features such as transcription units and CpG islands 
(342;343). 
The ability of Sleeping Beauty to stably integrate into host chromosomes has led to its 
development as a vector, principally as a means of integrating plasmid DNA delivered 
with non-viral vectors. In the first generation vector, pT, the transposon was split into 
two plasmids; the transposon vector plasmid contains a transgene expression cassette 
flanked by IRs, while the transposase plasmid drives expression of transposase. When 
both plasmids are introduced into target cells, transposase expression in trans enables 
transposition of the transposon from the vector plasmid into a host chromosome 
(344). In most systems transposase expression has been provided on a separate 
plasmid, but single vector systems carrying both transposon and transposase (345) and 
direct delivery of transposase mRNA (346) have also been reported. The level of 
transposase expression in target cells must be tightly controlled, as overexpression of 
transposase actually reduces the level of transposition in a phenomenon known as 
overproduction inhibition (347). The mechanism of overproduction inhibition is not 
known, but it has been reported in other Tc1/mariner transposons and may represent 
an autoregulatory system (348). 
The efficiency of transposition from the transposon vector plasmid declines with 
transgene size at an exponential rate of about 30% per additional kb, limiting its 
useful capacity (349;350). The efficiency of transposition was improved in the second 
generation vector pT2, which used IRs with a better fit to the known Tc1 consensus 
sequence to give a 4-fold enhancement of transposition (351). Although it was not 
realised at the time, this vector reconstruction also removed transposon sequences 
immediately flanking the IRs which are now known to promote weak transcription   61
into the transposon centre (352;353). A third generation vector plasmid, pT3, was 
constructed in which the right IR was replaced with an inverted copy of the left IR, 
resulting in a 2-fold increase in transposition (354). However, unlike pT2, pT3 
contains sequences adjacent to the IRs now known to have weak promoter activity. 
The Sleeping Beauty transposase has also undergone several generations of 
development through fitting to transposase consensus sequences and alanine scanning 
mutagenesis to identify residues which alter transposition activity (355-359). The first 
transposase, SB10, was able to confer resistance to the antibiotic G418 in 0.7% of 
HeLa cells following lipid-based co-transfection with the pT vector, while an 
improved transposase, SB11, resulted in 2% resistance (360). Codon-optimisation of 
SB10 to improve expression in human cells did not increase transposition activity 
(361). HSB17, an enhanced, codon-optimised transposase, produced 8.5% G418-
resistant HeLa cells following lipid-based transfection with the pT vector (an SB10 
control yielded 0.45% resistance in this experiment) (362). A recently developed 
hyperactive transposase, SB100, has been reported to be 100-fold more active in 
transposition than SB10 while retaining a virtually random integration profile (363). 
It has recently been suggested that Sleeping Beauty insertions are subject to a high 
degree of gene silencing. Garrison et al reported that as few as 1 in 15 chromosomal 
insertions in cell lines were able to express a fluorescent reporter gene, though 
treatment of cells with methyltransferase or histone deacetylase inhibitors raised this 
proportion to almost 100% (364). Similarly, Dalsgaard et al reported a 15-fold 
increase in the number of cells expressing an antibiotic reporter when chromosomal 
insulator elements were included within the transposon, though the rate of 
transposition was unaffected (365). The mechanism of silencing is not known, though 
a significant proportion of insertions are methylated (366). Tc1 transposon silencing 
can take place through RNAi following the production of double stranded RNA 
specific to the transposon IRs (367). 
Sleeping Beauty vectors have been tested in pre-clinical gene therapy models in 
tissues including liver (368;369), lung (370), and tumour (371). A clinical trial 
proposal has been presented to the NIH Recombinant DNA Advisory Committee 
which plans to use electroporated Sleeping Beauty plasmids to express an anti-CD19 
chimeric antigen receptor in autologous T-cells for immunotherapy of CD19
+ B-  62
lymphoid malignancies (372;373). However, approval of the trial has been postponed 
pending further studies into the risk of Sleeping Beauty integration causing insertional 
mutagenesis and unregulated T-cell expansion. To date, no case of oncogenic 
insertional mutagenesis has been reported in normal or cancer-prone animals treated 
with standard Sleeping Beauty vectors (374). 
Following the reconstruction of Sleeping Beauty, a number of other DNA transposons 
were investigated as integrating vectors in mammalian cells, including a second Tc1-
like transposon from the Northern leopard frog Rana pipens designated Frog Prince 
(375), the piggybac transposon from the cabbage looper moth Trichoplusia ni (376), 
and the hAT-like transposon Tol2 from the Japanese medaka fish Oryzias latipes 
(377). The piggybac transposon is reported to have a larger carrying capacity than 
Sleeping Beauty, up to 14kb without loss of transposition efficiency (378). Piggybac 
does not leave transposon footprints following excision and is not subject to 
overproduction inhibition, but is reported to integrate into transcription units more 
frequently than Sleeping Beauty (379). In direct comparisons in cell lines, piggybac 
was found to transpose approximately 2-fold more efficiently than an SB11-pT2 
system, resulting in 0.9% of HeLa cells becoming hygromycin resistant compared to 
0.4% with Sleeping Beauty. 
2.3.4.  Tyrosine and Serine Recombinases 
Recombinases are specialised proteins which catalyse site-specific recombination 
between short recognition sites present on two DNA molecules. Many recombinases 
have been identified in a large number of prokaryotes and eukaryotes, but almost all 
fall into two families, namely the tyrosine and serine recombinases. 
The tyrosine recombinase family (also known as λ integrases) include the Cre 
recombinase from bacteriophage (380) and Flp recombinase from the yeast 
Saccharomyces cerevisiae (381), while the serine recombinase family includes 
phiC31 integrase from bacteriophage (382;383). The mechanism of recombination 
used by each family has been well-studied (reviewed in (384;385)). Although the two 
are mechanistically quite distinct (for example, tyrosine recombinases establish a 
Holliday junction during recombination while serine recombinases do not), there are 
similarities between the two recombination processes.    63
Both tyrosine and serine recombination sites contain two inverted recombinase 
binding sites. The total recombination site size varies between recombinases but is 
greater than 30bp for the most commonly used systems. During recombination, the 
recombination site on each DNA molecule is bound by recombinase enzymes. Serine 
recombinases introduce one nick into each of the four DNA strands, while tyrosine 
recombinases nick only one strand on each parental DNA. Resolution of the nicked 
intermediates results in recombination of the two parental DNA molecules. When at 
least one parental molecule is circular (e.g. a plasmid) and the other is linear (e.g. a 
chromosome), the net result of recombination is to insert the circular parent into the 
recombination site of the linear parent. 
A number of recombinases have been investigated for use in gene therapy, principally 
the Cre and Flp recombinases and phiC31 integrase (386). A significant limitation is 
the requirement for target recombination sites in genome. Although human cells 
contain no perfectly matched recombination sites for any of these three enzymes, 
divergent pseudo-attP sites are present that can be used by phiC31 integrase with 
reduced efficiency (387). A survey of the integration sites used by phiC31 integrase in 
human cell lines found that several hundred potential sites exist, but the majority of 
integrations take place at a small subset of these (388). There are no reports of 
oncogenic transformation due to phiC31 integrase expression in vivo, but safety 
concerns have been raised following reports that the enzyme can cause chromosomal 
rearrangements in mammalian cells (389;390). 
In terms of efficiency, transfection experiments using phiC31 integrase expression 
and donor plasmids resulted in 0.1% stably G418-resistant HeLa cells (391). An 
enhanced phiC31 integrase has recently been developed which is 2-fold more efficient 
(392). 
2.3.5.  Site-Specific Nucleases for Gene Targeting 
In gene targeting, a DNA fragment introduced into cells is able to replace a portion of 
endogenous chromosomal DNA through homologous recombination (HR). For 
example, mouse embryonic stem (ES) cells can be transfected with partially 
homologous template DNA in order to produce specific genomic alterations (393). 
This has contributed greatly to basic biological research as it enables the production   64
of adult mice carrying specific genomic alterations (394). Gene targeting is a highly 
attractive approach to gene therapy as it offers the potential to insert therapeutic DNA 
at a known, safe location, or even to correct disease-causing mutations in situ. 
However, gene targeting in mammalian cells is extremely inefficient, with just 1 in 
10
6 mouse ES cells carrying the desired insertion and 100 to 1000-fold more carrying 
background integrations elsewhere in the genome. 
It was shown first in yeast (395) and later in mammalian cells (396) that the efficiency 
of gene targeting could be enhanced by the introduction of a double strand DNA 
break (DSB) at the target site using a site-specific endonuclease. The free ends at 
DSBs mark them as substrates for host DNA repair pathways, stimulating HR 
between the target and template DNA (reviewed in (397)). Rouet et al reported that 
the expression of a targeting endonuclease increased the rate of gene targeting 100-
fold (398). 
DSB repair can produce several outcomes. Repair via non-homologous end joining 
(NHEJ) may restore the original sequence, resulting in no change at the target site. 
NHEJ may also introduce small insertions of several base pairs. If a template DNA 
containing homology to the sequence flanking the DSB is available, homologous 
recombination (HR) repair may result in the replacement of DNA surrounding the 
DSB with DNA from the template. Competition between the NHEJ and HR pathways 
for DNA repair is a recognised problem for gene targeting approaches. 
A number of endonucleases have been employed for mammalian genome editing. 
Hundreds of naturally-occurring meganucleases have been identified which have 
recognition sites at least 12bp long, a length usually sufficient to be unique in 
mammalian cells. However, as with recombinases, none of these enzymes have useful 
target sites in human cells, and retargeting their substrate specificity by protein 
engineering has proven extremely difficult (reviewed in (399)). 
The ability to engineer proteins which bind specifically to useful DNA target sites has 
long been a goal in biotechnology. A possible solution was offered by the elucidation 
of the structure of the DNA binding domain from a zinc finger transcription factor 
(400). This showed a relatively simple recognition motif in which a series of looped 
polypeptides, or ‘fingers’, contact three DNA bases per finger using three amino acids   65
within each finger. The structure suggested that zinc finger transcription factors were 
in fact modular, and that the fingers could be interchanged to alter the DNA binding 
site specificity at will. The ‘modular assembly’ approach stimulated the collection of 
libraries of fingers, each finger recognising a different DNA triplet (401;402). 
Construction of artificial zinc finger domains proceeds by assembly of fingers to give 
the desired binding specificity followed by in vivo selection of functional domains 
(403). It has been shown that endonuclease domains such as that of FokI can be fused 
to zinc finger DNA binding domains to give zinc finger nucleases (ZFNs), artificial 
endonucleases which can be targeted against an extremely large number of 
chromosomal sites (404;405). ZFNs are not thought to be more efficient than natural 
endonucleases at stimulating gene targeting, but their flexibility of specificity has 
raised the prospect of useful applications. 
Using ZFNs and template DNA delivered by plasmid transfection, Urnov et al were 
able to introduce small sequence changes into the endogenous IL2RG locus in 20% of 
K562 cells and 5% of primary human CD4
+ T lympocytes (406). It was later shown 
that up to 8kb of heterologous sequence can be inserted into this locus in cell lines by 
flanking it with 750bp arms homologous to the sequence surrounding the DSB (407). 
Gene addition of this type was shown at the CCR5 locus in 39% of Jurkat cells and 
0.06% of primary CD34
+ haematopoietic progenitor cells (408). 
The insertion of base pairs during NHEJ can introduce frame-shift mutations if the 
DSB occurs within an exon. This strategy has been exploited to knock out expression 
of CCR5, a major co-receptor for HIV-1 infection of T lymphocytes, in order to 
protect these cells from HIV infection (409). In February 2009, Sangamo Biosciences 
commenced a clinical trial of this system. 
One concern with the application of nucleases for gene addition or knockout is the 
cytotoxicity observed with intracellular endonuclease expression (410;411). 
Overexpression of the meganuclease I-SceI from an adenovirus 5 vector was fatal in 
40% of mice (412). In general, endonuclease toxicity is thought to be due to off-target 
DNA cleavage and is generally greater for ZFNs than meganucleases. This issue is 
being addressed by the development of ZFNs with improved target specificity 
(413;414).   66
2.3.6.  Group II Introns 
Mobile group II introns are transposable elements found in a number of prokaryotes 
and the mitochondria and chloroplasts of some eukaryotes (reviewed in (415)). The 
integrated DNA-form is transcribed into RNA which is able to integrate elsewhere on 
prokaryotic chromosomes. Uniquely, integration involves in situ reverse transcription 
at the integration site, a process which is catalysed by an intron-encoded protein (IEP) 
with reverse transcriptase activity and significant homology to retroviral reverse 
transcriptases (416). The target site specificity of group II introns is determined 
through base pairing between 14 nucleotides of the intron RNA with the target site 
DNA; thus, integration site selection can be reprogrammed simply by editing these 
nucleotides, subject to few constraints. In addition, it is possible to insert heterologous 
sequences such as drug resistance markers into the intron (417). This high degree of 
flexibility has led to the development of the L1.LtrB group II intron from Lactococcus 
lactis as a programmable ‘targetron’ vector for site-specific integration in prokaryotes 
(418). Expression of a targetron vector in E. coli results in chromosomal integration in 
approximately 1% of cells and target site specificity is greater than 98% (419). 
L1.LtrB has also been investigated for activity in eukaryotic cells. Guo et al generated 
group II introns targeted against human CCR5 or HIV-1 pol and confirmed 
integration into target plasmids carrying these sequences in E. coli. Group II introns 
were then reconstituted in vitro using purified IEP and RNA and transfected into 
human cell lines together with the target plasmids. Site-specific integration into the 
target plasmids was detected by PCR (420). Recently, Mastroianni et al injected 
reconstituted introns into embryos of the frog Xenopus laevis or fly Drosophila 
melanogaster and demonstrated integration into target plasmids in approximately 3% 
of these cells in the presence of increased Mg
2+. Integration into eukaryotic 
chromosomes by a group II intron was demonstrated for the first time at the yellow 
gene in Drosophila, with successful targeting confirmed by PCR and sequencing of 
the intron-chromosome junction (421). Although the efficiency of the reaction was 
low, this study demonstrated the principle that targeted integration into eukaryotic 
chromosomes can be achieved without the need for protein engineering.   67
2.3.7.  Fusion Proteins to Retarget Integration 
The risk of insertional mutagenesis following semi-random integration of retroviruses 
or transposons makes retargeting integration to a particular chromosomal location an 
attractive goal. Retargeted integration would insert vector DNA in a predictable 
location and so reduce positional effects on transgene expression, as well as reducing 
the risk of insertional mutagenesis due to proto-oncogene or tumour suppressor gene 
disruption. The most common approach to retargeting an existing semi-random 
integration mechanism is to fuse elements of the preintegration complex to sequence-
specific DNA-binding domains (DBDs), thus tethering the complex to a desired 
chromosomal location where the integration mechanism can proceed. 
Two approaches have been taken to retargeting lentiviral vector integration. Ciuffi et 
al engineered an artificial tethering factor consisting of the integrase binding domain 
of LEDGF/p75 fused to the DNA-binding domain of the phage λ repressor. An in 
vitro integration reaction was performed using purified tethering factor and HIV-1 
integrase to catalyse integration into DNA containing the λ repressor target site. The 
presence of the tethering factor was found to increase the rate of integration at sites 
surrounding the target site (422). This effect has not yet been reported in cells. A 
second approach has been to fuse the HIV-1 integrase protein directly to a site-
specific DBD. This strategy was tested in cell lines using lentiviral vectors carrying an 
E2C-IN fusion protein targeted against the erbB2 site on chromosome 17. 1.5% of 
integration sites were found to lie near the erB2 target site in cells transduced with 
E2C-IN vector compared to 0.15% of sites in cells transduced with standard IN 
vector, an enrichment of almost 10-fold (423). 
Efforts have been made to target Sleeping Beauty integration to specific chromosomal 
target sites by constructing fusion proteins made up of the transposase and a 
sequence-specific DNA binding domain. C-terminal additions to the transposase 
appear to completely abolish activity, and even small N-terminal additions of 6 amino 
acids significantly reduce transposition efficiency (424;425). A transposase-DBD 
fusion protein targeted by Yant et al to the E2C site on chromosome 17 was able to 
enrich the frequency of integration close to a plasmid target site 10-fold compared to 
the expected value with an unmodified transposase. No increase in integration close to   68
the chromosomal target was observed (426). A similar study from Ivics et al reported 
no success with transposase-DBD fusions but was able to show targeted integration 
into chromosomes using a tethering factor consisting of a DBD specific for an 
artificial chromosomal tetO target and a protein-binding domain specific for the 
transposase protein (427). This factor was able to target 10-25% of all transposition 
events into TA-dinucleotides within 2kb of the tetO binding site, an enrichment of 
10
7-fold relative to standard transposition. 
Retargeting an existing integration mechanism is attractive as it offers the potential to 
retain the high efficiency of integration observed with the native pathway. However, 
the approaches attempted to date have been hampered by the fact that the native 
pathway remains able to integrate independently of the added retargeting system. The 
fact that off-target DNA is present in great excess relative to target DNA means that 
integrations at the target site usually constitute only a small proportion of the total 
integration events. 
2.3.8.  Hybrid Vectors 
An alternative approach to retargeting integration is to provide a given vector with an 
entirely new integration mechanism. A number of such hybrid vectors have been 
investigated which combine the gene transfer activity of one vector with the 
integration activity of another (Table 2.1). This combination is particularly useful 
where either the gene transfer vector is normally non-integrating or the integration 
system is unable to move between cells. In this way it is possible to generate vectors 
which combine desirable cell tropism and integration properties for particular gene 
therapy applications.  69
Gene transfer vector   
Lentivirus Herpes  virus  Adenovirus  AAV  Non-viral 
Sleeping Beauty 
transposase 
This study (428) 
Staunstrup 2009 
(429) 
Bowers 2006 
(430) 
Yant 2002 
(431) 
 
Ivics 1997 
(432) 
Retro/lentiviral 
integrase 
Naldini 1996 
(433) 
 
Murphy 2002 
(434) 
 
Shoji-tanaka 1994 
(435) 
AAV Rep 
Philpott 2007 
(pers. comm.) 
Heister 2002 (436) 
Wang 2002 (437) 
Recchia 1999 
(438) 
Zhang 2007 
(439) 
Surosky 1997 
(440) 
Cre/Flp 
recombinase 
Moldt 2008 
(441) 
   
Sauer 1990 (442) 
Koch 2000 (443) 
phiC31 
integrase 
Thornhill 2005 
(pers. comm.) 
 
Ehrhardt 2007 
(444) 
 
Groth 2000 
(445) 
Meganuclease 
Cornu 2007 
(446) 
  
Miller 2003 (447) 
Porteus 2003 (448) 
Rouet 1994 
(449) 
Integration 
method 
Zinc finger 
nuclease 
Lombardo 2007 
(450) 
   
Urnov 2005 
(451) 
 
Table 2.2 Hybrid vector publications.  
Literature search performed April 2009.   70
Hybrid vectors require the nucleic acid output from the gene transfer step to be a 
compatible substrate for the integration step. In this study we have generated a hybrid 
lentivirus-Sleeping Beauty transposon vector, so the remainder of this section will 
review the literature regarding hybrid vectors containing either a lentiviral vector or 
Sleeping Beauty component. 
Three hybrid lentiviral vectors have been published in which the endogenous HIV-1 
integrase activity was eliminated through the introduction of the Class I mutation 
D64V and integration was instead carried out by another mechanism. 
Firstly, Cornu et al reported a lentiviral vector able to undergo gene targeting by 
homologous recombination stimulated by the meganuclease SceI. In this study, an 
SceI expression cassette and the homologous repair template were cloned into two 
separate non-integrating lentiviral vectors (NILVs) and co-transduced into target cells. 
Gene conversion at a chromosomal eGFP target was observed in approximately 1% of 
HEK293 cells transduced with both NILVs and 0.03% of cells transduced with the 
template NILV only. Interestingly, gene conversion occurred in 12% of HEK293 cells 
when SceI was expressed from an integrating lentiviral vector (ILV). The authors 
suggest that low expression from NILVs (also reported elsewhere e.g. (452)) was a 
limiting factor in the gene targeting frequency (453). 
Secondly, Lombardo et al also generated NILVs able to integrate by homologous 
recombination. In this study, homologous recombination was stimulated by zinc 
finger nucleases (ZFNs). Target cells were transduced with three NILVs, two for 
expression of each half of the ZFN dimer and one for delivery of the homologous 
repair template. Gene conversion was observed at the IL2RG locus in 16% of K562 
cells transduced with all three vectors. The efficiency of conversion in the absence of 
the ZFN was not reported, but appears to have been low. As well as gene conversion, 
gene addition into the IL2RG locus in K562 cells was achieved with an efficiency of 
3.4% by flanking an eGFP expression cassette with arms homologous to the IL2RG. 
In the absence of the ZFN, 1.1% of cells became stably eGFP positive. Gene addition 
at the CCR5 locus occurred in 35% of K562 cells with a 2% background integration 
rate and 0.06% of CD34
+ haematopoietic progenitor cells with a 0.005% background 
integration rate (454). The authors argue that the low rate of gene targeting in   71
haematopoietic progenitor cells is due to the low efficiency of transduction commonly 
observed with these cells (455). 
Thirdly, Moldt et al presented a proof-of-principle vector in which cells were co-
transduced with two NILVs, one for expression of an enhanced Flp recombinase and 
the other providing a hygromycin resistance cassette adjacent to an FRT (Flp 
recombination) site. The mechanism of Flp-directed recombination is such that only 
circularised NILV molecules were able to insert as desired, but it is known that 
approximately one third of linear lentiviral DNA forms 1- and 2-LTR circles in target 
cells through the action of host DNA repair proteins (456). Co-transduction of an 
HEK293 cell line engineered to contain 3 chromosomal FRT sites resulted in stable 
expression of hygromycin resistance in 0.01% of cells compared to 0.4% of cells co-
transfected with plasmids carrying the same Flp expression and FRT-hygromycin 
resistance cassettes. No background integration was observed because the vector was 
designed so that hygromycin resistance could only be expressed following FLP-
mediated insertion at the target site. Sequencing of insertions confirmed that 1- and 2-
LTR circles were the substrate for Flp-mediated insertion. The authors used 
quantitative PCR to determine the efficiency of transfection or transduction, detecting 
copy numbers of 1.3 x 10
4 plasmids per cell and 22 2-LTR circles per cell 24 hours 
after gene transfer. They thus estimated the rate of integration due to Flp to be 2.8 x 
10
-7 insertions per plasmid versus 1.7 x 10
-5 per 2-LTR circle. The authors speculate 
that the greater efficiency of 2-LTR insertion per intracellular copy could be due to 
differences in subcellular localisation (e.g. improved nuclear entry of NILVs) or 
structural differences in the substrate DNA such as supercoiling. 
Three hybrid vectors based on Sleeping Beauty have been published. The first was the 
use of non-viral transfection to deliver Sleeping Beauty plasmids to target cells (457). 
Non-viral transfection of plasmid DNA is the gold standard for Sleeping Beauty 
delivery, and relatively little research has addressed the suitability of transfected 
plasmid DNA to act as a substrate for transposition. Yant et al reported that 
transposition from linearised plasmid DNA is 20-fold less efficient than transposition 
from circular plasmids (458). It is important to note that this study did not control for 
differences in the efficiency of transfection between linear and circularised plasmid 
DNA. While supercoiling is known to influence the efficiency of transposition in a   72
number of mobile elements, its importance for the Tc1/mariner transposon family is 
controversial and the requirement does not seem to be absolute (459;460). It was 
recently reported that experimentally-induced heterochromatinisation of Sleeping 
Beauty transposons integrated into chromosomes enhanced excision 100-fold, but this 
effect has not been demonstrated in plasmid systems (461). 
Yant et al reported the development of a hybrid Sleeping Beauty-adenoviral vector for 
in vivo gene delivery to mouse liver (462). When an adenoviral two vector system 
(one each for delivery of the transposon and transposase expression cassette) was 
delivered to mouse livers by tail vein injection, there was no difference in the long 
term level of the alpha-1 antitrypsin transgene product in blood plasma. On the basis 
of the linear versus circular plasmid transfection experiment described above, the 
authors decided to circularise the transposon vector in situ by adding the Flp 
transgene to the transposase expression vector and flanking the transposon with FRT 
sites. 45% of mouse hepatocytes were found to contain circularised vector genomes 5 
weeks after the initiation of Flp expression compared to 2% in the absence of Flp. 
When hepatocytes were induced to divide rapidly by administration of CCl4 to the 
transduced mice, the level of transgene persistence was estimated to be 11-fold higher 
in livers transduced with the active transposase. In addition, 7 chromosomal 
transposon integration sites were successfully recovered from these mice. The two 
adenoviral vector Flp circularisation system was tested in long term expression 
experiments in mouse livers, and significantly greater expression from a transposon-
borne coagulation factor fIX was observed at 23 weeks in mice transduced with an 
active transposase, though this level was 0.3% of the initial expression level achieved 
immediately after transduction. Finally, the transposon, Flp, FRT, and transposase 
elements were combined on a single adenoviral vector, and efficacy was demonstrated 
by the recovery of 7 integration sites from mouse liver transduced in vivo. The authors 
did not report integration efficiency data obtained in cell lines. 
Lastly, Bowers et al generated a hybrid Sleeping Beauty-herpes simplex virus vector 
in which a lacZ-neo transposon and a transposase expression cassette were carried on 
two separate vectors. Co-transduction of the BHK cell line demonstrated 10-15% 
stable G418 resistance in the presence of transposase compared to approximately 
0.6% background integration. In primary cortical neuron cultures, co-transduction   73
with an active transposase resulted in a 2-fold increase in the number of β-
galactosidase positive cells (the total cell number was not reported) and a 20-fold 
increase in vector copy number at days 4 and 9 post-transduction. Finally, mouse 
embryonic brains were injected with the hybrid vectors 1 week before term and the 
animals were sacrificed 90 days after birth. Significant β-galactosidase staining was 
observed in large regions of brains co-transduced with the transposon and an active 
transposase, and immunofluorescence microscopy revealed expression in a range of 
cell types. No β-galactosidase staining at all was observed in brains containing the 
transposon vector but no transposase. 4 chromosomal transposon integration sites 
were successfully recovered from brains co-transduced with transposase. 
The successful development of six hybrid vector systems containing either a non-
integrating lentivirus or Sleeping Beauty transposon component suggests that 
compatibility between the gene transfer vector and the downstream integration 
mechanism is not a common problem for either of these systems and supports the 
feasibility of a hybrid lentivirus-transposon vector. 
2.4.  Summary and Aims 
Successful clinical trials using gammaretroviral vectors have highlighted the 
usefulness of integrating vectors for gene therapy, particularly in mitotic tissues. 
However, the semi-random nature of retroviral integration introduces a risk of 
insertional mutagenesis, potentially leading to cell transformation and serious 
consequences for patients. The development of retroviral vectors with safer patterns 
of integration site selection would be an attractive solution to this problem. 
Retroviral vectors derived from gammaretrovirus, foamy virus, and lentivirus are able 
to transfer genes efficiently to a broad range of target cell types. However, 
gammaretroviral and foamy virus vectors integrate preferentially near transcription 
start sites and CpG islands, while lentiviral vectors integrate preferentially into active 
genes. In all three cases, the pattern of integration is biased towards important host 
genomic elements.  
By contrast, the Sleeping Beauty DNA transposon has an almost random integration 
profile with respect to underlying genomic features. It has been suggested that this   74
pattern of integration may theoretically reduce the risk of insertional mutagenesis. A 
significant hurdle to the wider application of Sleeping Beauty to gene therapy is the 
inability of the vector to enter target cells unaided. A common approach has been to 
transfect Sleeping Beauty plasmids into target cells using non-viral vector systems, 
but this is not practical for important targets such as haematopoietic stem cells where 
non-viral transfection is inefficient (463). 
Thus, the aim of this study was to develop a hybrid lentivirus-Sleeping Beauty 
transposon vector which would combine the efficient cell and nuclear entry properties 
of lentiviral vectors with the theoretically safer integration profile of Sleeping Beauty. 
 
Figure 2.11 Overview of the lentivirus-transposon vector.  
TN, Sleeping Beauty transposon; SB11, hyperactive Sleeping Beauty transposase; SIN, self-
inactivating (U3-deleted) HIV-1 long terminal repeat; cPPT, central polypurine tract; CMV, immediate 
early promoter of human cytomegalovirus; WPRE, woodchuck posttranscriptional regulatory element; 
IL, Sleeping Beauty transposon left inverted repeat; IR, Sleeping Beauty transposon right inverted 
repeat; SFFV, spleen focus forming virus U3 promoter; eGFP, enhanced green fluorescent protein.   75
3.  Materials and Methods 
3.1.  Materials 
Unless otherwise stated, tissue culture reagents were supplied by Gibco BRL 
(Invitrogen), general chemicals were supplied by Sigma, and recombinant enzymes 
for plasmid subcloning were supplied by Promega. DNA sequencing was performed 
by Functional Biosciences. 
3.1.1.  General Reagents and Enzymes 
1kb  Plus  DNA  ladder      Invitrogen 
NlaIII restriction endonuclease    New  England  Biolabs 
P r o t e i n a s e   K        V W R  
Agarose       Invitrogen 
A g a r         M E R C K  
Ampicillin       Stratagene 
G418        Invivogen 
TRIzol  Reagent      Invitrogen 
DNase I, Amplification Grade      Invitrogen 
M-MLV Reverse Transcriptase      Invitrogen 
Random  Primers      Invitrogen 
3.1.2.  Plasmids 
pLNT/SFFV-eGFP-WPRE is a previously described variant of the pHR second 
generation HIV-1-based vector containing a self-inactivating 3’ LTR, a central 
polypurine tract (cPPT), the spleen focus forming virus U3 promoter (SFFV), an   76
enhanced green fluorescent protein reporter gene (eGFP), and the woodchuck 
posttranscriptional regulatory element (WPRE) (464). pLNT/SFFV-MCS-WPRE uses 
the same backbone but carries a multiple cloning site instead of the eGFP coding 
sequence. 
The hyperactive transposase expression plasmid pCMV-SB11 (465), the mutant 
transposase expression plasmid pCMV-SBΔDDE (466), and the Sleeping Beauty 
transposon plasmid pT2/HB (467) were kind gifts from Scott McIvor at the University 
of Minnesota. 
3.1.3.  Cell Lines 
293T    Human embryonic kidney cell line (HEK293T) 
HeLa    Human cervix epitheloid carcinoma cell line 
3.1.4.  Antibodies 
MAB2798 Mouse  anti-SB11  monoclonal R&D  Systems 
SC8334  Rabbit anti-eGFP polyclonal   Santa  Cruz  Biotechnology 
NA934V  Donkey anti-rabbit HRP-linked  ECL 
HAF018  Donkey anti-mouse HRP-linked  R&D Systems 
3.1.5.  PCR 
Primers      Invitrogen 
GoTaq  DNA  Polymerase     Promega 
Pfu  DNA  Polymerase      Promega 
3.1.6.  Quantitative Real-Time PCR 
Primers      Invitrogen   77
P r o b e s         M W G  
Platinum qPCR SuperMix-UDG with ROX    Invitrogen 
3.1.7.  Kits 
Topo-TA  Cloning  Kit      Invitrogen 
Plasmid  preparation      Qiagen 
QiaQuik  Gel  Extraction     Qiagen 
QiaQuik  PCR  Purification     Qiagen 
HIV-1  p24  ELISA      Retrotek 
3.1.8.  Western Blotting 
Western blotting reagents and equipment were obtained from the Invitrogen NuPAGE 
system (Sample Buffer, Antioxidant, SeeBlue Plus 2 Pre-stained Standard, NOVEX 
Bis-Tris Gels, MES Buffer, Transfer Buffer). The chemiluminescent ECL Western 
Blotting Substrate was supplied by Pierce. 
3.1.9.  Bacteria 
Escherichia coli strains used: 
XL1-Blue       Stratagene 
Genotype: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ 
proAB lacI
qZΔM15 Tn10 (Tet
R)]  
Stbl3        Invitrogen 
Genotype: mcrB mrr hsdS20(rB
-, mB
-) recA13 supE44 ara-14 galK2 
lacY1 proA2 rpsL20(Str
R) xyl-5 λ
- leu mtl-1 F
-   78
Genes listed signify mutant alleles, except for genes on the F’ episome which are 
wild-type unless indicated otherwise.   79
3.2.  Methods 
3.2.1.  Growth and Maintenance of E. coli 
Escherichia coli (E. coli) were grown in LB broth (1% bactotryptone, 0.5% yeast 
extract, 1% NaCl) with shaking at 250rpm or streaked out on solid LB agar plates 
(1.5% agar dissolved in LB by heating) and maintained at 37°C. LB broth or agar 
containing 100µg/ml ampicillin was used for antibiotic selection. Bacterial cultures 
containing plasmids were stored at -80°C in LB broth containing 15% (v/v) glycerol. 
3.2.2.  Production of Electrocompetent XL-1 Blue E. coli 
1L LB broth was inoculated 1/100 with an overnight culture of XL-1 Blue E. coli and 
shaken at 37°C until the culture reached an OD600 of 0.6. The culture was chilled on 
ice for 15min and centrifuged at 6000g  for 10 minutes at 4°C. The pellet was 
resuspended in 10% (v/v) glycerol to a volume equal to the original culture and 
centrifuged as before. The pellet was resuspended in 10% glycerol to 1/2 volume of 
the original culture and centrifuged as before. The pellet was resuspended in 10% 
glycerol to 1/4 volume of the original culture and centrifuged as before. The pellet 
was resuspended in 10% glycerol to 1/50 volume of the original culture and 
centrifuged as before. The pellet was resuspended in 10% glycerol to 1/500 volume of 
the original culture and 50µl aliquots were stored at -80°C. 
3.2.3.  Production of Chemically Competent Stbl3 E. coli 
The method of Inoue (468) was used to produce high efficiency chemically competent 
E. coli. A 5ml starter culture of LB broth was made by inoculation with a single 
colony of Stbl3 E. coli and shaken at 37°C overnight. The next day this was used to 
inoculate 250ml SOB (2% bactotryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM 
KCl autoclaved and 10mM MgCl2 and 10mM MgSO4 sterile-filtered and added 
before use) and culture was shaken at 18°C to an OD600 of 0.6. The culture was 
chilled on ice for 15min and centrifuged at 2500g for 5min at 4°C. The pellet was 
gently resuspended in 80ml TB (10mM PIPES, 15mM CaCl2, 250mM KCl, 55mM 
MnCl2, 1M KOH to pH6.7), chilled on ice for 10min, and centrifuged as before. The   80
pellet was resuspended in 20ml 7% DMSO in TB, chilled on ice for 10min, and 50µl 
aliquots were snap frozen in liquid nitrogen and stored at -80°C. 
3.2.4.  Transformation of Electrocompetent E. coli 
10pg plasmid or 200ng desalted ligation products were gently mixed with a 50µl 
aliquot of electrocompetent E. coli, transferred to a 2mm electroporation cuvette, and 
electroporated at 2.5kV 200Ω 25µF with a Bio-Rad Gene Pulser II. 1ml LB broth was 
added to the cuvette and the combined contents were removed into a new tube and 
shaken at 37°C for 1 hour before plating out on an LB agar plate. 
3.2.5.  Transformation of Chemically Competent E. coli 
10pg plasmid or 200ng ligation products were gently mixed with a 50µl aliquot of 
electrocompetent E. coli and stored on ice for 30min. The cells were heated to 42°C 
for 45s and chilled on ice for 2min. The cells were transferred to a new tube 
containing 250µl SOC medium (20mM glucose in SOB as described in Section 3.2.3) 
and shaken at 37°C for 1 hour before plating out on an LB agar plate. 
3.2.6.  Plasmid DNA Preparation 
E. coli containing plasmids were cultured by shaking in LB broth with the relevant 
antibiotic at 37°C overnight. Plasmid DNA was extracted by alkaline lysis using a 
Qiagen Spin Miniprep (≤20µg plasmid DNA), Qiagen Plasmid Maxiprep (≤500µg), 
or Qiagen Spin Megaprep (≤2.5mg) kit according to the manufacturer’s instructions. 
DNA concentration was quantified by measuring the ABS260 on a NanoDrop ND-
1000 spectrophotometer. 
3.2.7.  Ethanol Precipitation of DNA 
DNA in solution was precipitated by adding 1/10 volume of 3M sodium acetate pH5.2 
and 2 volumes of 100% ethanol, storing at -20°C for 1 hour, and centrifuging at 
13,000rpm in a microcentrifuge for 30min. The pellet was washed with 70% ethanol, 
centrifuged as before, and resuspended in distilled water or TE (10mM Tris-HCl pH 
8.0, 1mM EDTA).   81
3.2.8.  Restriction Endonuclease Digestion of Plasmid DNA 
1-2µg plasmid was digested with one or two restriction endonucleases (<10% final 
volume), 1X buffer (provided by the enzyme manufacturer), and 0.1mg/ml BSA in a 
final volume of 20µl. Digestion was performed for 1-2 hours at the appropriate 
temperature for the enzyme being used. 
3.2.9.  Filling of 5’ Single Stranded DNA Overhangs 
5’ overhangs in 1µg digested DNA were filled using the 5’-3’ polymerase activity of 
1U DNA Polymerase I (Klenow Large Fragment) in 1X DNA Polymerase I buffer 
(provided by the enzyme manufacturer), 0.1mg/ml BSA, and 40µM of all four dNTPs 
in 20µl at room temperature for 10min. 
3.2.10.  Exonuclease Removal of 3’ Single Stranded DNA Overhangs 
3’ overhangs in 1µg digested DNA were removed using the 3’-5’ exonuclease activity 
of 5U T4 DNA Polymerase in 1X T4 DNA Polymerase buffer (provided by the 
enzyme manufacturer), 0.1mg/ml BSA, and 100µM of all four dNTPs in a total 
volume of 20µl at 37°C for 5min. 
3.2.11.  Dephosphorylation of 5’ DNA Termini 
5’ phosphate groups were removed from up to 10pmol digested DNA ends using 
0.05U Calf Intestinal Alkaline Phosphatase in 1X CIAP buffer (provided by the 
enzyme manufacturer) in a total volume of 50µl at 37°C for 1 hour. 
Dephosphorylation of recessed 5’ phosphate groups was enhanced by alternating 
incubations at 37°C and 56°C every 15 minutes for 1 hour and adding fresh enzyme 
after 30 minutes. 
3.2.12.  Agarose Gel Electrophoresis 
0.5-2% high melting point agarose or 4% low melting point agarose was dissolved in 
1X TAE buffer (40mM Tris-acetate, 5mM EDTA) by heating and 0.5µg/ml ethidium 
bromide was added before allowing the gel to set within an appropriate form. DNA 
samples were loaded with Orange G loading dye (10% glycerol, 0.1% Orange G), a   82
1kb Plus ladder was added as a standard and fragments were separated by 
electrophoresis in 1X TAE at 80-120V and visualised by exposure to ultraviolet light 
using a UviDoc gel documentation system. 
3.2.13.  Agarose Gel Purification of DNA Fragments 
Fragments separated by gel electrophoresis were excised from the gel using a scalpel 
and purified using the Qiaquick Gel Extraction kit. This uses a chaotropic salt solution 
to dissolve the agarose gel matrix and reversible DNA binding to a silica filter to 
purify the DNA. 
3.2.14.  Ligation of DNA Fragments 
100-200ng digested plasmid backbone was ligated to insert DNA in a 1:1 or 1:3 molar 
ratio using 3U T4 DNA ligase and 1X T4 DNA ligase buffer (provided by the enzyme 
manufacturer) in a total volume of 20µl. Ligation of sticky ends was performed for 3 
hours at room temperature and ligation of blunt ends was performed at 15°C 
overnight. Ligation products were subsequently transformed into competent E. coli to 
recover successful events. 
3.2.15.  Topoisomerase-T/A Cloning 
4µl fresh Taq polymerase-amplified PCR products were cloned into 10ng pCR2.1-
TOPO vector in the presence of 200mM NaCl 10mM MgCl2 at room temperature for 
30min. Products were immediately transformed into competent E. coli to recover 
successful events. 
3.2.16.  Isolation of Mammalian Genomic DNA by Salting Out 
Episomal and chromosomal DNA was extracted from cells using the salting out 
method of Miller (469). 10
6 cells were suspended in 3ml nuclear lysis buffer (10mM 
Tris-HCl pH8.2, 0.4M NaCl, 2mM Na2EDTA) to which 1/15 volume 10% SDS and 
1/6 volume Proteinase K solution (2mg/ml Proteinase K, 1% SDS, 2mM Na2EDTA) 
were added to lyse the cells. Lysis was performed at 37°C overnight. Cell debris was 
precipitated by the addition of 1/4 volume 6M NaCl followed by vigorous shaking. 
The debris was pelleted by centrifugation at 2500rpm for 15min. The supernatant was   83
removed into a fresh tube and the DNA was precipitated by the addition of 2 volumes 
of ethanol. The DNA was pelleted at 4000rpm for 30min, washed with 70% ethanol, 
and dissolved in TE at 37°C overnight. 
3.2.17.  Southern Blotting 
10μg genomic DNA was digested with 10-40U of restriction enzymes at 37°C 
overnight. Digestion products were separated by electrophoresis on a 0.8% agarose 
gel. The gel was shaken in 0.25M HCl for 30min, rinsed in distilled water, and then 
shaken in denaturation solution (1.5M NaCl, 0.5M NaOH) for two periods of 20min 
(replacing the solution between periods). The gel was rinsed in distilled water and 
shaken in neutralisation solution (1.5M NaCl, 0.5M Tris pH7) for two periods of 
20min (replacing the solution between periods). The DNA was then blotted overnight 
onto an Amersham Hybond-N membrane (GE Life Sciences, Piscataway, NJ) by 
capillary transfer using 20X SSC (3M NaCl, 0.3M trisodium citrate dihydrate). The 
membrane was washed in 2X SSC and dried. 
To visualise bands containing the eGFP coding sequence, a radiolabelled probe was 
produced by restriction digestion of plasmid pLNT/SFFV-eGFP-WPRE plasmid with 
BamHI and XbaI followed by gel extraction of the 750bp eGFP fragment. This was 
labelled using the Megaprime DNA Labelling System (GE Life Sciences, Piscataway, 
NJ). Briefly, the fragment was denatured by heating to 95°C and labelling buffer 
containing random 6nt primers, Klenow large fragment DNA polymerase, and 20μCi 
32P dCTP were added. The DNA polymerisation reaction was incubated at 37°C for 
10min. Unincorporated radioisotope was then removed by centrifugation through an 
Amersham MicroSpin-s-300 HR Column (GE Life Sciences, Piscataway, NJ), eluting 
radiolabelled probe. 
The membrane was wet in 2X SSC and placed in a hybridisation tube. The membrane 
was covered with Church mix (1% BSA, 7% SDS, 0.4M Na2HPO4, 0.1M NaH2PO4) 
and pre-hybridised by rotating at 68°C for 1h. The probe was denatured by heating 
and added to the hybridisation tube. Hybridisation was performed by rotating at 68°C 
overnight. The next day, the membrane was washed at 65°C with 0.5% SDS and 
decreasing concentrations of SSC (2X, 0.5X, 0.2X, 0.1X) until the background signal 
from the membrane as determined with a Geiger counter on an irrelevant region of the   84
membrane was low. The activity was visualised by exposing a phosphor screen to the 
membrane overnight and imaging using a Molecular Dynamics Typhoon 9410 
phosphorimager (GE Life Sciences, Piscataway, NJ). 
3.2.18.  PCR Amplification of Fragments for Plasmid Subcloning 
PCR was performed using 100ng template DNA, 1µM of each primer, 200µM each 
dNTP, 1.25U Pfu polymerase, and 1X Pfu polymerase buffer (provided by the 
enzyme manufacturer) in a total volume of 50µl. Initial denaturation was performed at 
95°C for 2min and followed by 30 amplification cycles consisting of denaturation at 
95°C for 30s, primer annealing at 58°C for 30s (the annealing temperature was 
adjusted with reference to the primer melting temperatures), extension at 72°C for 
1min/kb, and a final extension step of 5min at 72°C. 
3.2.19.  Screening Transformed E coli by Colony PCR 
Bacterial colonies were picked directly into wells in a 96-well PCR plate containing 
1µM of each primer, 2mM MgCl2, 200µM each dNTP, and 1X GoTaq polymerase 
buffer (provided by the enzyme manufacturer) in a total volume of 50µl. The block 
was heated to 100°C for 5min to lyse the cells. 1.25U GoTaq polymerase was added 
to each well before standard PCR temperature cycling. 
3.2.20.  Quantitative Real-Time PCR (qPCR) 
Approximately 100ng of genomic DNA was used as a template for each reaction. 
Reactions were performed in triplicate using 0.9 µM of each primer, 0.2 µM of 
fluorescent probe, and the Platinum qPCR SuperMix-UDG with ROX mastermix 
(Invitrogen). Real time PCR was carried out for 40 cycles of [95 °C 15s; 60°C 1min] 
and quantified using an ABI Prism 7000 (Applied Biosystems, Foster City, CA). 
Plasmid standards containing the human β-actin coding sequence or HIV-1 vector 
sequences were a kind gift from Mike Blundell at the Institute of Child Health, 
University College London.  
Human β-actin qPCR 
Forward primer   5′-TCA CCC ACA CTG TGC CCA TCT ACG A-3′   85
Reverse primer   5′-CAG CGG AAC CGC TCA TTG CCA ATG G-3′ 
Probe   5′-FAM-ATG CCC TCC CCC ATG CCA TCC TGC GT-
TAMRA-3′ 
WPRE qPCR 
Forward primer   5’-TTC TCC TCC TTG TAT AAA TCC TGG TT-3’ 
Reverse primer   5’-CGC CAC GTT GCC TGA CA-3’ 
Probe   5’-FAM-CTG TCT CTT TAT GAG GAG TTG TGG CCC G-
TAMRA-3’ 
HIV-1 primer binding site qPCR 
Forward primer   5'-TGT GTG CCC GTC TGT TGT GT-3’ 
Reverse primer   5'-GAG TCC TGC GTC GAG AGA GC-3’ 
Probe      5'-FAM-CAG  TGG  CGC CCG AAC AGG GA-TAMRA-3' 
3.2.21.  Ligation-Mediated PCR (LM-PCR) for Recovery of 
Integration Sites 
LM-PCR linker and primers 
Linker+  5’-GTA ATA CGA CTC ACT ATA GGG CTC CGC TTA 
AGG GAC CGC ATG-3’ 
Linker-     5’-P-CGG TCC CTT AAG CGG AG-3’ (note 5’ phosphate) 
Linker first round   5’-GTA ATA CGA CTC ACT ATA GGG C-3’ 
Linker nested    5’-AGG GCT CCG CTT AAG GGA C-3’ 
3’ LTR first round   5’-AGT GCT TCA AGT AGT GTG TGC C-3’ 
3’ LTR nested   5’-GTC TGT TGT GTG ACT CTG GTA AC-3’   86
IRDRR first round   5’-ACC CAC TGG GAA TGT GAT GAA AG-3’ 
IRDRR nested   5’-AAT AAA GTG GTG ATC CTA ACT GAC C-3’ 
All nucleotides were obtained from Invitrogen at 25nmol scale and desalted purity. 
Linker oligos were used in all LM-PCR reactions, 3' LTR oligos were used to recover 
HIV-1 integration sites and IRDRR oligos were used to recover SB integration sites. 
Sequences were modelled after Wu et al (470) and Ikeda et al (471).  
Linker cassette was produced by heating 100pmol Linker+ and 100pmol Linker- in 
200µl 250mM Tris pH7.5 100mM MgCl2 to 95°C for 5min in a hot block and 
allowing the solution to cool slowly to room temperature. Cassette was aliquoted and 
stored at -20°C. 
1µg genomic DNA was digested with NlaIII overnight and subsequently with BamHI 
to prevent recovery of any remaining transposon-plasmid or transposon-lentivector 
junctions. The mixture was heat inactivated at 65°C for 20min. The digested DNA 
was ligated to 1µl of cassette at room temperature for 3 hours and heat inactivated at 
70°C for 10min. First round PCR was performed using one tenth of the ligation 
reaction and GoTaq polymerase under conditions 95°C 2min; 30x [95°C 30s; 55°C 
30s; 72°C 1min]; 72°C 5min. 1/100 of the product was used for the nested PCR 
reaction under the same cycling conditions.  
In the first round of integration site sequencing, these LM-PCR products were Topo-
TA cloned into the pCR2.1 vector, transformed into Stbl3 cells and the plasmids were 
sequenced using conventional Sanger sequencing by Functional Biosciences of 
Madison, WI.  
In the second round of integration site sequencing, LM-PCR products were sent for 
454 pyrosequencing (472) by our collaborator Richard Gabriel in the laboratory of 
Manfred Schmidt at the German Cancer Research Center (DKFZ) in Heidelberg, 
Germany. In this method, additional PCR was performed on LM-PCR products using 
fusion primers A and B to add adaptor sequences for pyrosequencing. Each fusion 
primer A contained an individual barcode sequence of 6 nucleotides (N) that allowed 
identification of different samples sequenced in the same sequencing run. Briefly,   87
primer A was joined to a lentiviral vector specific LTR primer (fusion primer-A-LTR: 
Sequence: 5´-GCC TCC CTC GCG CCA TCA GNN NNN NTG TGT GAC TCT 
GGT AAC TAG) or Sleeping Beauty IRDR-R specific primer (fusion primer A-
IRDRR, Sequence: 5´-GCC TCC CTC GCG CCA TCA GNN NNN NGT ATT TGG 
CTA AGG TGT ATG) and fusion primer B was joined to a linker cassette specific 
primer (fusion primer B-LK, Sequence: 5´-GCC TTG CCA GCC CGC TCA GAG 
GGC TCC GCT TAA GGG AC). 40ng of purified LM-PCR products were amplified 
by fusion primer PCR under conditions 95°C 2min; 12x [95°C 45s; 60°C 45s; 72°C 
60s]; 72°C 5min.   A sample of the PCR products was analysed by agarose gel 
electrophoresis before pyrosequencing using a 454 GenomeSequencer Flx (454 Life 
Sciences, Branford, CT). 
3.2.22.  Integration Site Bioinformatics 
Raw sequence reads obtained after sequencing were trimmed and aligned to the 
human genome. Integration sites were considered to be valid if a vector-genome 
junction sequence was present and the flanking genomic region had a unique 
sequence match of at least 95% after alignment to the human genome release hg18 
(University of California at Santa Cruz, (UCSC) RefSeq genes and RepeatMasker 
(473). Chromosome graphs were generated using the UCSC Genome Graphs tool. 
HeLa cell expression data were obtained from the public Gene Expression Omnibus 
database with accession number GSM157868, a dataset obtained from total RNA 
using a GeneChip Scanner 3000 (Affymetrix). Sequence logos were produced with 
the WebLogo tool (474). 
3.2.23.  Propagation and Storage of Mammalian Cell Lines 
Adherent cells were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing GlutaMAX supplemented with 10% foetal calf serum (FCS) and 1% 
penicillin/streptomycin (hereafter referred to as ‘complete DMEM’). Suspension cells 
were maintained in RPMI 1640 medium containing GlutaMAX, serum, and 
penicillin/streptomycin as before. All cells were incubated at 37°C and a 5% CO2 
atmosphere. For long term storage, 1-5 x 10
6 cells were suspended in freezing 
medium (50% complete DMEM, 40% FCS, 10% DMSO) and frozen to -80°C slowly 
overnight in an isopropanol freezing box before long term storage in liquid nitrogen.   88
3.2.24.  G418 Selection of HeLa Cell Colonies 
HeLa cells were transfected or transduced in 24-well plates with a neomycin 
resistance cassette and incubated without selection for three days. On the third day 
cells were trypsinised and 1/10
th or 1/50
th of the suspension was seeded into a fresh 
24-well plate. Cells were maintained without trypsinisation in complete DMEM 
containing 1mg/ml G418 for two weeks with a medium change every three days. 
3.2.25.  Quantification of Mammalian Cell Colonies 
Colonies were fixed with 1% paraformaldehyde in PBS and stained with crystal violet 
in PBS. Plates were air-dried overnight and scanned using a Hewlett-Packard ScanJet 
scanner. The number of colonies in each image file was counted using CellProfiler 
image-processing software (475). 
3.2.26.  Lentiviral Vector Preparation 
1.2 x 10
7 HEK293T cells were seeded in 175cm
2 flasks one day before transfection to 
reach >90% confluence. For each flask, 50µg vector plasmid, 32.5µg packaging 
plasmid pCMV-dR8.74 (for integrating virus) or pCMV-dR8.74 D64V (non-
integrating virus), and 17.5µg vesicular stomatitis virus envelope plasmid pMDG2 
was added to 5ml Optimem and 0.22µm filtered. 1µl PEI was added to 5ml Optimem 
and also 0.22µm filtered. The two mixtures were combined and allowed to complex 
for 20min. Cells were washed with PBS, overlaid with the complex, and incubated at 
37°C 5%CO2  for 4 hours. The complex was removed and replaced with complete 
DMEM. 24 hours later, the medium was replaced. 48 and 72 hours after transfection 
the medium was removed, 0.22µm filtered, and centrifuged at 98,000g for 2 hours. 
Virus pellets were resuspended in Optimem and aliquots were stored at -80°C. 
3.2.27.  Titration of Lentiviral Vector Preparations 
3.2.27.1. Expression Titre 
10
5 cells of the cell line of interest were seeded into each well of a 24-well plate one 
day before transduction. For transduction, a 5-fold dilution series of virus in 500µl 
aliquots of complete medium was performed. Each aliquot of diluted virus was used   89
to replace the medium in one well. Transgene expression was measured by flow 
cytometry 48 hours post-transduction or by G418-resistant colony counting as 
described in Section 3.2.24. Expression titre was calculated by selecting the well in 
which 5-15% of transduced cells expressed the transgene of interest and dividing the 
number of transduced cells in this well by the volume of virus used to transduce them. 
3.2.27.2. Vector DNA Copy Number Titre 
Cells were transduced as above. 48 hours post-transduction, cells were trypsinised and 
DNA was extracted as described in Section 3.2.16. The WPRE copy number and the 
total cell number were determined by quantitative PCR as described in Section 3.2.20. 
The titre was calculated as the total WPRE copy number in all cells in the well 
divided by the volume of virus used to transduce them. 
3.2.27.3. Physical Titre 
The mass of HIV-1 p24 antigen in the lentiviral vector preparation was determined 
using the Retrotek HIV-1 p24 Antigen ELISA kit according to the manufacturer’s 
instructions. Concentrated vector preparation was diluted 1:90 in 450µl Optimem 
before the initial lysis step. Proteins present in the lysed vector were adhered to the 
wells of a microplate, and biotinylated anti-p24 antibody allowed to bind selectively 
to p24 antigen. Streptavidin-horseradish peroxidase was bound to the biotinylated 
antibody. The oxidation of tetramethybenzidine by peroxidase was quantified by 
measurement of A450 in a plate reader. The concentration of p24 antigen in the 
preparation was estimated from an A450 – p24 concentration standard curve using 
known standards supplied with the kit. 
3.2.27.4. RNA genome quantification 
Virion particles in concentrated lentiviral supernatant were lysed using TRIzol reagent 
for 5min and extracted with chloroform by shaking and centrifugation. The aqueous 
phase was transferred to a fresh tube, precipitated with isopropanol and pelleted by 
centrifugation. The pellet was washed with 75% ethanol and dissolved in RNase-free 
water. Plasmid carryover in the preparation was destroyed by digesting with 1U 
amplification grade DNase I per μg of RNA at room temperature for 15min. The   90
DNase I was heat-inactivated at 65°C for 10min. The RNA was reverse-transcribed 
using M-MLV reverse transcriptase and random primers according to the 
manufacturer’s instructions. The resultant cDNA was used as a template for 
quantitative PCR analysis. 
3.2.28.  Transduction of Target Cells 
10
5 cells of the cell line of interest were seeded into each well of a 24-well plate one 
day before transduction. Transductions were performed by adding virus to 500µl of 
complete medium in each well. 
3.2.29.  Transfection of Target Cells 
10
5 cells of the cell line of interest were seeded into each well of a 24-well plate one 
day before transduction. Plasmid DNA was complexed with Lipofectamine 2000 in a 
1:2 ratio in Optimem for 20min. Complex was added directly to 500µl complete 
medium in each well. 
3.2.30.  Flow Cytometry 
The fluorescence of cells expressing eGFP was measured using a CyAn ADP flow 
cytometry analyser (Dako, Glostrup, Denmark). Data was analysed using FlowJo 
version 7.2.4 (Tree Star Inc, Ashland, OR). 
3.2.31.  Western Blotting 
Cells were lysed in lysis buffer (1% Nonidet P40, 130mM NaCl, 20mM Tris-HCl pH 
8.0, 10mM NaF, 2mM sodium orthovanadate, 1% aprotinin, 10µg/ml leupeptin, 1mM 
phenylmethylsulfonyl fluoride, 2mM EDTA, 2µM Cytochalasin D, 2µM Latrunculin 
B) at 95°C for 2 minutes. 1X NuPAGE LDS Sample Buffer and 1X NuPAGE Sample 
Reducing Agent were added to the lysis products. The samples and the SeeBlue Plus2 
Prestained Standard were separated by electrophoresis in a Novex 4-12% Bis-Tris gel 
in 1X MES buffer at 200V for 35min. The separated proteins were wet-transferred 
onto a methanol-activated Immobilon-P PVDF membrane using the X-Cell II Blot 
Module and 1X NuPAGE Transfer Buffer containing 0.1% NuPAGE Antioxidant and 
10% methanol at 30V for 1 hour. The membrane was blocked in PBST (PBS   91
containing 0.5% Tween-20 and 5% BSA) for 1 hour. Primary antibody staining was 
performed for 1 hour with a 1:200 dilution of Santa Cruz rabbit anti-eGFP or a 1:500 
dilution of R&D Systems mouse anti-SB11 in PBST. After washing three times with 
PBST, secondary antibody staining was performed for 45min with either a 1:2000 
dilution of ECL horseradish peroxidase conjugated donkey anti-rabbit or a 1:1000 
dilution of R&D Systems horseradish peroxidase-conjugated donkey anti-mouse in 
PBST. After washing three times with PBST, peroxidase activity was visualised using 
the Pierce ECL Western Blotting Substrate and a UviChemi chemiluminescence 
detection system. 
3.2.32.  Confocal Microscopy 
Cells were seeded onto poly-L-lysine slides and transfected or transduced in complete 
DMEM culture medium. 48 hours later, cells were washed with PBS, fixed with 1% 
paraformaldehyde, and stained with a 1:200 dilution of DiI (Invitrogen) or a 1:40 
dilution of rhodamine phalloidin (Invitrogen) in PBS. Stained cells were washed in 
PBS and mounted with Vectashield Mounting Medium with DAPI (Vector 
Laboratories, Burlingame, CA). Confocal images were obtained using a Leica SP2 
confocal laser scanning microscope (Leica, Milton Keynes, UK).   92
4.  Lentivirus-Transposon Hybrid Vectors 
Expressing eGFP 
4.1.  Aims 
•  To incorporate the transposon and transposase elements of the Sleeping 
Beauty system into lentiviral vectors 
•  To demonstrate expression of the Sleeping Beauty transposase from a non-
integrating lentiviral vector 
•  To demonstrate transposition from a non-integrating lentiviral vector into host 
chromosomes 
4.2.  Introduction 
Successful clinical trials using gammaretroviral vectors to treat haematopoietic 
disorders have highlighted the usefulness of integrating vectors in mitotic tissues 
(476;477), but serious adverse events have been observed in which vector integration 
near proto-oncogenes led to cell transformation (478;479). Gammaretroviral, 
lentiviral, and foamy virus vectors are all being developed for gene therapy, and all 
three vectors integrate preferentially near host genes or regulatory elements (480-
482). By contrast, vectors based on the Sleeping Beauty transposon integrate almost 
randomly with respect to these elements and are potentially safer in this respect (483). 
Sleeping Beauty vectors are conventionally transfected into target cells as plasmids 
using non-viral techniques. However, non-viral transfection of important targets such 
as haematopoietic stem cells is higly inefficient. A hybrid vector combining the 
efficient cell and nuclear entry properties of HIV-1 vectors with the random 
integration profile of Sleeping Beauty would represent a theoretically safer alternative 
compared to conventional lentiviral vectors. This chapter describes the initial 
construction and testing of this hybrid vector using eGFP expression as a reporter for 
integration efficiency. 
Sleeping Beauty transposition within a target cell requires two components, namely a 
DNA transposon and the transposase protein to mediate the transposition reaction.   93
The two components can be delivered to target cells in  cis on the same vector 
molecule or in trans through simultaneous transduction or transfection with a 
transposon vector and a transposase-expression vector (484). The cis configuration is 
preferable from a clinical perspective as it requires only one vector to be developed, 
approved, and administered. There is also a theoretical efficiency gain to be made 
through guaranteeing the presence of transposon and transposase in the same cells, 
though this has not been widely reported. However, the need to accurately control the 
concentration of transposase in target cells is better served by a trans configuration 
which allows the two components to be titrated against one another, and generally the 
cis configuration is used to refine a trans Sleeping Beauty system once it is 
established. The trans approach was adopted in this chapter. 
Since the aim of the project was to reduce the risk of insertional mutagenesis due to 
integration mediated by the HIV-1 integrase, Sleeping Beauty components were 
delivered to target cells using non-integrating lentiviral vectors in which the catalytic 
activity of HIV-1 integrase is blocked by the D64V mutation (485). The lentivirus-
transposon vector was initially constructed so that the transposon was in the reverse 
orientation relative to the lentiviral backbone (Figure 4.1) in order to prevent 
termination of transcription at a known polyadenylation signal present within the 
Sleeping Beauty right inverted repeat (486). 
The hybrid vector strategy is illustrated in Figure 2.11. Target cells are co-transduced 
with two non-integrating lentiviral vectors for delivery of transposase expression and 
the transposon cargo. Following reverse transcription and nuclear localisation, the 
transposase protein is expressed and imported into the nucleus. Here transposase 
binds to the transposon inverted repeats and catalyses excision of the transposon from 
the episomal lentiviral vector backbone. The resulting preintegration complex is 
mobile and moves within the nucleus until it encounters a suitable target DNA. 
Transposase then catalyses the integration of the transposon into the target DNA. The 
lentiviral episomes are subsequently diluted through repeated cell division.   94
4.3.  Cloning and Testing of Lentivirus-Transposon Vectors 
4.3.1.  Plasmid Subcloning of eGFP Transposon and Transposase 
Expression Vectors 
 
Figure 4.1 Vector map of the eGFP transposon and transposase expression plasmids.  
(a) parental plasmids; (b) plasmids cloned in this study. MCS, multiple cloning site; SBΔDDE, 
truncated Sleeping Beauty transposase in which the DDE catalytic domain has been removed; pA, 
polyadenylation signal; 5’LTR, HIV-1 5’ long terminal repeat; Ψ, HIV-1 RNA packaging signal; SIN, 
self-inactivating (U3-deleted) HIV-1 long terminal repeat; cPPT, central polypurine tract; CMV, 
immediate early promoter of human cytomegalovirus; WPRE, woodchuck posttranscriptional 
regulatory element; IL, Sleeping Beauty transposon left inverted repeat; IR, Sleeping Beauty 
transposon right inverted repeat; SFFV, spleen focus forming virus U3 promoter; eGFP, enhanced 
green fluorescent protein.   95
pT2/SFFV-eGFP 
The eGFP expression cassette was derived from lentiviral backbone pLNT/SFFV-
eGFP-WPRE, a previously described variant of pHR containing a self-inactivating 3’ 
LTR, a central polypurine tract (cPPT), the spleen focus forming virus U3 promoter 
(SFFV), an enhanced green fluorescent protein reporter gene (eGFP), and the 
woodchuck posttranscriptional regulatory element (WPRE) (487). This was digested 
with BamHI, the ends filled in using DNA polymerase I Large (Klenow) Fragment, 
and then religated using T4 DNA Ligase to destroy this site. This plasmid was 
recovered and digested with EcoRI and XbaI to yield a fragment containing SFFV-
eGFP. This was cloned into Sleeping Beauty transposon plasmid pT2/HB (488) (a 
kind gift from Scott McIvor, University of Minnesota) between the EcoRI and XbaI 
sites to give pT2/SFFV-eGFP. 
pLNT/CMV-SB11 
The SFFV promoter was removed from pLNT/SFFV-MCS-WPRE by digestion with 
EcoRI and XhoI. The CMV promoter was obtained from the hyperactive transposase 
expression plasmid pCMV-SB11 (489) (a gift from Scott McIvor) with EcoRI and 
XhoI. Ligation of the two plasmids yielded pLNT/CMV-MCS-WPRE. 
pCMV-SB11 was digested with SacII to obtain the SB11 transposase coding 
sequence. This was cloned into pBluescript at the SacII site so that the pBS XhoI site 
was 5’ of SB11 and the pBS SacI site was 3’. The new plasmid was named 
pBS/SB11. 
pLNT/CMV-MCS-WPRE was digested with KpnI, the 3’ overhang removed with T4 
DNA polymerase, and then digested with XhoI. pBS/SB11 was digested with SacI, 
blunted with T4 DNA polymerase, and then digested with XhoI to obtain SB11. 
Ligation of SB11 into the lentiviral backbone yielded pLNT/CMV-SB11. 
pLNT/tn[SFFV-eGFP] REV 
pT2/SFFV-eGFP was digested with EcoRI. The ends were filled in using DNA 
polymerase I Large (Klenow) Fragment and then religated using T4 DNA Ligase to 
destroy the EcoRI site. The transposon from EcoRI-deleted pT2/SFFV-eGFP was   96
PCR-amplified using primer 5’-TGC CAA GAA TTC GGA TCC CTA TAC AG-3’ 
(this acts as both forward and reverse primer) to give it EcoRI ends. This fragment 
and lentiviral backbone pLNT/SFFV-MCS-WPRE (another pHR variant containing a 
multiple cloning site) were digested with EcoRI and ligated to give pLNT/tn[SFFV-
eGFP] REV SFFV. The eGFP transposon was obtained from pT2/SFFV-eGFP by 
BamHI digestion and ligated into the BamHI-digested pLNT/tn[SFFV-eGFP] REV 
SFFV backbone to give pLNT/tn[SFFV-eGFP] REV. Colonies were screened to 
ensure the transposon was in the reverse orientation.  
As a technical note, cloning of transposon constructs in Stratagene XL-1 Blue E. coli 
proved to be inefficient due to a very high proportion of rearranged plasmids, perhaps 
as a result of recombination between the highly homologous IRs. When cloning was 
performed using low recombination activity Invitrogen Stbl3 E. coli, the recovery of 
the desired constructs was less difficult. 
4.3.2.  Assaying Transposition from a Plasmid Donor 
A chromosomal integration assay was established to determine the level of 
transposition in target cells. Direct measurement of integration through quantitative 
PCR has been reported but such assays are not commonly used (490). A more 
conventional approach is to transfect or transduce a dividing cell population with the 
vector or vectors, allow the cells to divide repeatedly in order to dilute persisting 
episomal DNA, and at a suitable endpoint measure the proportion of cells which 
express the reporter gene. It is assumed that reporter gene expression detected after a 
sufficient number of cell divisions will be the product of integrated DNA. 
An assay of this type was used to assess transposition of the eGFP transposon from 
plasmid pT2/SFFV-eGFP (Figure 4.2). 293T cells were transfected with the 
transposon plasmid and an equal mass of plasmid expressing either the SB11 
transposase or a Sleeping Beauty transposase from which the catalytic domain had 
been removed (SBΔDDE). Equal efficiency of the initial level of gene transfer was 
confirmed by flow cytometry 2 days after transfection. Cells were passaged until 14 
days post-transfection in order to dilute unintegrated plasmid and the level of 
persistent gene expression was measured. The level of stable gene expression was 
greatly increased in cells transfected with the active rather than the truncated   97
transposase, demonstrating successful transposition of the pT2/SFFV-eGFP 
transposon.   98
 
 
Figure 4.2 Transposition from eGFP transposon plasmid pT2/SFFV-eGFP.  
10
5 293T cells were transfected with 400ng pT2/SFFV-eGFP and 400ng of either the active 
transposase plasmid pCMV-SB11 or the inactive mutant transposase plasmid pCMV-SBΔDDE. eGFP 
expression was determined by flow cytometry 2 and 14 days post-transfection. The proportion of cells 
expressing eGFP is given as a percentage within the gated area.   99
4.3.3.  Expression of Transposase from a Non-integrating Lentiviral 
Vector 
Transient transposase expression is desirable in Sleeping Beauty applications in order 
to minimise the risk of repeated transposon remobilisation. Transgene expression can 
be lost over time in dividing cells transduced with non-integrating lentiviral vectors 
through dilution of the episomal lentiviral DNA (491). In order to demonstrate this in 
the context of transposase expression, integrating and non-integrating lentiviral 
vectors for transposase expression were produced in parallel using vector plasmid 
pLNT/CMV-SB11. HeLa cells were transduced with equal volumes of the two 
vectors and passaged for two weeks. Cells were subcultured every three days, and cell 
pellets were frozen down to assess transposase expression over time by Western blot 
(Figure 4.3). 
When transposase was expressed from a non-integrating lentiviral vector, expression 
of the 40kDa SB11 protein was detectable 1 day post-transduction and reached its 
maximum on day 2. Expression subsequently fell until it was no longer detectable by 
day 7. Expression from integrating vector was also greatest on day 2 but subsequently 
remained stable.   100
 
 
Figure 4.3 Western blot for expression of transposase from lentiviral vectors.  
Integrating and non-integrating lentiviral vectors expressing transposase were prepared in parallel using 
plasmid pLNT/CMV-SB11. 10
6 HeLa cells were transduced with 5μl of virus per well. At 1, 2, 3, and 7 
days post-transduction, cell pellets of equal cell number were frozen down for Western blotting. U, 
untransduced; INT+, integrating vector; INT-, non-integrating vector. 
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4.3.4.  Physical and Functional Titration of Lentiviral Vector 
Carrying a Transposon in the Reverse Orientation 
To test whether lentiviral vectors are functionally able to deliver Sleeping Beauty 
transposons to target cells, non-integrating lentiviral vector was produced using the 
pLNT/tn[SFFV-eGFP] REV plasmid. Functional titration was performed by 
transducing 293T cells with a serial dilution of this vector and assessing eGFP 
expression by flow cytometry 2 days post-transduction (Figure 4.4). 
The functional titre was estimated to be 3.2x10
6 TU/ml. This is at least two orders of 
magnitude less than would be expected with a well-packaged lentiviral vector 
preparation concentrated by ultracentrifugation, and repeated vector preparations did 
not result in improved titre (data not shown). 
To further investigate this problem, the physical titre of the original vector preparation 
was measured by p24 ELISA. The physical titre measures the concentration of viral 
proteins in the vector preparation and measures the production of virions by producer 
cells rather than the functioning of the vector genome in target cells. The physical titre 
of the original vector preparation was found to be 1.6x10
6 pg p24/ml while the 
physical titre of non-integrating LNT/CMV-SB11 was 1.4x10
8 pg p24/ml. The 
expected physical titre of a well-packaged lentiviral vector is in the range 10
7-10
8 pg 
p24/ml after concentration by ultracentrifugation (492), indicating problems in the 
production of LNT/tn[SFFV-eGFP] REV but not LNT/CMV-SB11. The low physical 
titre of the LNT/tn[SFFV-eGFP] REV preparation may have been due to cytotoxicity 
of the vector plasmid to the producer cells, for example caused by contamination 
during plasmid preparation.   102
 
 
Figure 4.4 Functional titration of eGFP transposon lentivirus LNT/tn[SFFV-eGFP] REV.  
10
5 293T cells were transduced with serial dilutions of non-integrating LNT/tn[SFFV-eGFP] REV 
lentiviral vector. eGFP expression was determined by flow cytometry 2 days post-transduction. (a) 
untransduced;  (b) 10μl LNT/tn[SFFV-eGFP] REV; (c) 1 μl;  (d) 0.1μl. The proportion of cells 
expressing eGFP is given as a percentage within the gated area.   103
4.3.5.  Quantification of Lentivirus-Transposon Vector Genome 
Packaging 
In order to investigate the low titre of the transposon vector, RNA was extracted 
directly from concentrated lentiviral preparation, treated with DNaseI to remove 
contaminating plasmid, and quantified using RT-qPCR (Figure 4.5). Two primer-
probe sets were used, one at the 5’ end of the vector genome near the primer binding 
site (PBS), and one at the 3’ end of the genome within the WPRE.  
The RT-qPCR assay showed no significant difference in copy number between the 
PBS and WPRE signal for lentivirus-transposon vector. However, when compared to 
a standard lentiviral vector expressing eGFP, the packaged copy number for both 
primer-probe sets was over 100-fold lower. 
The continuing problem of producing high titre transposon vector preparations raised 
the possibility that the design of the vector needed to be changed. A relatively 
straightforward possibility was to reconstruct the transposon vector so that the 
transposon was in the same orientation as the lentiviral backbone.   104
 
 
Figure 4.5 Assessment of lentivirus-transposon vector genome packaging and integrity within 
virions.  
RNA was extracted from equal volumes of concentrated lentiviral vector preparation of either 
LNT/SFFV-eGFP-WPRE or LNT/tn[SFFV-eGFP] REV using Trizol reagent, treated with DNase I, 
and reverse-transcribed with Moloney murine leukaemia virus reverse transcriptase and random 
primers. The copy number was determined by quantitative real-time PCR using serially diluted plasmid 
standards.   105
4.3.6.  Reorientation of the Transposon 
The transposon was reorientated so that the HIV-1 LTR promoter and the SFFV 
promoter were facing in the same direction (Figure 4.6). Although this design makes 
the polyadenylation signal contained within the right inverted repeat available for 
vector genomic RNA processing, it was suggested that this signal might be ‘leaky’ 
enough to permit production of full length genomic RNA. Plasmid subcloning was 
performed as described in Section 4.3.1 except that colonies were screened for 
transposons in the forward orientation. 
 
Figure 4.6 Vector map of the forward eGFP transposon.  
5’LTR, HIV-1 5’ long terminal repeat; Ψ, HIV-1 RNA packaging signal; SIN, self-inactivating (U3-
deleted) HIV-1 long terminal repeat; cPPT, central polypurine tract; WPRE, woodchuck 
posttranscriptional regulatory element; IL, Sleeping Beauty transposon left inverted repeat; IR, 
Sleeping Beauty transposon right inverted repeat; SFFV, spleen focus forming virus U3 promoter; 
eGFP, enhanced green fluorescent protein. 
To assess the effect of this configuration on vector titre, non-integrating lentiviral 
vectors were produced in parallel using both pLNT/tn[SFFV-eGFP] FWD and 
pLNT/tn[SFFV-eGFP] REV. Functional titration was performed by transducing 293T 
cells with serial dilutions of vector and assessing eGFP expression by flow cytometry 
2 days post-transduction (Figure 4.7). 
The functional titres were estimated to be 9.9x10
5 TU/ml for LNT/tn[SFFV-eGFP] 
REV and 3.4x10
8 TU/ml for LNT/tn[SFFV-eGFP] FWD. Subsequent experiments 
were performed with the FWD vector.   106
 
 
Figure 4.7 The effect of transposon orientation on the functional titre of the lentiviral vector.  
10
5 293T cells were transduced with lentiviral vectors in which the transposon was in either the reverse 
orientation relative to the lentivirus, LNT/tn[SFFV-eGFP] REV, or the forward orientation, 
LNT/tn[SFFV-eGFP] FWD. eGFP expression was determined by flow cytometry 2 days post-
transduction. The proportion of cells expressing eGFP is given as a percentage within the gated area. 
(a) untransduced; (b) 10μl LNT/tn[SFFV-eGFP] REV; (c) 0.1μl LNT/tn[SFFV-eGFP] REV; (d) 10μl 
LNT/tn[SFFV-eGFP] FWD; (e) 0.1μl LNT/tn[SFFV-eGFP] FWD.   107
4.3.7.  Transposition from Lentiviral Plasmid 
The integration assay was repeated in order to demonstrate the ability of plasmid 
pLNT/tn[SFFV-eGFP] FWD to act as a transposon donor for transposition (Figure 
4.8). 293T cells were transfected with pLNT/tn[SFFV-eGFP] FWD and a transposase 
expression plasmid in a 1:1 ratio as before. Additionally, pLNT/tn[SFFV-eGFP] 
FWD-transfected cells were transduced with serial dilutions of non-integrating 
transposase expression lentiviral vector or transfected with serial dilutions of 
transposase expression plasmid in order to investigate the effects of titrating 
transposase expression. 
When cells were co-transfected with transposon and transposase plasmids in a 1:1 
ratio, the proportion of eGFP
+ cells after 14 days was approximately 2-fold greater 
than the background level of expression in cells transfected with transposon plasmid 
alone. Titration of the transposase expression plasmid showed a decline in reporter 
gene persistence below 100ng transposase plasmid per 10
5 cells (Figure 4.8f).  
When cells were co-transduced with a transposase expression lentiviral vector, the 
highest proportion of eGFP
+ cells observed was 4-fold higher than background and 
increased with the volume of transposase vector (Figure 4.8e). The proportion of 
eGFP
+ cells was generally higher when transposase expression was provided by 
lentiviral vector rather than plasmid in this particular experiment, possibly as a result 
of a suboptimal plasmid transfection.  
These results suggest that the pLNT/tn[SFFV-eGFP] FWD plasmid can be used as a 
transposon donor in the transposition reaction, and that expression of transposase 
from a non-integrating lentiviral vector can drive the transposition reaction. However, 
this experiment would need to be repeated with multiple repetitions of each sample 
for it to have sufficient statistical power to support strong conclusions.   108
 
Figure 4.8 Transposition from pLNT/tn[SFFV-eGFP] FWD.  
10
5 293T cells were transfected with 400ng pLNT/tn[SFFV-eGFP] FWD and either transduced with 
non-integrating LNT/CMV-SB11 lentiviral vector or transfected with pCMV-SB11. eGFP expression 
was determined by flow cytometry 14 days post-transfection/transduction. The proportion of cells 
expressing eGFP is given as a percentage within the gated area. (a) untransfected/untransduced; (b) 
400ng pLNT/tn[SFFV-eGFP] FWD; (c) 400ng pLNT/tn[SFFV-eGFP] FWD and 400ng pCMV-SB11 
(d) 400ng pLNT/tn[SFFV-eGFP] FWD and 10μl LNT/CMV-SB11. e and f show the effect of titrating 
the volume of LNT/CMV-SB11 and mass of pCMV-SB11 respectively. NILV, non-integrating 
lentiviral vector.   109
4.3.8.  Transposition from a Lentiviral Vector 
The integration assay was next used to determine the ability of non-integrated 
lentiviral DNA to act as a transposon donor. When 293T cells were transduced with 
non-integrating LNT/tn[SFFV-eGFP] FWD at a functional multiplicity of infection 
(MOI) of 1 and transduced or transfected with serial dilutions of transposase 
expression lentiviral vector or plasmid respectively, eGFP persistence at day 14 was 
almost undetectable under all conditions tested (data not shown).  
In order to test the possibility that increasing the transposon vector MOI would 
increase the level of transposition, 293T cells were transduced with nonintegrating 
LNT/tn[SFFV-eGFP] FWD at a functional MOI of 20 and co-transfected with a 
transposase expression plasmid (Figure 4.9). The initial level of gene transfer was 
extremely high, with over 96% of cells expressing eGFP 2 days post-transduction. 
After 14 days, the proportion of eGFP
+ cells was approximately 2-fold higher in cells 
co-transfected with transposase expression plasmid than in those which were not co-
transfected, suggesting that the non-integrated lentiviral DNA may have been acting 
as a substrate for transposition, albeit inefficiently. However, the low increase in 
eGFP persistence in this experiment combined with the lack of repetitions means that 
the statistical power of this result is not strong.   110
 
 
Figure 4.9 Transposition from an eGFP transposon lentiviral vector.  
10
5 293T cells were either untransduced/untransfected (a, d), transduced at MOI 20 with 
LNT/tn[SFFV-eGFP] FWD and co-transfected with 400ng pCMV-SB11 (b, e), or not co-transfected 
(c, f). eGFP expression was determined by flow cytometry 2 days (a-c) and 14 days (d-f) post-
transfection/transduction. The proportion of cells expressing eGFP is given as a percentage within the 
gated area.   111
4.3.9.   Analysis of Hybrid Vector Integration by Ligation-Mediated 
PCR 
The most direct evidence for transposition is provided by cloning and sequencing 
transposon-chromosome junctions from target cells. This was performed on the 
eGFP
+-sorted DNA samples by ligation-mediated PCR (Figure 4.10). The genomic 
DNA was digested with NlaIII, a restriction enzyme which has a 4bp recognition 
sequence and so cuts genomic DNA frequently. The digested DNA was ligated to 
synthetic linker DNA and subjected to nested PCR using primer pairs which bind in 
the linker DNA and the transposon right inverted repeat. This allows the amplification 
of transposon-chromosome junctions for subsequent plasmid cloning and sequencing. 
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Figure 4.10 Ligation-mediated PCR schematic overview.    112
(1) DNA containing transposon-chromosome junctions is (2) digested with restriction enzymes to 
produce smaller fragments with known overhangs. (3) These are ligated to an excess of synthetic linker 
DNA with matching overhangs, resulting in transposon-chromosome junctions flanked by a known 
sequence at both ends. (4) These junctions are amplified by nested PCR and (5) shotgun-cloned using 
topoisomerase-linked plasmids. (6) The plasmids are recovered and made clonal by bacterial 
transformation and plasmid DNA is extracted and sequenced. This sequence can be compared to 
genome databases in order to identify the location of transposon integration.  113
Transposon 
Donor 
Junction Sequence                                 
(see legend for colour code) 
Integration 
Type  Integration Location 
Plasmid 1 
TAAACTTCCGACTTCAACTGTAGCTTGATTTCTACAAAATTCTTAA
GTTCTGAATGAGACTTTGGTTTTAACTCACCCAAAAATTCAGCATG
TGAGTTTCG 
Transposition  Chromosome 8, + strand, 125,589,969-125,590,049 
Plasmid 2 
TAAACTTCCGACTTCAACTGTATCTTCCCATAAAAACTAGACAGAA
GCATTCTCAGAGACTTATTTGTGATGTGTGTCCTCAACTAACAGAG
TTGAACCTTTCTTTTGATACAGCAGTTTGGAAACACTCTTTTTGTA 
Transposition Repeat  sequence 
Plasmid 3 
TAAACTTCCGACTTCAACTGTAGATTCTAACTGGAAGAGAGCCTCA
GAAAGGACCTCAGAAAGGGGATGGGAGGGGTATATATGTATATCTA
TCAAATATCA 
Transposition  Chromosome 11, - strand, 99,947,423-99,947,502 
Plasmid 4 
TAAACTTCCGACTTCAACTGTATTAGTTGAGATCATGGGAATTTAA
GAAATAGGAACTGGGCAGGTGCGGTGGCTCACGCCTCTAATCTCAG
CATTTTGGGAGGCCGAGGCGGGTGAATCACCTGAGCCCAGCAGTTC 
Transposition  Chromosome 3, - strand, 152,607,497-152,607,614 
Plasmid 5  TAAACTTCCGACTTCAACTGTACATTGTCG                   (Transposition) Unknown  –  sequence too short to identify 
NILV 1  TAAACTTCCGACTTCAACTGTATAGGGATCCGAATTCG  Background Not  mobilised 
NILV 2  TAAACTTCCGACTTCAACTGTATAGGGATCCGAATTCGA  Background Not  mobilised 
NILV 3  TAAACTTCCGACTTCAACTGTATAGGGATCCGAATTCGA  Background Not  mobilised 
NILV 4 
GGTACCAAGCTTGATGCATAGCTTGAGTATTCTATAGTGTCACCAA
AATAGCTTGGCGTAATCATGGTCATAACTGTTTCCTGTGTGAAATT
GTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAA 
DNA not 
identifiable  Unknown 
NILV 5 
AAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACCTTA
ATTGCCTTGCCCTCA 
DNA not 
identifiable  Unknown 
Table 4.1 Integration sites recovered from eGFP
+-sorted DNA.  
10
5 293T cells were transfected with 400ng pCMV-SB11 and transduced with LNT/tn[SFFV-eGFP] FWD at MOI 20 (NILV sites) or co-transfected with 400ng pT2/SFFV-
eGFP (Plasmids sites). Cells were passaged for 14 days and the eGFP
+ population for each condition was isolated by fluorescence-activated cell sorting. These populations 
were expanded and genomic DNA was extracted. Integration sites were recovered from this DNA by ligation-mediated PCR and sequenced. The DNA flanking the 
transposon inverted repeat was identified by Blat searching the hg18 March 2006 database hosted by the UCSC Genome Server. Red, transposon inverted repeat; black 
underlined, TA junction; blue, chromosomal DNA; green, lentiviral backbone; grey, unknown.   114
Plasmids containing LM-PCR fragments were screened by PCR and five from each 
condition were sent for sequencing of the junction. The sequencing results are shown 
in Table 4.1. All five of the junctions cloned from eGFP
+ plasmid transposon DNA 
showed the three essential features of a successful transposition event. Firstly, the full 
inverted repeat sequence was present. Secondly, the inverted repeat was immediately 
upstream of a TA-dinucleotide. Thirdly, the TA-dinucleotide was immediately 
upstream of chromosomal DNA (as identified by a Blat search on the UCSC Genome 
Server), and a TA-dinucleotide was present at the correct position in the human 
genome sequence database. By contrast, three of the eGFP
+  lentivirus-transposon 
DNA junctions showed that the transposon had not moved from its initial position in 
the lentiviral backbone. The other two cloned inserts contained DNA which could not 
be identified by Blat search or comparison with the lentiviral backbone.   115
4.4.  Summary 
•  An eGFP-based integration assay was established using plasmid transfection. 
Transposon integration into chromosomes was confirmed by ligation-mediated 
PCR.  
•  High titre non-integrating lentiviral vectors carrying the eGFP transposon 
could be prepared using constructs in which the transposon was in the same 
direction as the lentiviral backbone. 
•  Transient expression of transposase from non-integrating lentiviral vectors 
was demonstrated by Western blot. These vectors were able to drive 
transposition from plasmids in the eGFP integration assay. 
•  When cells were transduced with a lentivirus-transposon vector at high MOI 
and transfected with a transposase expression plasmid, there was a slightly 
increased persistence of eGFP expression relative to background integration. 
However, the low level of signal and weak statistical power of the experiment 
did not clearly support the hypothesis that transposon mobilisation from a 
lentiviral backbone was taking place. 
•  Transposon mobilisation from a lentiviral backbone was not detected by 
ligation-mediated PCR. 
In this chapter it was shown that lentiviral vector delivery of Sleeping Beauty 
transposons and transposase to target cells is feasible. In cells transduced at a high 
MOI with a non-integrating lentiviral vector carrying a transposon, the rate of 
integration increased 2-fold in the presence of transposase. However, the absolute 
efficiency of this reaction was low, resulting in 5.3% of cells becoming stably eGFP
+ 
with transposase compared to 2.7% without. The lack of statistical power in this 
experiment meant that the strong conclusion of transposition from a lentiviral 
backbone could not be drawn. In addition, integration sites resulting from Sleeping 
Beauty transposition could not be recovered from these cells by ligation-mediated 
PCR. 
A possible solution to this problem would be to test a wider range of conditions to see 
if there are more optimal circumstances for transposition out of a lentiviral backbone. 
For example, the transposon and transposase vector dose can be titrated against one   116
another to identify the optimal ratio. In the literature, there is significant variation 
between authors in terms of transposase expression vector designs, transfection 
conditions, and methods of reporting transposition efficiency. Some authors report 
optimisation methods such as a 1:1 or 20:1 ratio of transposon to transposase plasmid 
in their transfection mixes, though presumably the final number of plasmids per target 
cell and the ultimate level of transposase expression within each cell can vary greatly 
depending on the method of transfection, the cell type, and the transposase expression 
plasmid being used. 
Another solution would be to develop a more sensitive assay for chromosomal 
integration. Persistence of eGFP expression on day 14 is not ideal as fluorescent cells 
may contain only episomal DNA or eGFP protein (though the latter is unlikely to 
contribute significantly as its half life in mammalian cells is about 26 hours (493)). 
Perhaps more importantly, the efficiency of Sleeping Beauty transposition is such that 
even under the best conditions for transposition there is a large proportion of cells 
(90-99%) in which no integration event takes place. The presence of these cells in the 
population makes it more difficult to analyse integration by other means (such as LM-
PCR) as it increases the sensitivity requirement of these other assays. 
One way to exclude cells not containing an integration event from the LM-PCR 
reaction would be to use a reporter gene which confers resistance to an antibiotic such 
as neomycin. Adherent cells are transduced or transfected as appropriate and seeded 
at low density under selective conditions. Cells in which integration has taken place 
give rise to resistant colonies while the rest are lost. While antibiotic selection cannot 
distinguish between background integration and transposition, it is a much more 
efficient method of generating genomic DNA containing integration events than cell 
sorting and so makes it practical to screen a larger number of samples for 
transposition events. 
Given the data and theoretical considerations presented in this chapter, it was decided 
to replace the eGFP reporter in the lentivirus-transposon vector with a neomycin 
phosphotransferase reporter which confers resistance to the antibiotic neomycin. In 
addition, it was decided to screen a large number of conditions in which the amounts 
of transposon and transposase were varied in an attempt to identify more optimal 
conditions for transposition out of a lentiviral backbone, as well as to perform   117
multiple repetitions of each condition in order to increase the statistical power of the 
resulting data.   118
5.  Lentivirus-Transposon Hybrid Vectors 
Conferring Antibiotic Resistance 
5.1.  Aims 
•  To produce a high titre lentivirus-transposon vector expressing the antibiotic 
resistance gene neomycin phosphotransferase 
•  To optimise the conditions for lentivirus-transposon integration 
•  To confirm transposition out of a lentiviral backbone by cloning and 
sequencing transposon-chromosome junctions 
•  To determine the integration profile of lentivirus-transposon vector integration 
5.2.  Introduction 
The primary chromosomal integration assay used in the previous chapter was based 
on persistence of eGFP expression after passaging cells for two weeks following gene 
transfer. The assay hinges on the assumption that two weeks of cell division will 
dilute episomal DNA to the point where it no longer contributes significantly to 
reporter gene expression within the population. 
In the work described in this chapter, the eGFP reporter gene within the transposon 
was replaced with a neomycin phosphotransferase expression cassette, which confers 
resistance to the antibiotic G418. In the revised assay, cells were transduced or 
transfected as appropriate, cultured under non-selective conditions for 3 days to 
permit reporter gene expression, and then seeded at low density into fresh plates in 
triplicate and cultured with G418 selection for 2 weeks. Cells containing a stably 
integrated neomycin phosphotransferase expression cassette are able to divide under 
selective conditions and give rise to resistant colonies, while cells lacking the 
transgene or containing only episomal DNA do not produce colonies. 
This G418-resistant colony assay is based on the same assumption as the eGFP 
persistence assay, namely that continued gene expression after 2 weeks of cell 
division must be due to integrated vector DNA. However, it has two important 
advantages over the previous system. Firstly, it should be better able to distinguish   119
between persistent integrated and episomal DNA: although both types are able to 
confer G418-resistance on individual target cells, those carrying only episomal DNA 
cannot give rise to colonies. Secondly, selection against cells which do not contain 
integrated transgene results in a cell population which is greatly enriched for 
integration events. This enrichment may reduce the level of sensitivity required for 
recovery of integration sites by LM-PCR. 
This chapter describes the production of a lentivirus-transposon vector expressing 
neomycin-phosphotransferase, the optimisation of its use, the recovery of hybrid 
vector integration sites, and bioinformatic analysis of these sites to determine the 
integration profile relative to the parental lentiviral and plasmid-based systems. 
5.3.  Production and Testing of Lentivirus-Transposon 
Vectors Expressing Neomycin Phosphotransferase 
5.3.1.  Plasmid subcloning of pLNT/tn[SV40-Neo] 
A Sleeping Beauty transposon containing a simian virus 40 promoter and neomycin 
phosphotransferase coding sequence was obtained from plasmid pT2/SV40-Neo (494) 
(a kind gift from Scott McIvor, University of Minnesota) by BamHI digestion. The 
fragment was ligated into the lentivirus-transposon backbone described in Section 
4.3.1 at the BamHI site so that the neomycin phosphotransferase transposon replaced 
the eGFP transposon. Colonies were screened for transposons inserted in the forward 
orientation as shown in Figure 5.1.   120
 
 
Figure 5.1 Vector map of neomycin transposon and lentiviral plasmids.  
SV40, simian virus 40 promoter; neo, neomycin phosphotransferase. pA, polyadenylation signal from 
simian virus 40; 5’LTR, HIV-1 5’ long terminal repeat; Ψ, HIV-1 RNA packaging signal; SIN, self-
inactivating (U3-deleted) HIV-1 long terminal repeat; cPPT, central polypurine tract; WPRE, 
woodchuck posttranscriptional regulatory element; IL, Sleeping Beauty transposon left inverted repeat; 
IR, Sleeping Beauty transposon right inverted repeat; SFFV, spleen focus forming virus LTR promoter. 
5.3.2.  Production and Titration of Neomycin Resistant Hybrid 
Vectors 
In order to test expression from this vector, integrating lentiviral vector was produced 
in parallel using pLNT/tn[SV40-Neo] and a standard pLNT/SFFV-Neo construct (a 
kind gift from Luis Apolonia, University College London). HeLa cells were used to 
assess G418 resistance because 293T cells were originally engineered using a 
neomycin phosphotransferase construct (495) and initial experiments with HT1080 
cells resulted in large, diffuse colonies. HeLa cells were transduced with serial 
dilutions of the two vectors, passaged without selection for 3 days, trypsinised and 
seeded at low density into 6 well plates and incubated in medium containing G418 for 
2 weeks to produce cell colonies. The plates were fixed with paraformaldehyde, 
stained with crystal violet, and imaged using a conventional office flatbed scanner 
(Figure 5.2). By counting the resistant colonies, the integrating titre of the 
LNT/tn[SV40-Neo] construct was estimated to be 2.88 x 10
8 TU/ml versus 9.91 x 10
8 
TU/ml for LNT/SFFV-Neo (Figure 5.3a).   121
 
 
Figure 5.2 G418-resistant HeLa cell colonies following transduction with integrating lentivirus-
transposon vector.  
Lentiviral vector was produced using pLNT/tn[SV40-Neo] and an integrase-proficient packaging 
plasmid. 10
5 HeLa cells were transduced with serial dilutions of vector, incubated for 3 days without 
selection, trypsinised and 1/10th of the cell suspension was seeded into a fresh 6-well plate. Cells were 
maintained in medium containing 1mg/ml G418 for two weeks before fixing and staining. (a) 1μl 
LNT/tn[SV40-Neo];  (b) 0.2 μl;  (c) 0.04 μl;  (d) 0.008 μl;  (e) 0.0016 μl;  (f) 0.00032 μl;  (g) 
untransduced.    122
Next, non-integrating LNT/tn[SV40-Neo] and LNT/CMV-SB11 were produced in 
parallel. HeLa cells were transduced with serial dilutions of both vectors. 3 days after 
transduction total DNA was extracted for vector titration by quantitative PCR using 
primers and probes in the vector WPRE and the host β-actin. The estimated titres of 
LNT/tn[SV40-Neo] and LNT/CMV-SB11 were 4.02 x 10
8 TU/ml and 4.68 x 10
8 
respectively (Figure 5.3b). HeLa cells are a genetically stable but aneuploid cell line 
(496), so the β-actin copy number within a given sample is expected to be 
proportional to but not double the value of the cell number as would be expected for 
normal diploid cells. 
The physical titre of the two vectors was measured by HIV-1 p24 ELISA. The 
estimated physical titres of LNT/tn[SV40-Neo] and LNT/CMV-SB11 were 2.85 x 10
8 
pg p24/ml and 2.57 x 10
8 pg p24/ml respectively (Figure 5.3c). 
Together these titration data suggest that the hybrid neomycin phosphotransferase 
vector could be produced at similar titres to standard ultracentrifuge-concentrated 
lentiviral vectors.   123
 
 
Figure 5.3 Titration of neomycin resistant lentivirus-transposon vectors.  
(a) Integrating functional titre. 10
5 HeLa cells were transduced with serial dilutions of integrating 
LNT/SFFV-Neo or integrating LNT/tn[SV40-Neo]. 3 days post-transduction the cells were trypsinised 
and 1/10
th of the cell suspension seeded into a fresh 6-well plate. The cells were incubated in medium 
containing 1mg/ml G418. 2 weeks post-transduction colonies were fixed, stained, and counted. (b) 
Non-integrating quantitative PCR titre. 10
5 HeLa cells were transduced with serial dilutions of 
nonintegrating LNT/CMV-SB11 or LNT/tn[SV40-Neo]. Total DNA was extracted 3 days post-
transduction and the copy number of the viral WPRE or the host cell β-actin determined by quantitative 
PCR. Titres are expressed as the ratio of the WPRE copy number to the β-actin copy number for each 
sample. (c) Non-integrating physical titre. The concentration of the HIV-1 p24 antigen in concentrated 
preparations of non-integrating LNT/CMV-SB11 or LNT/tn[SV40-Neo] was assessed by ELISA.   124
5.3.3.  Automated Mammalian Cell Colony Counting 
Initial experiments using G418-resistant HT1080 colonies showed that mammalian 
cell colonies can be heterogeneous in shape and size, making accurate and unbiased 
manual counting difficult. The process is also labour-intensive and counts may vary 
between operators or even the same operator at different times. This places limits on 
the number of conditions and replicates that can be tested at any one time. 
In order to address this problem, a protocol for automated colony counting was 
established using the CellProfiler software platform in Matlab ((497) and Figure 5.4). 
Cell colonies were fixed with paraformaldehyde, stained with crystal violet, and 
imaged using a conventional office flatbed scanner. In order to maintain consistency 
between scanned images, a card template was produced which sits in the scanner bed, 
thus ensuring that well locations were consistent between plates. Image files were 
loaded by the CellProfiler software and well locations were manually described via 
point-and-click. Each well image was automatically cropped and inverted, and the 
background intensity was manually defined. Colonies were identified by size, shape, 
intensity, and separation using user-defined values, and the results were displayed 
graphically for verification by the user (Figure 5.4e). The combination of standardised 
image processing and visual verification enabled high throughput counting of 
mammalian colonies with minimal user-introduced bias. 
  125
 
 
Figure 5.4 Cell colony counting using CellProfiler software.  
Before counting, colonies are fixed with paraformaldehyde and stained with crystal violet, then dried and imaged using a conventional office scanner. (a) loading image files; 
(b) converting images to grayscale; (c) cropping the image to single wells; (d) inverting the well image to show colonies in white; (e) automated identification and counting 
of colonies based on shape, size, separation, and staining intensity; (f) setting the background intensity manually.   126
5.3.4.  Relating the Level of Transposition to the Initial Transposon 
Number 
For a hybrid vector to combine the gene transfer mechanism of one vector with the 
integration mechanism of another, the DNA output of the gene transfer step must be 
compatible with the DNA input of the integration step. Many factors may influence 
the ability of a gene transfer vector to act as a substrate for Sleeping Beauty 
transposition, such as the physical state of the DNA (e.g. whether it is supercoiled, 
circular, or linear (498)), its subcellular location (e.g. cytoplasmic or nuclear), or copy 
number.  
In order to investigate the relationship between episomal transposon copy number and 
the level of transposition, HeLa cells were transfected with the transposase expression 
plasmid pCMV-SB11 or mutant transposase plasmid pCMV-SBΔDDE and co-
transfected or co-transduced with a serial dilution of transposon plasmid 
pLNT/tn[SV40-Neo] or non-integrating lentiviral transposon vector LNT/tn[SV40-
Neo]. After three days, cells were trypsinised and samples taken to determine the 
vector copy number per cell by quantitative PCR. A fraction of each cell suspension 
was seeded at low density into fresh 6-well plates and cultured with G418 for 14 days. 
Colonies were fixed, stained, and counted using CellProfiler. 
The results are shown in Figure 5.5 below. When cells were transfected with small 
masses of plasmid (transfection plasmid masses below 20ng per 10
5 cells) so that the 
measured transposon copy number was less than 30, there was little observable 
difference in the rate of integration in the presence or absence of active transposase. 
However, at higher copy numbers in the range of 500 to 10,000 plasmids per cell, 
expression of active transposase increased the level of integration 8-fold relative to 
cells containing inactive transposase. 
When transposons were delivered by non-integrating lentiviral vector, there was no 
observable change in the level of integration in the presence of transposase, even at 
the highest transposon copy number of 20. It is possible that the much lower copy 
numbers of NILV compared to plasmids meant that there was insufficient transposon 
substrate within cells for a detectable level of transposition to take place for this 
vector. In addition, the rate of NILV background integration in the absence of   127
transposase activity was much greater than that observed for plasmid. It has been 
reported that linear episomal DNA is integrated by host DNA repair pathways into 
chromosomes more efficiently than circular DNA (499). 
 
 
Figure 5.5 The effect of transposon copy number on the rate of transposition.  
10
5 HeLa cells were transfected in triplicate with 400ng active transposase plasmid pCMV-SB11 (+ 
transposase) or 400ng inactive mutant transposase pCMV-SBΔDDE (- transposase) and either co-
transfected with serial dilutions of pLNT/tn[SV40-Neo] or co-transduced with serial dilutions of non-
integrating LNT/tn[SV40-Neo]. On day 3 post-transduction, cells were trypsinised and 1/10
th of the cell 
suspension was seeded into a fresh 6-well plate. Cells were incubated for 2 weeks in medium 
containing 1mg/ml G418 and colonies were fixed and stained for counting. The copy number of 
plasmid or lentiviral genome was determined on day 3 by WPRE/β-actin quantitative PCR using the 
SB11-transfected samples. Vector copy numbers are expressed as the ratio of the WPRE copy number 
to the β-actin copy number for each sample.   128
5.3.5.  Optimisation of Transposase Delivery 
Optimisation of transposase expression has been reported to enhance the rate of 
transposition by ensuring the presence of sufficient transposase protein for the 
transposition reaction while avoiding ‘overproduction inhibition’, a reported decline 
in transposition efficiency when transposase is overexpressed (500). In order to 
determine the sensitivity of the transposition reaction to the level of transposase 
expression, HeLa cells were transfected with pLNT/tn[SV40-Neo] and transduced 
with serial dilutions of nonintegrating LNT/CMV-SB11 which had been previously 
titred by quantitative PCR. A G418 colony assay was performed as previously 
described. The results are shown in Figure 5.6. 
The rate of transposition generally increased with transposase NILV copy number, 
reaching a maximum level of 300 colonies per well (2.5% gene marking above 
background) at a transposase vector copy number of 29 (corresponding to 4μl of 
lentiviral vector preparation per 10
5 cells).   129
 
 
Figure 5.6 The effect of transposase optimisation on transposition efficiency.  
10
5 HeLa cells were transfected in triplicate with 400ng pLNT/tn[SV40-Neo] and transduced with 
serial dilutions of nonintegrating LNT/CMV-SB11. 3 days post-transduction the cells were trypsinised 
and 1/10
th of the cell suspension seeded into a fresh 6-well plate. Cells were maintained in medium 
containing 1mg/ml G418 for 2 weeks before fixing and staining for colony counting. The transposase 
MOI was determined by WPRE/β-actin quantitative PCR using non-transfected HeLa cells. Vector 
copy numbers are expressed as the ratio of the WPRE copy number to the β-actin copy number for 
each sample.   130
As both the transposon and transposase vector copy numbers were found to affect the 
rate of transposition, a double titration of both the transposon and transposase 
components was next performed on the basis that this approach was the most 
thorough way to identify the optimal conditions for transposition out of a lentiviral 
backbone. 
HeLa cells were transfected or transduced with serial dilutions of both the transposon 
and transposase components and integration was measured using the G418-resistant 
colony assay. Three conditions were tested: plasmid transposon, plasmid transposase; 
plasmid transposon, NILV transposase; NILV transposon, NILV transposase. To 
ensure a high level of gene transfer, the maximum plasmid mass used was 8 μg per 
10
5 cells and the maximum lentiviral vector volume was 80μl containing 2.4μg of p24 
antigen. It is worth noting that this latter volume is approaching the maximum that 
can be achieved using concentrated lentiviral vector in a single transduction because 
transductions were performed in a total volume of 500μl per well. 
The results are shown in Figure 5.7. When both Sleeping Beauty components were 
transfected on plasmids (Figure 5.7a,b), the highest rate of gene marking observed 
was 1.4% ± 0.4% at 4μg pLNT/tn[SV40-Neo] and 1μg pLNT/CMV-SB11 per 10
5 
cells. The background (no transposase) rate was 0.4% ± 0.2% for this condition 
(p<0.02). When transposase NILV was provided with transposon plasmid (Figure 
5.7c,d), the highest rate of gene marking was 3.1% ± 0.4% (background 0.5% ± 0.2%, 
p<0.0005) at 2μg pLNT/tn[SV40-Neo] and 0.52μg p24 LNT/CMV-SB11 per 10
5 
cells. When both components were delivered by NILV transduction (Figure 5.7e,f), 
the highest rate of gene marking was 2.6% ± 0.2% (background 1.4% ± 0.6%, p<0.03 
by 2-tailed t-test) obtained at 2.4μg p24 LNT/tn[SV40-Neo] and 0.13μg p24 
LNT/CMV-SB11 per 10
5 HeLa cells. The rate of gene marking detected at the other 
transposase NILV concentrations tested was not significantly different from the rate 
of background integration at the 5% level, although the 0.03μg and 0.5μg p24 
LNT/CMV-SB11 conditions were significant at the 10% level.   131
 
Figure 5.7 Double titration optimisation of transposon and transposase delivery.  
10
5 HeLa cells were transduced or transfected with Sleeping Beauty components in a double titration 
integration assay. The transposon amounts tested are given by the y-axis labels in a, c, and e, while the 
transposase amounts are given by the x-axis labels. All transposon-transposase combinations were 
tested, and each combination was tested in triplicate. (a) plasmid transposon, plasmid transposase; (b) 
cross-section of (a) where the transposon plasmid mass was 4 μg;  (c) plasmid transposon, NILV 
transposase; (d) cross-section of (c) where the transposon plasmid mass was 2μg; (e) NILV transposon, 
NILV transposase; (f) cross-section of (e) where the NILV transposon vector dose was 1.2μg p24. The 
rate of integration was assessed by the number of G418-resistant colonies formed and is expressed as a 
percentage of the transduced or transfected cell number assuming 100% plating efficiency. 
The results presented in this section suggest that transposition out of a non-integrating 
lentiviral backbone is detectable by G418-resistant colony assay, and that expression 
of transposase from a non-integrating lentiviral vector is sufficient to catalyse this 
reaction at high vector copy numbers. A 2-fold increase in transposon integration was 
observed at the optimised transposase vector concentration, suggesting that 
transposition from episomal NILV DNA into chromosomes occurs at a rate similar to 
background integration under these conditions.   132
5.4.  The Integration Profile of Hybrid Lentivirus-
Transposon Vectors 
5.4.1.  LM-PCR Recovery of Integration Sites from G418-resistant 
HeLa Cells 
In order to confirm transposition from the non-integrated lentiviral vector, integration 
sites were recovered from transduced cells by ligation-mediated PCR (LM-PCR). 
HeLa cells were transduced with integrating LNT/tn[SV40-Neo] or non-integrating 
LNT/tn[SV40-Neo] alone, non-integrating LNT/tn[SV40-Neo] plus LNT/CMV-
SB11, or transfected with plasmids pLNT/tn[SV40-Neo] plus pLNT/CMV-SB11 
under the previously optimised conditions. After passaging for 3 days without 
selection, the cells were trypsinised, re-seeded at a 1 in 10 dilution, and incubated 
with G418 for two weeks. Genomic DNA was extracted and integration sites were 
recovered by LM-PCR (Figure 4.10). 3’ LTR-specific primers were used to amplify 
integration sites from cells transduced with integrating or non-integrating 
LNT/tn[SV40-Neo] alone. Transposon-specific primers were used for cells 
transfected with the two plasmids or transduced with the two non-integrating 
lentiviral vectors. LM-PCR products were shotgun-cloned into the TopoTA vector 
and 192 individual clones for each condition were sequenced commercially using the 
conventional Sanger method (501). 
A Blat search of the sequenced products against the UCSC human genome was used 
to identify junctions between chromosomal DNA and the transposon IR or the viral 3’ 
LTR. In total, 83 unique, mappable integration sites were recovered from cells 
transfected with the two Sleeping Beauty plasmids (SB-Plasmid sites) and 26 sites 
were recovered from cells transduced with both Sleeping Beauty NILVs (SB-NILV 
sites), confirming transposition from non-integrated lentiviral DNA. In addition, 43 
sites were isolated from cells transduced with integrating LNT/tn[SV40-Neo] (ILV 
sites), but no sites were recovered from cells transduced with non-integrating 
LNT/tn[SV40-Neo] alone (NILV sites). 
In order to increase the recovery of integration sites from these samples, the LM-PCR 
products were sent for 454 pyrosequencing (502) by our collaborator Richard Gabriel   133
in the laboratory of Manfred Schmidt at the German Cancer Research Center (DKFZ) 
in Heidelberg, Germany. In this method, LM-PCR products are amplified by PCR 
using fusion primers to attach short adaptor sequences to the ends of the molecules. 
The adaptor sequences allow the LM-PCR products to be annealed to 40μm diameter 
DNA capture beads under conditions in which one LM-PCR molecule anneals to each 
bead. An oil-water emulsion is then created so that each bead is confined to its own 
water solution ‘microreactor’ which is separated from other beads by the surrounding 
oil. Further PCR amplification and annealing is performed within this emulsion so 
that each DNA bead carries many copies of the same LM-PCR product. Beads are 
then loaded onto a plate covered with 50μm wells so that one bead settles into each 
well. Sequencing is performed by second-strand DNA synthesis of the LM-PCR 
products. dNTPs are washed over the plate one by one (e.g. first dGTP, then dCTP, 
etc). In wells where the supplied dNTP corresponds to the next base in the sequence 
being synthesised, DNA polymerase adds the relevant dNTP to the nascent DNA 
strand, releasing pyrophosphate as a by-product. This initiates a reaction cascade 
within the well such that luciferase in the reaction mixture emits light. This light is 
detected by a camera and the identity of the dNTPs added in each well is recorded in 
sequence. The high density of wells on the plate and small reaction volumes within 
each well enable a large number of sequence reads to be performed economically.  
In this study, 1234 unique ILV integration sites were recovered of which 976 could be 
mapped to a unique genomic position by Blat, 185 SB-NILV sites of which 161 could 
be mapped, and 917 SB-Plasmid sites of which 752 could be mapped. Although 
NILV-only genomic DNA containing only background integration events was sent for 
454 sequencing, it was not possible to recover a set of sites for integration site 
analysis. Of the sites which could not be mapped to a unique genomic location, the 
majority were within known repeat elements (Table 5.1).  134
 
Sites mapped to unique 
genomic position  Genomic repeat type of sites not mapped to unique genomic position   
Total 
unique 
sites  In gene  Not in 
gene 
Total 
mapped  SINE LINE  LTR 
element 
DNA 
transposon
Satellite 
or simple 
repeat 
No 
known 
repeat 
Total 
not 
mapped 
ILV 1234  751 
(0.77) 
225 
(0.23) 
976 
(1) 
134 
(0.52) 
33 
(0.13) 
10 
(0.04) 
3 
(0.01) 
3 
(0.01) 
75 
(0.29) 
258 
(1) 
SB-NILV 185  86 
(0.53) 
75 
(0.47) 
161 
(1) 
2 
(0.08) 
2 
(0.08) 
1 
(0.04) 
1 
(0.04) 
1 
(0.04) 
17 
(0.71) 
24 
(1) 
SB-
Plasmid  917  321 
(0.43) 
431 
(0.57) 
752 
(1) 
17 
(0.10) 
60 
(0.36) 
10 
(0.06) 
1 
(0.01) 
5 
(0.03) 
72 
(0.44) 
165 
(1) 
 
Table 5.1 Hit genomic features at vector integration sites.  
Integration sites were recovered from genomic DNA by ligation-mediated PCR and 454 pyrosequencing. Sequences were mapped to the UCSC human genome 
(version hg18) by Blat search. The proportion of mapped integration sites within RefSeq genes was scored and is expressed as a proportion of the mapped sites in 
parentheses. Where sites could not be mapped to a unique site, the hit repeat type was identified using RepeatMasker. The proportion of unmapped sites within each 
repeat type is expressed in parentheses.   135
The proportion of ILV integration sites within RefSeq genes was 77%, significantly 
greater than SB-NILV (53%) and SB-Plasmid (43%) sites (p<0.001, χ
2 test). The rate 
of integration within genes was greater for SB-NILV than for SB-Plasmid (p<0.013). 
To estimate the expected rate of random integration into genes, 1000 random 
integration sites were also generated through bioinformatics by multiplying the total 
length of the human genome by a randomly generated number between 0 and 1, and 
converting this value into a (chromosome, strand, bp) coordinate. 34% of random 
sites were within genes, and all three vector types were found to integrate within 
genes more frequently than the random site set (p<0.001). The SB-Plasmid and ILV 
proportions are similar to previous reports (503;504). 
5.4.2.  Fidelity of Vector-Chromosome Junctions 
Inspection of the primary sequence data showed that integration occurred with high 
fidelity at the ILV, SB-NILV, and SB-Plasmid integration sites (Table 5.2). A 
complete LTR-chromosome junction was found at 1215 of the 1234 ILV sites, with 
19 sites showing small deletions from the end of the LTR. 15 of the 19 junctions were 
missing one LTR base pair and the remaining 4 varied between 3 and 23 missing base 
pairs. No bases were found to be missing from Sleeping Beauty IRs in either the SB-
NILV or SB-Plasmid datasets. 
Integration 
condition  Junction sequence  Chromosomal 
location 
AAATCTCTAGCAGCAGCAGTTCGTGCTGTGACTTCACTTC  1 q25.2 
AAATCTCTAGCAGTCAAGCATAAAAGTTAAAATAATTTAT  2 q37.1 
AAATCTCTAGCAGGTGTCTACCTTGTCAAGCCTATGTTTG  20 q13.2  ILV 
AAATCTCTAGCAGTATGGTTATATTTTTCCTGGTCTAAGG  22 q13.33 
CGACTTCAACTGTATGTCTACTTTTCTACATTGGTTGGATTT  1 p22.1 
CGACTTCAACTGTATGTATAGCCTTTTACTTGTTTGAGCCTC  8 q13 
CGACTTCAACTGTAATTTAATTAAATACTGCCAACTTCCCTC  9 p25.3  SB-NILV 
CGACTTCAACTGTATATATGTGTGTATATATATGTATATATA  14 q25.2 
CGACTTCAACTGTAGAAAGCATTGGTTGTCTTTCATCTGGG  1 p36.22 
CGACTTCAACTGTATGTACCTATGACAACAAATGTACCATTA  3 q11.2 
CGACTTCAACTGTATCTCAAGTCAGAGTCACTTGACAAATC  9 q22.1  SB-PLASMID 
CGACTTCAACTGTATTACAAAGAGAATACAAGGCAAAAATA  X p22.31 
Table 5.2 Sample integration site sequences recovered from G418-resistant HeLa cells by LM-
PCR.  
Only the beginning of the flanking chromosomal sequence is shown. Underlined, HIV-1 3’-LTR (ILV) 
or transposon IR (SB-NILV and SB-PLASMID); not underlined, chromosomal DNA. ILV, integrating 
lentiviral vector; SB-NILV, Sleeping Beauty transposition from non-integrating lentiviral vector; SB-
PLASMID, Sleeping Beauty transposition from plasmid.   136
5.4.3.  Primary Sequence at Integration Sites 
The preferred primary sequence composition at HIV-1 and Sleeping Beauty 
integration sites has been well characterised. Sleeping Beauty insertion occurs 
exclusively at TA-dinucleotides and shows a weak preference for locations where this 
dinucleotide is flanked by the palindromic sequence 5’-RCAYATATRTGY-3’ (505). 
The transposon is inserted before the underlined TA and this TA is duplicated at both 
ends of the insertion by host DNA repair proteins (506). HIV-1 integration also shows 
a weak preference for a palindromic integration site 5’-TNG(GTNAC)CAN-3’, where 
integration occurs before the 5bp sequence indicated by parentheses and this sequence 
is also duplicated by host repair proteins at both ends of the insertion site (507;508). 
In order to investigate the primary sequence preferences of the recovered integration 
sites, a Visual Basic script was written to download 100bp of primary sequence 
flanking each integration site from the UCSC human genome server (March 2006 
hg18 version). Sequences were downloaded for both the real and 1000 site random 
control datasets. 
Biases in base composition at the aligned integration sites were analysed using the 
WebLogo sequence logo tool (509). In a sequence logo, the height assigned to each 
base represents the amount of information required to describe its frequency at that 
position (510). For DNA, which contains 4 possible bases at each position, the 
maximum information required to describe each position is 2 bits (e.g. in binary, A = 
00, T = 01, G = 10, C = 11). 
The sequence logos generated for the integration sites from this study are shown in 
Figure 5.8. As previously reported, the primary sequence preference for integrating 
lentiviral vectors was found to be weak, but a preferred 5’-GTNAN-3’ downstream 
flanking sequence was detectable (Figure 5.8a). For Sleeping Beauty transposition 
from both non-integrating lentivirus and plasmid, a ubiquitous TA-dinucleotide 
immediately flanking the integration site was observed, as well as a wider, weaker 
palindromic flanking sequence, 5’-ANA(TA)TNT-3’ (Figure 5.8b,c). As expected, no 
information content was detected at randomly-generated integration sites. 
Interestingly, the heights of the stacks indicate that the total information content of 
Sleeping Beauty sites was much higher than that of integrating lentivirus sites, at least   137
at the level of primary sequence. This primary sequence constraint may mean that 
fewer sites within the genome are suitable substrates for Sleeping Beauty insertion. 
However, with a total haploid genome size of over 3 x 10
9 base pairs, the number of 
accessible sites for Sleeping Beauty insertion is still likely to be very large.   138
 
 
Figure 5.8 Sequence logo for base composition at integration sites.  
A sequence logo was generated using the WebLogo tool to identify preferred base-pair usage at the 
three integration site types. Position 0 denotes the first base of the flanking chromosomal sequence 3’ 
of the integration site. (a)  ILV, integrating lentiviral vector; (b)  SB-NILV, transposase-mediated 
integration of transposons from nonintegrating lentiviral vector; (c)  SB-PLASMID, transposase-
mediated integration of transposons from plasmid; (d) RANDOM, randomly generated sites. 
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5.4.4.  Genomic Distribution of Integration Sites 
In order to understand the genomic distribution of the three integration site datasets, 
sites were mapped on to human chromosomes (Figure 5.9) using the UCSC Genome 
Graphs tool (511). All three datasets contained integrations throughout the genome, as 
is expected from the known semi-random integration pattern of Sleeping Beauty and 
HIV-1. 
 
Figure 5.9 Chromosomal map of integration sites.  
Sequences were mapped to the UCSC human genome by Blat search and integration sites were 
depicted relative to chromosomes using the UCSC Genome Graphs tool. Note that HeLa cells are 
karyotypically abnormal. ILV, integrating lentiviral vector (blue, top line); SB-NILV, transposase-
mediated integration of transposons from non-integrating lentiviral vector (red, middle line); SB-
PLASMID, transposase-mediated integration of transposons from plasmid (green, bottom line).   140
To estimate possible biases in integration towards particular chromosomes, the 
proportion of integration sites on each chromosome was divided by its size relative to 
the HeLa genome (512) (Figure 5.10a). Integrating lentiviral vectors appeared to 
show a preference for integration into chromosomes 17 and 19, as has been previously 
reported (513;514). Biases in Sleeping Beauty integration relative to chromosomes 
have not been reported in human cells (515;516), but no significant association with 
particular chromosomes was found in mouse cells (517). Under the assumption that 
randomly distributed integration sites integrate into chromosomes with a frequency 
proportional to chromosome size, all three integration site types in this study were 
found to be non-randomly distributed with respect to chromosomes (ILV p<0.001, 
SB-NILV p<0.028, SB-Plasmid p<0.001 by χ
2 test). 
When integrations within or immediately upstream of genes were mapped relative to 
their position within the gene or upstream region (Figure 5.10b), no bias towards 
transcription start sites was detected and no significant variation in integration pattern 
was observed along the length of the gene. This has been reported for HIV-1 and 
Sleeping Beauty but not the gammaretrovirus MLV, which integrates preferentially 
near transcription start sites (518). 
It has been reported that lentiviral vector integration occurs preferentially within 
transcriptionally active genes (519). We estimated the transcription activity of all 
RefSeq genes in HeLa cells using a published HeLa microarray transcriptome.  All 
genes were then categorised as having low, medium, or high transcription activity 
(each level containing equal numbers of genes). When considering only genes 
containing integration sites, ILV integration exhibited a clear preference for genes 
with high levels of transcriptional activity (p<0.001), whereas SB-NILV and SB-
Plasmid integration showed no significant bias towards any particular level of 
transcription, and resembled the profile generated for random integration events 
(Figure 5.10c). 
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Figure 5.10 Factors influencing integration frequency.  
(a) Integration sites per chromosome. The proportion of integration sites on each chromosome was 
divided by the proportion of the genome accounted for by the chromosome. The dashed line indicates 
the null hypothesis that the number of integrations per chromosome is proportional to chromosome 
size. (b) Intragenic position of integration sites within genes. RefSeq genes containing integration sites 
were divided by length into ten equally-sized regions and a 5kb upstream region, and the proportion of 
integration sites within each region was counted. To allow statistical comparison of integration 
preferences with average genomic content, 1000 random chromosomal sites were generated by 
multiplying the total length of the genome by a random number between 0 and 1 and converting this 
value to a chromosomal coordinate. Vector integration frequencies are expressed relative to the 
proportion of random sites within each region. (c) Transcriptional activity of genes containing 
integration sites. All RefSeq genes were scored for transcription in HeLa cells using a published 
microarray dataset (GEO accession number GSM157868). All genes were then assigned to one of three 
transcription levels (containing equal numbers of genes) to give low, medium, and highly transcribed 
genes. Integration sites within genes were then scored according to whether the hit gene was 
transcribed at a low, medium, or high level. For each vector type, the number of intragenic sites per 
transcription level is expressed as a percentage of the total number of intragenic sites. A dashed line at 
33.3% of sites is included to show theoretically equal distribution of sites between the transcription 
levels. ILV, integrating lentiviral vector, SB-NILV, transposase-mediated integration of transposons 
from non-integrating lentiviral vector; SB-PLASMID, transposase-mediated integration of transposons 
from plasmid.   142
5.5.  Summary 
This chapter has described the optimisation and characterisation of the hybrid 
Sleeping Beauty-lentivirus vector: 
•  A hybrid vector expressing a neomycin phosphotransferase reporter gene was 
cloned and tested, and a high-throughput G418-resistance integration assay 
was established. 
•  The efficiency of Sleeping Beauty transposition per plasmid copy and the 
level of background integration of plasmid and non-integrating lentiviral DNA 
were quantified. 
•  Transposase expression was optimised. Under optimal conditions, the 
efficiency of transposase-mediated integration was similar to the efficiency of 
background integration. 
•  Transposase-mediated integration sites were cloned and sequenced from 
hybrid vector-transduced cells, demonstrating the feasibility of Sleeping 
Beauty transposition from non-integrating lentiviral vectors. 
•  The integration profile of the hybrid vector was found to resemble that of 
Sleeping Beauty. Hybrid vector integration into active genes was significantly 
reduced relative to a standard integrating lentiviral vector. 
The data presented in this chapter demonstrate that under optimised conditions, 
Sleeping Beauty transposition from a non-integrating lentiviral DNA can be carried 
out by transposase expressed from a second non-integrating lentiviral vector. Thus, 
the concept of a Sleeping Beauty-lentivirus hybrid vector is feasible. Furthermore, the 
hybrid vector showed a significantly reduced bias for integration into active genes 
relative to a standard integrating lentiviral vector. The hybrid vector integration 
profile may therefore be preferable to that of standard integrating lentiviral vectors in 
terms of the risk of insertional mutagenesis and cell transformation, but this will need 
to be demonstrated experimentally using established assays for genotoxicity 
(520;521).  
Significant background integration of non-integrating lentiviral vector DNA was also 
observed in cells transduced with the hybrid vector. The pattern of background   143
integration, the efficiency of the process in vivo rather than cell lines, and the 
associated risk of insertional mutagenesis are poorly understood and should be studied 
before non-integrating lentiviral vectors move into clinical trials. 
A recent study by Staunstrup et al also demonstrated the feasibility of a hybrid 
Sleeping Beauty-lentivirus vector (522). In the Staunstrup vector, the Sleeping Beauty 
IRs were inserted into the lentiviral backbone such that transposition would only 
occur after NILV circularisation into 1- or 2-LTR circles. Around 30% of NILV 
genomes circularise within three days of transduction (523), and it has been suggested 
that circular DNA is an efficient substrate for Sleeping Beauty transposition (524). It 
is not clear whether this is advantageous, as the vector configuration used in this 
thesis means that the Sleeping Beauty IRs are in the correct orientation for 
transposition in all NILV species regardless of circularisation state. Furthermore, 
transposition of the Staunstrup vector after circularisation results in chromosomal 
integration of lentiviral backbone elements such as the HIV-1 LTRs and the WPRE, 
while the vector used in this thesis results in transposition of a simpler IR-flanked 
promoter and transgene cassette. 
 
Figure 5.11 Comparison of Sleeping Beauty-lentivirus hybrid vector configurations.  
Maps from this study and (525). Both systems use co-transduction with a second non-integrating 
lentiviral vector for expression of transposase as in Figure 2.11. SV40, simian virus 40 promoter; neo, 
neomycin phosphotransferase. pA, polyadenylation signal from simian virus 40; 5’LTR, HIV-1 5’ long 
terminal repeat; Ψ, HIV-1 RNA packaging signal; SIN, self-inactivating (U3-deleted) HIV-1 long 
terminal repeat; cPPT, central polypurine tract; WPRE, woodchuck posttranscriptional regulatory 
element; IL, Sleeping Beauty transposon left inverted repeat; IR, Sleeping Beauty transposon right 
inverted repeat; PGK, human phosphoglycerate kinase promoter; puro, puromycin resistance reporter 
gene. 
An interesting question arising from the present study is whether the pattern of 
integration observed with the hybrid vector is significantly different from that   144
observed with plasmid-based Sleeping Beauty transposition. Although both of these 
systems showed no observable integration bias due to transcriptional activity, the 
hybrid vector integrated into genes significantly more often than the plasmid-based 
Sleeping Beauty vector (54% versus 43%, p<0.001). Standard integrating lentiviruses 
are believed to be tethered to chromosomes by the host factor LEDGF/p75, and it is 
thought that preferential chromosomal binding of LEDGF/p75 within genes may 
cause HIV-1 integration to be biased towards them (526). Similar tethering of non-
integrating lentiviral vector DNA could also bias Sleeping Beauty transposition 
towards genes. Although this is theoretically possible, a significantly greater 
integration bias of the hybrid vector towards should be demonstrated with other cell 
types and reporter genes to confirm that it is a robust effect. In the Staunstrup study, 
26 of 87 integration sites recovered from transduced cells were within genes (30%). 
This is close to the proportion which is theoretically expected from random 
integration, but the sample size is small and SB-Plasmid and ILV controls were not 
done for comparison. 
In terms of the efficiency of the hybrid vector presented in this study, it was found 
that HeLa cells transduced with a transposon NILV contained a vector copy number 
of approximately 30 on day 3 at the highest vector doses tested (Figure 5.5), and 
under optimised transposase conditions the level of transposition as measured by 
G418-resistant colonies was 1.2% above background (Figure 5.7). A simple ratio of 
these values gives an estimated transposition frequency of 4 actively expressed 
chromosomal insertions per 10
4 NILV copies. At this NILV vector dose, background 
integration resulted in 1.3% of cells becoming G418-resistant, similarly giving an 
estimated background integration frequency of around 4 per 10
4 NILV copies, similar 
to previous reports (527). Under optimised conditions, 40μl of transposon NILV and 
5μl of transposase NILV were able to produce 1200 G418-resistant HeLa (after 
accounting for dilution during seeding) and so have a combined integrating titre of 2.7 
x 10
4 TU/ml. By contrast, a standard ILV with an identical backbone gave a G418-
resistant HeLa titre of 2.9 x 10
8 TU/ml, an improvement of four orders of magnitude. 
The efficiency of Sleeping Beauty transposition in terms of integrations per 
intracellular vector has not been previously reported. Yant et al created HeLa cell 
lines in which a single transposon copy was integrated at a chromosomal location so   145
that it disrupted a G418-resistance cassette (528). Several cell lines were created, and 
the transposon was integrated at a different chromosomal position in each. When 
these cell lines were transfected with a plasmid for transposase expression, the rate of 
transposon excision could be estimated by the rate at which cells became G418-
resistant. The authors report that SB10 caused a mean of 1 in 10
5 HeLa cells in each 
cell line to become G418-resistant, while an enhanced transposase conferred 
resistance to 1 in 10
4. Assuming that the rate of transposition from transfected 
plasmids into chromosomes is similar to that from transposons already integrated into 
chromosomes, the upper bound estimate for the rate of Sleeping Beauty transposition 
is 10
-4 integrations per intracellular vector. The true rate may be lower, as excision is 
only the first half of the transposition process and it has been reported that 
approximately half of excised transposons fail to reintegrate elsewhere in the genome 
(529). Furthermore, Sleeping Beauty reintegration occurs preferentially on the same 
donor molecule (including plasmid donors), a phenomenon known as ‘local hopping’ 
(530), meaning that transposition from a plasmid into a chromosome is expected to be 
less efficient than excision from a chromosome. 
The necessity for integration during the retrovirus life cycle means that the efficiency 
of retroviral integration is not often considered. However, quantification of DNA 
intermediates during lentiviral vector transduction of cell lines showed that the total 
vector copy number peaked at 15-20 per cell while the integrated copy number 
peaked at 1-2, suggesting an efficiency of integration on the order of 10
-1 integrations 
per intracellular vector genome (531). 
In their hybrid vector, Staunstrup et al used the recently developed hyperactive 
Sleeping Beauty transposase SB100 which has been reported to be 100-fold more 
active than the original SB10 (or approximately 30-fold more active than SB11) 
(532;533). In that study, the rate of hybrid vector integration was 25-fold greater than 
background integration when transposase was expressed from a plasmid in target 
cells, or 10-fold greater than background when transposase was expressed from a 
second non-integrating lentiviral vector. This compares to a 2-fold increase in 
integration relative to background in the present study. These data suggest that even 
using the most active transposase available, the integrating titre of a hybrid Sleeping 
Beauty-lentivirus vector is around 3 orders of magnitude less than that of standard   146
ILVs, which integrate 10
4-fold above background as measured by NILV integration 
(534). It should be noted here that when Staunstrup et al performed a transduction 
with equal p24 doses of either an ILV or their hybrid vector, only 12-fold fewer 
puromycin-resistant colonies resulted from the hybrid condition. However, neither the 
p24 vector dose nor the number of cells seeded for colony counting were detailed for 
this result, and it is difficult to reconcile it with the study’s reported integration 
efficiencies relative to background integration. 
It is possible that all presently available Sleeping Beauty transposases are catalytically 
much less active than HIV-1 integrase. HIV-1 integrase and the Sleeping Beauty 
transposase are quite similar, evolutionarily related proteins which catalyse the 
integration reaction using essentially the same nucleophilic attack mechanism via a 
DDE catalytic domain (535), and it is not immediately clear why such similar proteins 
should be so different in their catalytic activities. A second possibility is that HIV-1 
integrase has a kinetic advantage in that the formation of the preintegration complex 
takes place using co-localised components within the virion and so is not rate-limiting 
for integration, whereas the Sleeping Beauty transposase must be expressed in the 
cell, bind to the transposon, catalyse its excision and the formation of the 
preintegration complex, and only then catalyse the integration reaction. By 
performing the early steps of this process in a more conducive environment within the 
virion, HIV-1 integrase may obtain a large efficiency gain.  
An informative test might be an in vitro integration assay using purified HIV-1 
integrase and Sleeping Beauty transposase to estimate the enzyme catalytic coefficient 
(536), but such assays are technically challenging and perhaps not capable of yielding 
quantitative comparisons. However, it is feasible to clone the Sleeping Beauty 
transposase into the HIV-1 Gag-Pol polyprotein in a manner that mimics HIV-1 
integrase’s own incorporation, so that Sleeping Beauty transposase would be 
transported within virions as a protein. Perhaps more importantly, this approach has 
the advantage that no DNA expressing the transposase protein would need to enter the 
target cell, which is preferable as it reduces the risk of background integration of the 
transposase gene into target cell chromosomes. Research towards this approach is 
described in the next chapter.   147
6.  Delivery of Transposase Protein by Lentiviral 
Virions 
6.1.  Aims 
•  To construct fusion proteins which allow packaging of eGFP and transposase into 
lentiviral virions 
•  To investigate virion incorporation and processing of these proteins 
•  To determine the effect of heterologous protein incorporation on virion function 
•  To assess delivery of eGFP and transposase to target cells by lentiviral virions 
6.2.  Introduction 
Protein transduction is direct delivery of proteins to target cells, and has been an 
active area of study since it was first reported that the Tat protein of HIV-1 contains 
an 11 amino acid protein transduction domain (PTD) which can be fused to 
heterologous proteins, allowing them to enter cultured cells directly from the 
surrounding medium (537-539). PTDs able to deliver heterologous proteins were 
subsequently identified in other proteins, including the Drosophila Antennapedia 
homeodomain protein (540) and Kaposi fibroblast growth factor (541). The 
mechanism of protein transduction is controversial, but it has been suggested that 
proteins fused to highly cationic peptides such as the Tat-PTD first interact with 
negatively charged cell surface molecules such as proteoglycans, and that these bound 
proteins undergo macropinocytosis before escape into the cytoplasm (542). Tat-
mediated protein transduction is being developed for a number of therapeutic 
applications, including treatments for cancer, ischemia, and neurodegenerative 
diseases (reviewed in (543)). 
The ability to manipulate the protein content of cells without gene transfer may be 
advantageous in removing the risk of insertional mutagenesis due to integration of 
transgenic DNA. In addition, protein transduction of enzymes with the ability to 
rearrange DNA such as Cre recombinase or Sleeping Beauty transposase would 
ensure that their presence is transient in both dividing and non-dividing target cells,   148
reducing potential genotoxic risks associated with these proteins. Successful protein 
transduction of enzymes with the ability to rearrange DNA has been shown 
previously, such as lipid-mediated transfection of the AAV Rep protein to mediate 
site-specific integration in target cells (544) or protein transduction using a Cre 
recombinase fused to a cell-penetrating peptide (545). 
In a hybrid vector such as the Sleeping Beauty-lentivirus vector presented in previous 
chapters, it may be advantageous to deliver the integrating protein as an internal 
component of the gene transfer vector (Figure 6.1). This approach mimics the 
behaviour of retroviruses, which integrate using molecules of retroviral integrase 
which enter target cells in a complex with the viral genome and other components. 
Co-delivery of the integrating protein in this way may be a more efficient strategy 
than expression of the integrase gene within target cells, for example by removing the 
need for the integrating protein to locate the viral genome within the cell or by 
minimising the delay between cell entry and integration of the viral genome, during 
which time the viral genome may be lost to processes within the cell.  
HIV-1-mediated delivery of heterologous proteins has been previously reported. The 
general approach is to fuse the heterologous protein to an HIV-1 protein so that it is 
incorporated into vector particles in producer cells, and then to transduce target cells 
and investigate the intracellular distribution of protein. Virion-mediated protein 
transduction may enable protein delivery with the broad cell tropism of VSVg-
pseudotyped lentiviral vectors. Fusions are most commonly made with the Vpr 
protein, such as a Vpr-eGFP fusion to investigate the biology of HIV-1 assembly 
(546) or cell entry and trafficking (547;548), a Vpr-β-lactamase fusion to measure 
virion fusion efficiency (549), and a Vpr-linamarase fusion for prodrug-mediated 
tumour killing (550). Vpr may be a good candidate for protein transduction fusions as 
it remains associated with the viral DNA in the cytoplasm, thus demonstrating its 
ability to escape from endosomes (551). A Nef-HSV-TK fusion for prodrug-mediated 
cell killing has also been reported (552). 
Although these authors were able to show protein transduction using HIV-1, 
alternative vector configurations may be preferable. Firstly, accessory proteins such as 
Vpr and Nef have been removed from second and third generation lentiviral vectors in 
order to simplify vector composition (553) and eliminate undesirable effects these   149
accessory proteins may have on target cells (554;555). Secondly, the level of 
accessory protein incorporation into virions is not high, with a 1:7 Vpr:Gag and 1:20 
Nef:Gag molar ratio in each virion. (There are estimated to be 2000-5000 molecules 
of Gag in each HIV-1 virion (556).) Thus, the stoichiometry of HIV-1 virions means 
that direct fusion to Gag has the largest potential cargo capacity for virion-mediated 
protein transduction.  
This chapter presents work towards the development of HIV-1-mediated protein 
transduction to deliver the Sleeping Beauty transposase. 
 
Figure 6.1 Schematic overview illustrating the goal of HIV-1-mediated protein transduction.  
Sleeping Beauty transposase is expressed in the producer cell as a fusion with the HIV-1 Gag protein, 
allowing it to be packaged into virions. During virion maturation, HIV-1 protease cleaves the protease 
cleavage site between Gag and transposase. When the mature virion fuses with the target cell, 
transposase is released into the cytoplasm at the same time as the viral capsid. The nuclear localisation 
signal present within transposase may enable nuclear import of the protein.   150
6.3.  Design and Plasmid Subcloning of Gag-eGFP and 
Gag-Transposase Fusion Proteins 
Gag is present in virions at the highest stoichiometric ratio of any protein in the virion 
lumen. Since this offers the highest potential protein transduction cargo capacity, 
constructs were generated in which eGFP and SB11 were fused to Gag. The goal was 
to generate fusion proteins which would not interfere with normal virion assembly, 
maturation, and infection. Sleeping Beauty transposase tolerates N- and C-terminal 
fusions poorly (557;558), so constructs were generated in which Gag and eGFP or 
SB11 were separated by a pre-existing protease cleavage site (Figure 6.2). 
In order to minimise the effects of heterologous protein fusion on Gag 
multimerisation during virion assembly, proteins were fused near the C-terminus of 
Gag, away from the Gag I-domain which is necessary for Gag-Gag interactions (559).  
The HIV-1 Gag and Gag-Pol proteins are expressed and packaged in the producer cell 
as polyproteins. During virion maturation, HIV-1 protease undertakes sequential 
cleavage of the polyproteins at the protease cleavage sites which link their constituent 
proteins. Processing of the polyproteins takes place in an ordered fashion due to 
differences in the rate of cleavage at each site. Ordering is regulated by polyprotein 
interactions with RNA, local sequence, the presence of spacer peptides, and possibly 
oligomerisation of proteolytic intermediates (560-564). In HIV-1 Gag, cleavage 
occurs first between the p2 peptide and NC, then at the MA-CA and p1-p6 
boundaries, and finally at the CA-p2 and NC-p1 boundaries. In Gag-Pol, p2-NC 
cleavage is followed by cleavage at the RT-IN and MA-CA boundaries, and lastly 
sites flanking PR (565). It is not known whether the ordering of cleavage events has 
any biological significance. In order to ensure proper proteolytic processing of eGFP 
and SB11 from the fusion proteins, the p6 protein of Gag was replaced with these 
proteins while retaining the p1-p6 cleavage site. The first 5 amino acids of p6 were 
retained to ensure the proper context for proteolytic processing (see Appendix 8.1 for 
annotated amino acid sequences).   151
 
 
Figure 6.2 Protein transduction constructs.  
The standard second generation lentiviral vector packaging plasmid is pCMV-dR8.74, while pCMV-
dR8.74 p6:eGFP and pCMV-dR8.74 p6:SB11 are the fusion constructs generated in this study. CMV, 
human cytomegalovirus immediate early promoter; MA, matrix protein; CA, capsid protein; p2, linker 
peptide; NC, nucleocapsid protein; p1, linker peptide; p6, Vpr-interacting protein; TAT, transactivator 
of transcription protein; REV, enhancer of translation; fs, ribosomal frameshift site; PR, protease; RT, 
reverse transcriptase; IN, integrase; eGFP, enhanced green fluorescent protein; SB11, Sleeping Beauty 
transposase; *, first 5 amino acids of p6 fused to the N-terminus of eGFP or SB11. 
To generate the SB11 fusion construct, pBluescript was digested with SacII, blunted 
using T4 DNA polymerase, and then religated to destroy the site. A fragment of the 
pCMV-dR8.74  gag  sequence was amplified by PCR using Pfu polymerase and 
primers FWD 5’ – TAA TCA GAATTC GGC CGG CCG CGT TG and REV 5’ – 
ATA ACT GAATTC CCG CGG GGT CTG CTC and cloned into this plasmid using 
EcoRI. SB11 was digested from pCMV-SB11 using SacII and cloned into this 
plasmid at the SacII site so that the transposase and viral coding sequences were in the 
same orientation. The gag:SB11 fusion fragment was cloned into pCMV-dR8.74 
between the ApaI and EcoRI sites so that it replaced the p6 and pol coding sequences. 
To generate the eGFP fusion construct, eGFP was amplified from LNT/SFFV-eGFP 
using primers FWD 5’ CAG TCC GCG GCC TGC AGG GTA TGG TGA GCA 
AGG GCG AG and REV 5’ CGC ACC CGC GCC CGG TCG ACT TAC TTG TAC 
AGC TCG TC and this fragment was cloned in place of SB11 in the   152
pBluescript/gag:SB11 plasmid using SacII and so that eGFP and gag were in the 
same orientation. The gag:eGFP fragment was cloned into pCMV-dR8.74 between 
the ApaI and SalI sites.   153
6.4.  Expression, Virion Incorporation, and Processing of 
Fusion Proteins 
6.4.1.  Expression and Membrane Targeting of Gag-eGFP 
To test expression of the Gag-eGFP fusion protein, 293T cells were transfected with 
either the standard non-integrating lentiviral packaging plasmid or the Gag-eGFP 
fusion plasmid (Figure 6.3). Green fluorescence was clearly visible, indicating 
expression of the fusion protein. 
 
Figure 6.3 Fluorescence microscopy to demonstrate expression of Gag-eGFP.  
10
5 293T cells were transfected with 800ng pCMV-dR8.74 D64V or pCMV-dR8.74 p6:eGFP. eGFP 
expression was imaged by fluorescence microscopy using a 40x objective 48 hours post-transfection. 
Gag is myristoylated during translation in the cytosol (566), whereby the 14-carbon 
fatty acid myristate is attached to the N-terminal glycine of Gag. The myristate moiety 
acts together with a basic N-terminal membrane binding (M) domain (567) to allow 
Gag to become membrane-associated.  
In order to test the hypothesis that the Gag-eGFP fusion protein is membrane-
associated in the same way in producer cells, 293T cells were transfected with   154
pCMV-dR8.74 p6:eGFP and pLNT/SFFV-eGFP and imaged by confocal microscopy 
(Figure 6.4). In cells expressing the Gag-eGFP fusion protein, green fluorescence was 
seen preferentially at the plasma membrane, while cells expressing the standard eGFP 
were fluorescent throughout the cell volume. These results suggest that the Gag-eGFP 
fusion protein is expressed and targeted to the plasma membrane correctly. 155
 
Figure 6.4 Confocal microscopy to show subcellular localisation of Gag-eGFP in producer cells.  
10
5 293T cells were transfected with 800ng pCMV-dR8.74 p6:eGFP or pLNT/SFFV-eGFP. 48 hours post-transfection, cells were stained with the lipophilic die DiI to allow 
visualisation of the plasma membrane and the nuclear stain DAPI. Images represent an xy slice with a 1μm z-axis thickness and were captured with a 63x/1.4 oil objective 
lens. UT, untransfected.   156
6.4.2.  Production and Titration of Lentiviral Vectors Containing 
Gag Fusion Proteins 
In order to assess the tolerance of lentiviral vector assembly and budding to co-
expression of Gag-eGFP and Gag-SB11, vector was produced in the standard way 
(293T transfection with PEI, VSVg pseudotype, concentration by ultracentrifugation) 
except that the mass of packaging plasmid (37.5μg per 12x10
6 293T cells) was held 
constant and divided between the standard pCMV-dR8.74 D64V Gag-Pol and the 
fusion Gag-eGFP or Gag-SB11 plasmids in fixed ratios. The ratios tested were 1:0 
Gag-Pol:Gag-Fusion, 30:1, 10:1, 3:1, 1:1, 1:3, 1:10, 1:30, and 0:1, so that a 1:0 ratio 
represents standard non-integrating plasmid only while a 0:1 ratio represents vector 
containing the fusion protein only and no full-length Gag-Pol. Vector was produced 
simultaneously in parallel for all ratios described and titred in duplicate by p24 
ELISA (Figure 6.5). 
The vector titre appeared to be unaffected by increasing the proportion of fusion 
protein up to a plasmid ratio of 1:3 Gag-Pol:Gag-eGFP or Gag-Pol:Gag-SB11, 
beyond which the physical titre declined. This suggests that virion assembly and 
budding is able to tolerate a high level of fusion protein co-expression, though it is 
important to note that high expression of fusion protein within producer cells does not 
necessarily imply that high levels of fusion protein are incorporated into virions that 
bud away from these cells.   157
 
Figure 6.5 Titration of lentiviral vector containing Gag-Fusion constructs by p24 ELISA.  
Vector was generated in parallel as described in the text and titred in duplicate. Empty vector, 
lentivirus vector genome containing LTRs, packaging signal, cPPT, and WPRE but no promoter-
transgene cassette; tn[SV-40-Neo] vector, lentivirus-transposon vector genome.   158
6.4.3.  Western Blotting of Vectors for Protein Transduction 
Gag and Gag-Pol are initially expressed and packaged into virions as polyproteins. 
During or soon after virion budding away from the producer cell, maturation occurs 
whereby the HIV-1 protease sequentially cleaves these polyproteins into their 
constituent proteins, allowing assembly of the mature virion core and causing the 
virion to become infectious. 
The fusion constructs described in this chapter were designed to retain the p1-p6 
protease cleavage site N-terminal to eGFP or SB11. To assess proteolytic processing 
of fusion proteins incorporated into virions, samples of concentrated vector were 
lysed under denaturing conditions and the component proteins were separated by 
electrophoresis and visualised by Western blotting (Figure 6.6).   159
 
Figure 6.6 Western blot to show proteolytic processing of Gag-Fusion proteins.  
Lentiviral vectors were prepared by transfection of 293T cells as described in Section 1.1.1 and 
concentrated by ultracentrifugation. 10μl of each preparation was lysed in reducing Western lysis 
buffer and separated by polyacrylamide gel electrophoresis followed by Western blotting. (a) Vector   160
containing eGFP fusion proteins was probed with mouse anti-eGFP primary antibody; (b) Vector 
containing SB11 fusion proteins was probed with mouse anti-SB11 transposase primary antibody. 
When vector containing the Gag-eGFP polyprotein was produced, both unprocessed 
Gag-eGFP and fully cleaved eGFP forms were visualised (Figure 6.6a). The 
concentration of fully cleaved eGFP in the vector preparation increased with the 
proportion of Gag-eGFP plasmid in the producer cell up to a 3:1 Gag-Pol:Gag-eGFP 
plasmid ratio, and declined thereafter. The concentration of unprocessed Gag-eGFP 
peaked at a Gag-Pol:Gag-eGFP plasmid ratio of 1:3.  
Vector containing Gag-SB11 fusion protein showed a similar but less clear trend on 
Western blotting (Figure 6.6b). The concentration of fully processed SB11 protein 
peaked at a higher proportion of Gag-SB11 plasmid (1:3 Gag-Pol:Gag-SB11), 
implying that the Gag-SB11 protein is not expressed and/or packaged as efficiently as 
Gag-eGFP. In addition, multiple smaller bands were detected whose intensity is 
proportional to that of the full-size SB11 bands in their respective lanes, indicating 
that they are truncated forms of SB11. It has been previously reported that that the 
Sleeping Beauty transposase is extremely prone to folding errors and truncation (568). 
In summary, Western blotting suggested that both eGFP and SB11 were packaged 
into virions and could be correctly processed by the HIV-1 protease.   161
6.5.  Protein Delivery to Target Cells 
6.5.1.  Visualisation of Protein Delivery by Microscopy 
The objective of protein transduction is to deliver functional heterologous proteins to 
target cells. As proof of this principle, eGFP fluorescence was used to assess delivery 
to cells by fusion protein vectors. 293T cells were transduced with concentrated 
vectors containing varying ratios of the Gag-eGFP fusion protein and visualised by 
UV microscopy (Figure 6.7). 
Green fluorescence was clearly visible in wells transduced with vestor prepared with 
Gag-Pol:Gag-eGFP ratios between 3:1 and 1:10. Little fluorescence was observed at 
more extreme Gag-Pol:Gag-eGFP ratios. It is important to note that this assay would 
not distinguish between functional virions containing Gag-eGFP protein and cell 
debris containing eGFP which was co-purified during lentiviral vector preparation. 
To assess whether the green fluorescent matter present within the well was taken up 
by target cells, 293T cells were seeded onto polylyisine-treated microscope slides, 
transduced as above, and visualised by confocal microscopy (Figure 6.8). 
Punctate eGFP fluorescence was clearly visible at the cell surface and within cells for 
all vectors containing Gag-eGFP. This eGFP distribution was significantly different 
from that in cells transduced with an equal volume of integrating eGFP lentiviral 
vector (prepared in parallel), which showed homogenous eGFP fluorescence 
throughout the cytoplasm and nucleus. 
The punctate fluorescence observed could mean that material containing eGFP is 
sequestered in a membrane-bound organelle, possibly endosomes. It is important to 
note that punctate fluorescence has been previously observed with Tat-eGFP protein 
transduction, but that this pathway is able to deliver useful quantities of therapeutic 
proteins (569). Again, it should be emphasised that this assay does not demonstrate 
that the green fluorescent material taken up by target cells represents functional 
lentiviral virions containing eGFP.   162
 
 
Figure 6.7 Fluorescence microscopy to visualise Gag-eGFP virus transduction.  
10
5 293T cells were transduced with concentrated lentiviral vector (diluted 8-fold in culture medium) produced with the Gag-Pol : Gag-eGFP plasmid ratios indicated. 6 
hours post-transduction, cells were imaged by bright field and UV (ultraviolet) microscopy using a 40x objective.   163
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Figure 6.8 Confocal microscopy to assess subcellular eGFP distribution following lentiviral 
protein transduction.  
10
5 293T cells were transduced with concentrated lentiviral vector preparation (diluted 8-fold in culture 
medium) produced with the indicated Gag-Pol : Gag-eGFP plasmid ratios. 24 hours post-transduction, 
cells were stained with rhodamine-phalloidin to allow visualisation of the actin cytoskeleton and the 
nuclear stain DAPI. Images represent an xy slice with a 1μm z-axis thickness and were captured using 
a 63x/1.4 oil objective lens. UT, untransduced.   165
6.5.2.  Measurement of Protein Delivery by Integration Assay 
An objective of the work presented in this chapter was to enable transposase protein 
incorporation into virions together with the transposon vector genome. It was 
hypothesised that co-delivery of these two elements would result in transposase-
mediated integration (Figure 6.1). 
To test the feasibility of the system, fusion protein vector was produced in parallel for 
both Gag-eGFP and Gag-SB11. As before, the plasmid ratio of Gag-Pol to Gag-eGFP 
or Gag:SB11 was varied to allow optimisation of the balance between vector fitness 
and heterologous protein incorporation. The vector genome was pLNT/tn[SV40-Neo]. 
HeLa cells were transduced with a range of vector concentrations and the integration 
efficiency was determined by G418-resistant colony formation (Figure 6.9). It was 
found that increasing the proportion of SB11 transposase in virions did not result in a 
detectable increase in the level of integration above background as measured by 
transduction with the Gag-Pol-only vector. At each Gag-Pol:Gag-SB11 ratio, the rate 
of integration was not significantly different to that observed in the matching Gag-
Pol:Gag-eGFP condition (Figure 6.9c). In addition, increasing the proportion of Gag-
SB11 plasmid beyond 3:1 Gag-Pol:Gag-SB11 or Gag-eGFP resulted in greatly 
reduced background integration, implying a significant loss of vector fitness at these 
ratios.   166
 
Figure 6.9 Integration assay to assess the effect of transposase fusion protein incorporation on the 
level of integration.  
Concentrated lentiviral vectors were produced in parallel containing either Gag-eGFP or Gag-SB11 
and the pLNT/tn[SV40-Neo] vector genome. 10
5 HeLa cells were transduced with an 8-fold dilution of 
these vectors, incubated for 3 days without selection, and then re-seeded into fresh 24-well plates at a 
1:50 dilution and incubated in the presence of 1mg/ml G418 for 14 days. Integration efficiency was 
assessed by G418-resistant colony counting.   167
6.6.  Summary 
This chapter described the construction and development of the Gag-eGFP and Gag-
SB11 fusion proteins to allow lentiviral protein transduction of target cells: 
•  Fusion proteins were cloned and Gag-eGFP was found to express in producer 
cells 
•  Fusion to Gag was found to target eGFP to the plasma membrane in producer 
cells 
•  Proteolytic processing of fusion proteins was demonstrated by Western 
blotting concentrated lentiviral vector preparation 
•  Incorporation of transposase protein into virions did not result in a detectable 
increase in the level of vector integration. The fitness of vector particles was 
found to decline where the Gag-Pol:Gag-SB11 or Gag-eGFP ratio was less 
than 3:1. 
The data presented in this chapter demonstrate that it is possible to incorporate 
heterologous proteins into lentiviral virions when fused to Gag, and these fusion 
proteins can be correctly processed by the HIV-1 protease during virion maturation to 
release the heterologous protein. 
When cells were transduced with lentiviral vector preparation produced with the Gag-
eGFP fusion protein, green fluorescent matter was detectable within cells by confocal 
microscopy 24 hours post-transduction. However, significant further study would be 
required to determine whether this material represents functional lentiviral particles or 
simply debris containing eGFP which was co-purified with virions during vector 
preparation. 
In this study, transposition from an NILV genome catalysed by transposase protein 
transduction was not observed. This could be due to a number of factors, including an 
absence of transposase within functional virions even using this targeting strategy.   168
7.  Discussion 
The growing number of gene therapy clinical trials resulting in a clear therapeutic 
benefit for patients has underscored the power of this approach to treat conditions for 
which conventional alternatives are unattractive or unavailable (32;570-576). Many of 
these trials have used gene transfer vectors which integrate their DNA into patient 
chromosomes, allowing therapeutic DNA to be passed to daughter cells during 
mitosis and enabling stable gene expression in dividing tissues. However, five serious 
adverse events which occurred in two clinical trials for X-linked severe combined 
immunodeficiency have raised concerns as to the safety of commonly used integrating 
vectors (577;578). In these patients, semi-random integration of gammaretroviral 
vectors into patient chromosomes appears to have dysregulated expression of nearby 
T-cell proto-oncogenes such as LMO2, leading to T-cell leukaemia-like expansions 
(579). 
It has been suggested that the genomic integration pattern of a vector may influence 
its ability to cause insertional mutagenesis in this way. The integration preferences of 
the major vectors have now been well-characterised. Gammaretroviral vectors 
integrate preferentially near transcription start sites, while lentiviral vectors show a 
preference for integration within actively transcribed genes (580;581). Adeno-
associated virus vectors integrate preferentially within CpG islands and the first 1kb 
of genes (582). The Sleeping Beauty transposon has a near random integration profile 
with a low preference for genes and no detectable bias towards regions of active 
transcription (583;584).  
An attractive approach to addressing the problem of insertional mutagenesis may be 
to alter the genomic integration pattern of gene transfer vectors in such a way as to 
reduce the probability of oncogenic events such as proto-oncogene activation or 
tumour suppressor gene inactivation. This could be achieved through the development 
of hybrid vectors which combine the gene transfer activity of one vector with the 
preferable integration profile of another. 
In this study, a hybrid vector was developed which combines the efficient gene cell 
and nuclear entry properties of an HIV-1 based lentiviral vectors with the integration 
mechanism of the Sleeping Beauty transposon. The integrating activity of the HIV-1   169
integrase was prevented by the use of the catalytic mutant integrase D64V. It was 
found that non-integrating lentiviral vectors were able to deliver Sleeping Beauty 
transposon DNA and a functional transposase expression cassette to target cells, and 
that co-transduction with these components resulted in a 2-fold increase in vector 
integration relative to background. Chromosomal integration sites were recovered by 
ligation-mediated PCR and sequenced, demonstrating successful Sleeping Beauty 
transposition from a non-integrating lentiviral vector donor. Comparison of the 
integration pattern of the hybrid vector with that of a standard integrating lentiviral 
vector revealed a reduced frequency of integration in genes and no bias in integration 
towards actively transcribing genes when the hybrid vector was used.  
The observed level of hybrid vector integration was relatively low, causing 2.5% of 
HeLa cells to become stably G418-resistant when transposase was provided compared 
to 1.3% background integration in the absence of transposase. Other authors using this 
Sleeping Beauty vector in plasmid transfections have reported efficiencies of 1-3% 
G418-resistant HeLa cells (585), so the efficiency of the hybrid vector is within the 
expected range. The high rate of background integration is most likely due to a 
combination of the high vector doses necessary to achieve detectable transposition 
together with the high background integration frequency of linear DNA such as non-
integrating lentiviral vectors relative to circular DNA such as transfected plasmids. As 
calculated in Section 5.5, 40μl of transposon NILV and 5μl of transposase NILV were 
able to produce 1200 G418-resistant HeLa cells under optimised conditions and so 
have a combined integrating titre of 2.7 x 10
4 TU/ml. By contrast, a standard ILV 
with an identical backbone gave a G418-resistant HeLa titre of 2.9 x 10
8 TU/ml, a 
difference of four orders of magnitude. As with the hybrid system reported by 
Staunstrup et al (586), the efficiency of the system in this study might be improved by 
the use of the novel hyperactive transposase SB100X, possibly increasing the 
efficiency of transposition by 10- to 25-fold (587). However, the integration 
efficiency of the hybrid vector would most likely remain 2 to 3 orders of magnitude 
below that of standard integrating lentiviral vectors. 
It is often difficult to compare integration efficiencies between authors because there 
are few standard assays or units of measurement. Integration efficiencies are 
commonly reported as ‘number of colonies’ or ‘x-fold increase in integration relative 
to background’ (588-593). The latter measure is likely to be particularly high in   170
plasmid transfection experiments as a result of the low rate of background integration 
of circular plasmid DNA in most cells. It is not clear why these measurements are 
often used in the literature rather than the more transparent ‘% of cells stably 
transduced’, which is trivial to calculate from the same data.  
Even the measure ‘% of cells stably transduced’ can be misleading as it implies that 
100% transduction is a perfect result. It is important to remember that this measure 
combines the efficiency of gene transfer to cells with the efficiency of integration. In 
experiments where an extremely high efficiency of gene transfer is readily obtained 
(e.g. plasmid transfection of 293T cells), a reasonably high ‘% of cells stably 
transduced’ can be achieved even with an inefficient integrating system. A more 
accurate measure of integration efficiency would separate gene transfer and 
integration, for example by dividing the frequency of integration by the number of 
intracellular vector copies per cell after gene transfer. Although this is a grossly 
simple measure for a complex and heterogenous entity such as a cell, it could be used 
in combination with appropriate standards for cell type, transfection method, and 
means of quantifying integration efficiency. 
Reporting efficiency results in relative terms can be confusing for those outside of the 
field as it leads to unrealistic expectations of what the currently available integrating 
systems are capable of in absolute terms. Indeed, the other integrating vector systems 
introduced in Section 2.3 appear to have significantly lower integration efficiencies 
than standard gammaretroviral and lentiviral vectors. Quantification of DNA 
intermediates during lentiviral vector transduction of cell lines showed that the total 
vector copy number peaked at 15-20 per cell while the integrated copy number 
peaked at 1-2, suggesting an efficiency of integration on the order of 10
-1 integrations 
per intracellular vector genome (594). It has been estimated that the efficiency of both 
wildtype AAV site-specific integration by Rep and rAAV non-targeted integration is 
approximately 10
-3 integrations per intracellular vector genome (595). In this study, 
the rate of Sleeping Beauty transposition due to the SB11 transposase was estimated 
to be 4 x 10
-4 active chromosomal insertions per intracellular NILV genome, and the 
efficiency of the novel SB100X transposase is estimated to be 10- to 25-fold more 
efficient than this (596). The efficiency of insertion due to Flp recombinase was 
reported to be 2 x 10
-5 per NILV 2-LTR circle (597). The efficiency of site-specific 
chromosomal insertion due to site-specific nucleases such as zinc finger nucleases has   171
not been reported in terms of insertions per intracellular genome, but ‘% transduction’ 
values of 20-40% have been achieved in cell lines (598;599) and 0.06% of primary 
CD34
+ human haematopoietic stem cells (600). Although a side-by-side comparison 
has not yet been performed, conventional gammaretroviral vectors are able to 
transduce up to 60% of primary CD34
+ human haematopoietic stem cells (32). 
In gene therapy applications where high copy number gene transfer is available, the 
relatively low efficiency of alternative integrating systems relative to retroviruses may 
not be rate limiting. For example, stable gene marking of 50% of human peripheral 
blood lymphocytes has been reported following electroporation with Sleeping Beauty 
plasmids (601). Interestingly, two recent reports using the novel transposase SB100X 
have shown Sleeping Beauty mediated gene marking of electroporated primary 
CD34
+ human haematopoietic stem cells which were subsequently able to reconstitute 
NOD-SCID  γc-null mice (602;603). The authors reported 8% stable marking of 
human-derived cells in these animals (604) and the same integration sites were 
recovered from both lymphoid and myeloid lineages in individual mice, confirming 
transposition within a common progenitor (605). The risk of insertional mutagenesis 
due to this approach relative to gammaretroviral or lentiviral vectors will need to be 
confirmed in established genotoxicity assays (606;607). 
In the final part of this study, the possibility of incorporating transposase protein into 
lentiviral vector particles in the same way as the HIV-1 integrase was investigated. It 
was found that heterologous proteins such as eGFP and the Sleeping Beauty 
transposase could be fused to the viral Gag polyprotein for packaging into vector 
particles, and that these polyproteins were processed by the viral protease as would be 
expected for Gag-Pol, the polyprotein which contains the HIV-1 integrase. However, 
no increase in the level of target cell integration could be detected when transposase 
was targeted into vector particles by fusion to the Gag protein, and this study did not 
demonstrate whether functional lentiviral particles containing transposase can be 
produced using this strategy. Assuming that the transposase can be targeted to virions 
and would be functional (though this must be shown directly), it is possible that 
transposition activity in target cells would require binding of transposase protein to 
the vector genome in sufficient quantities for transposition, just as the HIV integrase 
protein remains bound to the PIC/RTC throughout its transit to chromosomes. It is 
possible that continued association with the RTC/PIC after transduction could be   172
achieved by tethering transposase to a viral protein which is associated with the vector 
genome up to the point of integration, perhaps NC or even IN. The fact that 
retroviruses are able to package their own functional integrating protein, integrase, 
into virions shows that the approach has been made to work in nature. The ability to 
carrying integrating systems into cells as protein rather than nucleic acids may 
minimise any wider effects of the vector on the target cell, offering potential safety 
improvements in future integrating vectors. 
 
 
At present, it seems likely that future generations of gene therapy vectors will 
incorporate heterologous mechanisms of transgene integration in order to improve the 
efficacy and/or safety of the gene therapy treatment. In this thesis it was shown that a 
hybrid lentivirus-Sleeping Beauty transposon vector can be generated which 
combines the cell entry properties of lentiviral vectors with the integration mechanism 
of Sleeping Beauty. As well as demonstrating that this class of hybrid vector is 
possible and functional, this study has highlighted a number of issues to be addressed 
in the future development of effective hybrid vectors. Significantly these include the 
requirement for efficient co-delivery of the integration mechanism to be employed 
and the importance of quantifying and optimising integration efficiency.   173
8.  Appendix 
8.1.  Fusion Protein Amino Acid Sequences 
8.1.1.  Gag 
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQ
TGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNI
QGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINE
EAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTHNPPIPVGEIYKRWIILGLNKIVRM
YSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEE
MMTACQGVGGPGHKARVLAEAMSQVTNPATIMIQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCW
KCGKEGHQMKDCTERQANFLGKIWPSHKGRPGNFLQSRPEPTAPPEESFRFGEETTTPSQKQEPIDKEL
YPLASLRSLFGSDPSSQ- 
MA-CA-P2-NC 
P1 
P6 
8.1.2.  Gag-Pol 
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQ
TGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNI
QGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINE
EAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTHNPPIPVGEIYKRWIILGLNKIVRM
YSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEE
MMTACQGVGGPGHKARVLAEAMSQVTNPATIMIQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCW
KCGKEGHQMKDCTERQANFFREDLAFPQGKAREFSSEQTRANSPTRRELQVWGRDNNSLSEAGADRQGT
VSFSFPQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGIGGFIKVGQYDQILI
EICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNFPISPIETVPVKLKPGMDGPKVKQWPLTEEKIKAL
VEICTEMEKEGKISKIGPENPYNTPVFAIKKKDSTKWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKQK
KSVTVLDVGDAYFSVPLDKDFRKYTAFTIPSINNETPGIRYQYNVLPQGWKGSPAIFQCSMTKILEPFR
KQNPDIVIYQYMDDLYVGSDLEIGQHRTKIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYELHPDKWTV
QPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVRQLCKLLRGTKALTEVVPLTEEAELELAENREIL
KEPVHGVYYDPSKDLIAEIQKQGQGQWTYQIYQEPFKNLKTGKYARMKGAHTNDVKQLTEAVQKIATES
IVIWGKTPKFKLPIQKETWEAWWTEYWQATWIPEWEFVNTPPLVKLWYQLEKEPIIGAETFYVDGAANR
ETKLGKAGYVTDRGRQKVVPLTDTTNQKTELQAIHLALQDSGLEVNIVTDSQYALGIIQAQPDKSESEL
VSQIIEQLIKKEKVYLAWVPAHKGIGGNEQVDGLVSAGIRKVLFLDGIDKAQEEHEKYHSNWRAMASDF
NLPPVVAKEIVASCDKCQLKGEAMHGQVDCSPGIWQLDCTHLEGKVILVAVHVASGYIEAEVIPAETGQ  174
ETAYFLLKLAGRWPVKTVHTDNGSNFTSTTVKAACWWAGIKQEFGIPYNPQSQGVIESMNKELKKIIGQ
VRDQAEHLKTAVQMAVFIHNFKRKGGIGGYSAGERIVDIIATDIQTKELQKQITKIQNFRVYYRDSRDP
VWKGPAKLLWKGEGAVVIQDNSDIKVVPRRKAKIIRDYGKQMAGDDCVASRQDED- 
MA-CA-P2-NC 
PRO 
POL 
8.1.3.  Gag-eGFP 
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQ
TGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNI
QGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINE
EAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTHNPPIPVGEIYKRWIILGLNKIVRM
YSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEE
MMTACQGVGGPGHKARVLAEAMSQVTNPATIMIQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCW
KCGKEGHQMKDCTERQANFLGKIWPSHKGRPGNFLQSRPRGLQGMVSKGEELFTGVVPILVELDGDVNG
HKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYV
QERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIK
VNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITL
GMDELYK- 
MA-CA-P2-NC 
P1 
FIRST 5aa OF P6 
LINKER 
EGFP 
8.1.4.  Gag-SB11 
MGARASVLSGGELDRWEKIRLRPGGKKKYKLKHIVWASRELERFAVNPGLLETSEGCRQILGQLQPSLQ
TGSEELRSLYNTVATLYCVHQRIEIKDTKEALDKIEEEQNKSKKKAQQAAADTGHSNQVSQNYPIVQNI
QGQMVHQAISPRTLNAWVKVVEEKAFSPEVIPMFSALSEGATPQDLNTMLNTVGGHQAAMQMLKETINE
EAAEWDRVHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIGWMTHNPPIPVGEIYKRWIILGLNKIVRM
YSPTSILDIRQGPKEPFRDYVDRFYKTLRAEQASQEVKNWMTETLLVQNANPDCKTILKALGPGATLEE
MMTACQGVGGPGHKARVLAEAMSQVTNPATIMIQKGNFRNQRKTVKCFNCGKEGHIAKNCRAPRKKGCW
KCGKEGHQMKDCTERQANFLGKIWPSHKGRPGNFLQSRPRGRSDIMGKSKEISQDLRKKIVDLHKSGSS  175
LGAISKRLKVPRSSVQTIVRKYKHHGTTQPSYRSGRRRVLSPRDERTLVRKVQINPRTTAKDLVKMLEE
TGTKVSISTVKRVLYRHNLKGRSARKKPLLQNRHKKARLRFARAHGDKDRTFWRNVLWSDETKIELFGH
NDHRYVWRKKGEACKPKNTIPTVKHGGGSIMLWGCFAAGGTGALHKIDGIMRKENYVDILKQHLKTSVR
KLKLGRKWVFQQDNDPKHTSKHVRKWLKDNKVKVLEWPSQSPDLNPIENLWAELKKRVRARRPTNLTQL
HQLCQEEWAKIHPTYCGKLVEGYPKRLTQVKQFKGNATKY- 
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